INDEX TO VOLUME 56—1988

AUTHOR INDEX

Original articles are indicated by (O), editorial (E), correspondence (C), news and notes (N), obituaries (Ob), abstracts (A), and book reviews (B).

ABALOS, R. M., (A) 648
ABDUL-ATY, M., (A) 153
ABEL, L., (A) 665
ABEYAGUNAWARDANA, D. V. P., (A) 669
ABUD-MENDOZA, C., (A) 491
ACHARYA, S., (C) 471
ADALLA, S., (A) 363
ADIGA, R. B., (A) 347, 483, 484, 496
AGARWAL, S. C., (A) 157
AGGARWAL, S. K., (A) 485
AGIS, F., (O) 527
AGIUS, G., (A) 354
AGRAWAL, M. N., (C) 628
AGUSNI, I., (O) 394
AIZAWA, M., (A) 147
AKHWAND, R., (A) 510
AKHYNOV, S. B., (A) 512
AKIYAMA, T., (A) 678
AL SHIMALI, B., (A) 153
AL-MOHAYA, S. A., (O) 599
AL-SUHAIBANI, M. O., (O) 599
ALCOCER-VARELA, J., (A) 491
ALI, S. M. K., (A) 131
ALKHDER, A. A., (O) 599
ALLEN, B. W., (A) 365
ALLEN, J. L., (C) 630
ALTMANN, D. M., (A) 497
ALVARENGA, F. B. F., (A) 660
ALVAREZ-MENDOZA, A., (A) 655
AMBROSE, E. J., (O) 481
AMEZCUA-CHAVARRIA, M.-E., (A) 655
AMJITEATROVA, N. F., (A) 511
AMRITMAHAL, A., (A) 667
ANDERSEN, B. R., (A) 657
ANDERSON, D. C., (A) 655
ANDERSON, R., (A) 348, 348, 485
ANTIA, N. H., (A) 138, 152, 152, (E) 310, (A) 342, 354, (O) 481, (C) 619, 632
ARANZAZU, N., (A) 656
ARCE, P., (O) 428
AREVALO, N., (A) 372
ARORA, P. N., (A) 485
ARORA, S. K., (A) 134, 349, 485
ASCHHOFF, M., (A) 647
ASHERSON, G. L., (A) 492
ASHMALLA, L., (A) 371
ASPINALL, G. O., (A) 145
ATKIN, S. L., (A) 349
AUGUSTIN, G. P., (A) 491
AZIZ, A., (A) 510
AZULAY, R. D., (Ob) 323, (A) 349

BACH, M.-A., (A) 360, 504, (O) 527
BAGGA, A. K., (A) 660
BAGSHAWE, A., (A) 490
BAH, M. D., (A) 350
BAHMER, F. A., (A) 131
BAHR, G. M., (A) 153
BAI, G. L., (A) 487
BAILLARGEAU, E., (A) 354
BAKAYA, V., (A) 648
BAKER, C., (A) 159
BAKER, M. K., (A) 650
BALABANOVA, M., (A) 512
BALACHANDRAN, C., (A) 485
BALAKRISHNAN, S., (A) 482, 487, 510, 649
BALANCHANDRAN, C., (C) 471
BALLOU, W. R., (A) 514
BANSAL, N. K., (A) 132
BANSAL, R. D., (A) 483
BARANDA, L., (A) 491
BARAS, M., (A) 115
BARBIERI, G., (C) 361
BARNES, P. F., (A) 688
BARON, L. S., (A) 514
BARROS, U., (A) 138, 354
BARRY, M. E., (A) 655
BARTEL, P. R., (A) 650
BASKIN, G. B., (O) 61, (A) 147, 369, (O) 443, (A) 667
BASTEN, A., (A) 139, 153, 490, 490, 491, 495
BASTIAANS, A. H., (A) 136
BATES, J. H., (A) 154
BAUMGART, K., (A) 490
BEAVIS, D., (A) 349
BECK, J. S., (A) 359
BEHBEHANI, K., (A) 153
BEHRA, R. N., (A) 355
BALHAJ, M. S., (C) 110
BELSEY, E., (A) 379
BELYAKOVA, O. I., (A) 668
BEN-ISHAY, Z., (A) 665
BEOHAR, P. C., (A) 142
BEOLETTO, C., (O) 259
BERCOVIER, H., (A) 665
BETZ, T. G., (A) 371
BHAGOLIWAL, S. K., (A) 133

Bhagria, A., (A) 144
Bharadwaj, V. P., (A) 138, 144, 146, 146, 368, 500, 664
Bhatia, A. H., (A) 510
Bhatia, V. N., (A) 142, 482, 487, 490, 649, 662
Bhattacharya, A., (A) 511
Bhattacharya, S., (A) 511
Bian, T., *et al.*, (A) 148
Biggins, T., (A) 655
Binford, C. H., (O) 61, (A) 147, (O) 302, (A) 369, (O) 443, (A) 667
Birdi, T. J., (E) 310, (A) 354
Blanchard, J. L., (A) 147, 369
Bliss, L., (A) 374, 666
Bloom, B. R., (A) 493, 493, 678, 682
Bodian, M., (A) 482
Boening, L. F., (A) 371
Boerrigter, G., (O) 408
Bogle, G., (A) 159
Bolla, K., (A) 349
Bombach, B., (A) 349
Bonfa, E., (A) 355
Booth, R. J., (A) 490
Bos, J. D., (N) 339
Boucher, P., (A) 151, 374
Bourland, J., (A) 347, 650
Bradley, D. J., (A) 374
Brand, P. W., (A) 374
Brauner, M., (A) 132
Breger, D., (A) 151
Brennan, P. J., (A) 145, 357, 360, 367, 368, 493, (O) 537, (A) 682, 683
Brett, S. J., (A) 370, 375
Brey, R. N., (A) 514
Britton, S., (A) 139
Britton, W., (A) 490
Britton, W. J., (A) 139, 153, 490, 491, 495
Brown, A., (A) 667
Brown, I. N., (A) 370
Brozna, J. P., (A) 670
Brudnaya, Y. E., (A) 511
Brunel, W., (A) 509
Buchanan, T. M., (A) 367, 655
Burchfield, H. P., (A) 515
Burgess, P., (O) 243
Butler, R., (A) 375
Butov, Y. S., (A) 651
Butter, C., (O) 283

Caire-Loyer, P., (A) 652
Calegari, L., (A) 670
Camacho Martinez, F., (A) 489
Campbell, D. A., (A) 361
Campbell, P. B., (A) 355
Cartel, J.-L., (A) 345, 504, (O) 527
Casal, M., (A) 154
Castellanos, P. L., (A) 363
Castells, A., (A) 349
Castells, E. G., (A) 371
Castets, M., (A) 354
Castilla Garrido, J. M., (A) 489
Castro, L. E., (A) 372
Cellona, R. V., (A) 648
Chacko, C. J. G., (O) 523
Chae, G. T., (A) 683
Chaise, F., (A) 374
Chakkalath, H. R., (A) 141
Chakrabarty, A. K., (A) 353, (O) 559
Chakrabarty, A. N., (A) 366, 366, 498
Chakravarti, R. N., (A) 503
Chan Pin Jin, J. C., (O) 552
Chan, H.-L., (A) 652
Chanteau, S., (A) 504
Char, D. F. B., (A) 342
Charoen, W. S., (A) 135
Chatterjee, B. C., (A) 356
Chattopadhyay, S. P., (A) 485, 651
Chaturvedi, R. M., (O) 27, (A) 666
Chaudhary, S. G., (A) 651
Chaudhury, S., (A) 356
Chaudhury, S. K., (A) 498
Chaudhury, S. N., (A) 356
Chauhan, V. S., (A) 653
Chaumet, S., (A) 132
Chehl, S., (A) 365
Chen, J., *et al.*, (A) 345
Chen, L., *et al.*, (A) 481, 651
Chen, P. C. Y., (A) 342, 342
Cherian, E., (A) 662
Chernousova, L. N., (A) 378
Chirmule, N. B., (O) 27
Chong, Y. W., (A) 346
Chopra, J. S., (O) 389
Choudhary, M. S., (A) 134
Christian, M., (O) 418
Chugh, T. D., (A) 153
Chulay, J. D., (A) 514
Chyugun, M., (A) 681
Clark, K. A., (A) 371
Clark-Curtiss, J. E., (A) 679
Clarkson, J. A., (O) 243
Clavel-Seres, S., (A) 345
Clement, F., (A) 345
Cocito, C., (A) 154, 366, 366, 367
Coene, M., (A) 366, 366, 367
Cohn, Z. A., (A) 358, 658, 685
Collaborative Study Group for Treatment of Leprosy in Zaire and Rwanda, (A) 347
Collings, L. A., (A) 361
Collins, F. M., (A) 160
Collins, J. V., (A) 376
Colston, M. J., (A) 492, 663
Combrink, P., (A) 650
Conalty, M. L., (A) 482
Converse, P. J., (A) 656
Convit, J., (A) 363, 493, 493, 656
Coode, P. E., (O) 599
Corcos, M. G., (C) 106
Correa, P., (A) 350
Cottenot, F., (A) 360, 372

COURTRIGHT, P., (A) 351
COURTRIGHT, P. D., (O) 556
COWLEY, S. A., (O) 283
COX, R. A., (A) 154, 663
CRAWFORD, C. L., (A) 502
CRAWFORD, J. T., (A) 154
CREE, I. A., (O) 296, 394, (A) 651
CROXSON, M. S., (A) 135
CRUZ, N., (A) 144
CRYZ, S. J., (A) 514
CURTIS, J., (A) 141, 144, (O) 283
CYNAMON, M. H., (A) 375

D'ARCY HART, P., (A) 375
D'SOUZA, D., (A) 651
D'SOUZA, G. A., (A) 485
DAFFÉ, M., (A) 155, 662
DAMAVANDI, N. M., (A) 140
DANDEKAR, S. R., (A) 356
DANIEL, T. M., (A) 379
DANN, F. J., (A) 350
DARBORD, J. C., (A) 500
DAS, P., (A) 356
DAS, R. K., (O) 574
DAS, S., (A) 366, 498
DASTIDAR, S. G., (A) 366, 366, 498
DATTA, A. K., (A) 144, 146, 146, 664
DATZ, F. L., (A) 134
DAUDEN TELLO, E., (A) 671
DAVID, H. L., (A) 345, 378, 379
DAVIS, G. A., (A) 497
DAYAL, S. G., (A) 352
DE ANDA, G., (A) 670
DE FILIPPIS, V., (A) 361
DE KESEL, M., (A) 366
DE LA CRUZ, E. C., (C) 326
DE MILLAN, S. G., (A) 669
DE MUYNCK, A., (O) 580, (A) 650
DE RIDDER, K., (O) 580
DE SOUZA, J. M., (A) 355
DE SOUZA, P. R. C., (A) 660
DE VRIES, R. R. P., (A) 497
DE WIT, M. Y. L., (A) 140, 663
DECLERCQ, E. E., (A) 149
DEENABANDHU, A., (A) 647
DELVILLE, J., (A) 366
DEMENAIS, F., (A) 665
DEO, M. G., (O) 27, (E) 455
DESIKAN, K. V., (A) 136, 138, 484, (O) 546, (A) 653, 655, 664
DEVARAJAN, L., (A) 504
DEVASUNDARAM, J., (C) 328
DEY, S. K., (A) 356
DHAND, R., (O) 389
DHAND, U. K., (O) 389
DHANDAYUTHAPANI, S., (A) 487
DHARIWAL, K. R., (A) 155
DHARMSHAKTU, N. S., (A) 504
DHOPLE, A. M., (A) 663
DICK, W. C., (A) 349
DICKINSON, J. M., (A) 155, 156, 156
DIESSELHOFF-DEN DULK, M. M. C., (O) 552
DIGGS, C., (A) 501
DIMITROVA, J., (A) 512
DOCKRELL, H. M., (A) 660
DOLZHANSKY, V. M., (A) 668
DONCHENKO, A. S., (A) 160
DONETS, O. T., (A) 156
DOROZHKOVA, I. R., (A) 377
DORVADI, M. H., (A) 140
DOUGLAS JONES, A. G., (A) 657
DOUGLAS, J. T., (A) 356, 491, 497, 648
DOUTRE, M. S., (A) 351
DRAPER, C. C., (O) 243
DREVET, D., (A) 372
DUBINA, I., (A) 377
DUMAS, M., (A) 132
DURAI, V., (A) 510
DURGAMBAL, K., (A) 351
DUTTA, R. K., (A) 488, 654
DWIVEDI, M. P., (A) 653

EDWARDS, A. J., (A) 158
EHRENBERG, J. P., (A) 356, 656
ELKON, K. B., (A) 355
ELLARD, G. A., (A) 648
ELLIS, B. P. B., (A) 493
ELLIS, M. E., (A) 156
ELLIS-PEGLER, R. B., (A) 135
ELSHANSKAYA, M. P., (A) 512
ENGERS, H. D., (N) 640, 641
ENGLEMAN, E. G., (A) 679
ENGLISH, C. K., (A) 511
ENNA, C. D., (B) 129
ERIYAGAMA, N. B., (A) 141, 142, 362, 362, 362, 495
ERRICO, F., (A) 670
ESCOBAR-GUTIERREZ, A., (A) 655
ESPINOSA, M., (A) 660
ESQUENAZI, D., (A) 660
ESTRADA-G., I., (A) 492
ESTRADA-G., I. C. E., (A) 663

FAIN, O., (A) 486
FAJARDO, T., (A) 648
FANG, D., (A) 481
FASSKE, E., (A) 501
FEENSTRA, P., (A) 505
FERNANDEZ, R. M. G., (A) 149
FEUREISL, R., (A) 511
FIGUEIREDO, A. A., (A) 660
FINE, P. E. M., (O) 243, (A) 374, (O) 408, (A) 666
FISH, D. G., (A) 142
FISHER, C. A. H., (O) 296
FISHER, J. H., (A) 159
FISSETTE, K., (O) 580
FLAGEUL, B., (A) 360
FLEURY, R. N., (O) 302
FLIESS, E. L., (A) 357
FLORES, J., (A) 372
FLORES-ALONSO, O., (A) 652

Flores-Romero, R. M., (A) 652
Fondaminskaya, L. D., (A) 514
Fornage, B. D., (A) 135
Fortier, A. H., (A) 668
Foster, F. N., (E) 66
Foster, R. L., (E) 66
Franceschini, G., (A) 357
Franzblau, S. G., (A) 143, 367, 498, 499, (O) 588, (A) 663, 677
Fraser, A. G., (A) 135
Frehel, C., (A) 357
Frey, F. L. P., (A) 656
Fried, P., (A) 360
Fritschi, E. P., (A) 151
Fu, Z., *et al.*, (A) 148
Fuchs, D., (A) 142
Fujii, H., (A) 147
Fujiwara, T., (C) 112, (A) 145, 367, 682
Fukunishi, Y., (A) 501
Fukutomi, Y., (A) 684
Fumo, G., (A) 361

Gabriel, M., (A) 153
Gallinoto, M. E., (A) 656
Ganapathi, R., (A) 356
Ganapati, R., (A) 131, 133, 501
Gangowar, D. N., (A) 133
Ganguly, N. K., (A) 503, 503
Gao, Q., *et al.*, (A) 482
Gao, S., (A) 505
Garcia, R., (A) 491
Gardiner, C. A., (O) 296
Garg, S. K., (A) 648
Garsia, R. J., (A) 490, 491
Gaylord, H., (A) 357, 367
Gayraud, M., (A) 486
Gebre, N., (A) 356, 655
Gelber, R. H., (A) 135, 147, 351, 370, 509, 679
Gent, R., (A) 353
George, J., (A) 482, 649
Georgiev, G. D., (C) 101, (A) 346, (E) 603
Gerochi, L. N., (A) 151
Gerone, P. J., (O) 61, (A) 667
Gezuele, E., (A) 670
Ghorpade, A., (A) 133
Giam, Y. C., (A) 652, 652
Gibbels, E., (A) 656
Gidoh, M., (A) 676
Gilburd, B. S., (A) 157, 378
Gill, H. K., (O) 36
Gillis, T. P., (O) 274, 422, (A) 657
Gilpin, T. P., (A) 376
Gimenez, M. F., (A) 669
Gimenez, M. M., (A) 669
Girdhar, A., (A) 486, (O) 546
Girdhar, B. K., (A) 136, 484, 486, 659
Glynn, A. A., (A) 370
Gnanadoss, A. S., (A) 350
Godal, T., (O) 36
Goh, K.-S., (A) 378
Golyshevskaya, V. I., (A) 512
Goncalves, A., (A) 372
Gonzales Segredo, A. B., (A) 371
Gonzalez, A., (A) 140
Gonzalez, J., (A) 154
Gonzalez-Abreu, E., (A) 140
Gonzalez-Amaro, R., (A) 491
Good, R. C., (A) 378
Gooi, H. C., (A) 135
Gordon, A. H., (A) 375
Goren, M. B., (A) 669, 670
Gormus, B. J., (O) 61, (A) 147, 369, (O) 443, 537, (A) 667
Gorodezky, C., (A) 372
Gottlieb, A. B., (A) 656
Goyal, B. M., (A) 352
Grange, J. M., (C) 111, (A) 359, 363, 364, 502
Green, K. J., (A) 663
Greer, W. E., (O) 61
Grillone, S., (A) 347, 650
Groenen, G., (A) 347, 507, 650
Gross, A., (A) 656
Gross, J. M., (A) 670
Grosset, J. H., (O) 259, (A) 345, 482
Grossetete, G., (O) 21, (A) 650
Grugni, A., (A) 649
Gudz, E. A., (A) 157
Guelpa-Lauras, C.-C., (O) 259, (A) 482
Guha, P. K., (A) 486
Guidi, C., (O) 527
Guill, M. A., III, (A) 137
Guillevin, L., (A) 486
Gundersen, S. G., (A) 148
Guo, C., *et al.*, (A) 152
Gupta, A. K., (A) 352, 653
Gupta, C. M., (O) 45, (A) 651
Gupta, H. P., (A) 134
Gupta, P. R., (A) 131
Gupta, S., (A) 654
Gupta, V., (A) 651
Gutierrez, J., (A) 154

Hale, W. A., (A) 647
Hammond, C., (C) 466
Hammond, M., (A) 376
Handa, F., (A) 654
Hanson, P. J. V., (A) 376
Harboe, M., (A) 144, (O) 552
Harikrishnan, S., (A) 662
Harris, D. P., (A) 490, 657
Harris, E. B., (A) 499, (O) 588, (A) 663
Hartskeerl, R., (A) 140
Hassan, M., (A) 132
Hastings, R. C., (E) 82, (O) 274, 291, (A) 365, 367, (O) 422, 437, (A) 494, 499, 501, (O) 588, (C) 630, (A) 677
Hausen, A., (A) 142
Hazra, S., (A) 356
He, H., (A) 350
He, H., *et al.*, (A) 350

Heifets, L. B., (A) 376
Hellqvist, L., (A) 139, 153, 491
Hendrix, R., (A) 661
Henke-Lubke, U., (A) 656
Hibino, T., (A) 689
Hilson, G. R. F., (A) 499
Hiranras, S., (O) 255
Hirata, T., (A) 681
Hirzel, C., (A) 151
Hockmeyer, W. T., (A) 514
Hodes, R. M., (O) 228
Hodges, E. J., (A) 351
Hoffman, V. N., (A) 486
Holzer, T. J., (A) 657
Horibe, S., (A) 667
Hottat, F., (A) 367
Howland, K., (A) 359
Hsu, P. S., (A) 689
Hugh-Jones, M. E., (A) 148
Hugon, J., (A) 132
Humphrey, D. M., (A) 376
Hunter, S., (A) 682
Hunter, S. W., (A) 145, 368, 493, 683
Huong, P. L. T., (A) 661
Husain, S., (A) 136, 486
Hussain, A., (A) 131
Husser, J. A., (A) 650
Hut, R., (A) 501

Ibegbu, C., (A) 145, 358, 360
Ichiyama, S., (A) 160
Ikeda, M., (A) 682
Ilias, M. I., (O) 394
Ilnitsky, I. G., (A) 156
Inglis, A. S., (A) 153
Ingole, D. L., (A) 671
Inui, S., (A) 684
Irudaya Raj, P. P., (A) 647
Isenberg, D. A., (A) 658
Ishaq, M., (A) 510
Isozaki, Y., (A) 689
Ito, T., (A) 501, 678, 687
Ivanyi, J., (A) 139, 359, 362
Iwais, B., (A) 349
Izaki, M., (A) 500
Izaki, S., (A) 500, 689
Izumi, S., (A) 367, 682

Jacob, M., (O) 56
Jacobs, J. M., (A) 152, 152
Jacobs, W. R., Jr., (A) 678
Jacobson, R. R., (O) 437
Jadhav, V. H., (A) 650
Jaffer, N. A., (A) 510
Jain, R. K., (A) 351
James, M. M., (A) 141
Jamet, P., (A) 649
Janardhanam, B., (A) 158
Janssens, L., (A) 347, 650
Jeevan, A., (A) 492

Jessen, K. R., (A) 364
Jesudasan, K., (A) 353, (O) 418
Ji, B., (C) 326, (N) 640, 641
Jiang, Z., *et al.*, (A) 152
Jiangqu Hospital, (A) 149
Jimenez Misas, C. A., (A) 377
Jimenez-Castellanos Ballesteros, R., (A) 489
Jindal, S. K., (A) 485
Jirillo, E., (A) 361
Job, A., (O) 523
Job, C. K., (A) 147, 148, (O) 291, (A) 358, 365, (O) 437, (A) 501, (C) 630, (A) 658
Jones, W. D., Jr., (A) 159, 512
Jopling, W. H., (C) 104
Joseph, M. S., (A) 135, 346
Josse, R., (A) 372
Josseran, R., (A) 372
Juang, W.-M., (A) 513
Julien, J., (A) 351

Kadir, A. H. A., (A) 668
Kalaivani, S., (A) 351
Kalambo, M., (A) 666
Kale, V., (A) 145, 358, 360
Kalla, N. R., (A) 654
Kalugina, N. M., (A) 511
Kandji, T., (A) 350
Kannan, K. B., (A) 144, 146, 146
Kaplan, G., (A) 358, 658, 685
Kaplan, M., (A) 509
Kapoor, K. K., (A) 653
Kar, H. K., (A) 351
Kardjito, T., (A) 359
Kashyap, A., (O) 559
Kato, L., (A) 145, (C) 631
Katoch, K., (O) 1, (C) 105, (A) 132, 138, 146, (C) 622, (A) 660, 664
Katoch, V. M., (A) 144, 146, 146, 154, 664
Kaufman, H. C., (A) 158
Kaufmann, S. H. E., (A) 359
Kaur, I., (A) 132, 133, 136, 136, 488
Kaur, S., (A) 132, 133, 136, 136, (O) 389, (A) 485, 488, 503, 503, 648
Kawatra, V. K., (A) 510
Kawuma, H. J., (A) 343
Kazda, J., (O) 449, (A) 501
Khaleque, A., (A) 131
Khan, A. K., (A) 131
Khandekar, P. S., (O) 592
Kharakter, Z. Z., (A) 668
Khare, A. K., (A) 132
Kharkar, R. D., (A) 483, (C) 625, 627
Khomenko, A. G., (A) 377, 377
Khupulsup, K., (O) 255
Kielstrup, R. W., (A) 346
Kiessling, R., (A) 655
Kim, D.-I., (A) 505
Kim, S. H., (A) 371
Kingston, A. E., (A) 492
Kini, M. S., (A) 649

KINO, H., (A) 493
KIRAN, K. U., (A) 648
KITAGAWA, T., (A) 502
KIZLAITIS, L., (A) 657
KLATSER, P. R., (A) 140, 663
KLENERMAN, P., (C) 466
KLINGMULLER, G., (A) 656
KOBAYASHI, S., (A) 488
KOHSAKA, K., (A) 501, 678
KOLK, A., (A) 501
KOLK, A. H. J., (A) 140
KON, S., (A) 689
KORANNE, R.V., (A) 652
KORANNE, V., (A) 486
KORZENIOWSKI, O. M., (A) 486
KOSHY, A., (A) 136
KOTHANDAPANI, V. G., (A) 647
KRAHENBUHL, J. L., (A) 143, 355, 494, 657, 660, 683
KRISHNAMURTHY, V., (A) 487
KRISHNAN, S. A. R., (O) 296
KUCHEROV, A. L., (A) 512
KULKARNI, V. C., (C) 632
KULKARNI, V. N., (A) 509
KUMAR, A., (A) 157, (O) 223, (A) 351, 653
KUMAR, B., (A) 132, 133, 136, 136, (O) 389, (A) 485, 488, 503, 503, 648
KUMAR, M., (A) 487
KUMAR, R., (A) 492
KUMAR, V., (A) 515
KUNZ, K., (A) 351
KUO, T.-T., (A) 652
KUSAKA, T., (A) 499
KUSHWAHA, S. S., (A) 653

LAAL, S., (O) 401
LABADIE, H., (A) 132
LACAVE, C., (A) 155
LACHANT, N. A., (A) 649
LADIWALA, U., (A) 354
LAGUENY, A., (A) 351
LAI, K. N., (A) 346
LAI A FAT, R. F. M., (O) 552
LAL, H., (A) 651
LAL, R., (A) 648
LAM, S. K., (A) 135
LAMB, F. I., (A) 492, 663
LAMB, J. R., (A) 157, 359
LAMBERT, M. A., (A) 378
LAMFERS, E. J. P., (A) 136
LANCHBURY, J. S. S., (A) 513
LANEELLE, G., (A) 155
LANEELLE, M.-A., (A) 155, 662
LARA-PADILLA, E., (A) 655
LARSSON, L., (C) 468
LATAPI-CONTRERAS, F., (A) 652
LATHIGRA, R., (A) 661
LAU, B. H. S., (E) 66
LAUNOIS, P., (A) 360
LAVANIA, R. K., (O) 45, (A) 136, 659
LAW, A. S., (A) 343
LAW, H. G., (A) 344
LAZAROVA, A., (A) 512
LECHAT, M. F., (N) 122, (A) 149, 481
LEELARUSAMEE, A., (O) 255
LEGUIZAMON, O. R., (A) 133
LEIGH, I. M., (A) 363
LENNON, J. L., (E) 611
LEON, A., (A) 486
LEVIS, W. R., (A) 360, 656
LEVY, L., (C) 115, 326, 621, (A) 665
LÉVY-FRÈBAULT, V., (A) 378
LEZVINSKAYA, E. M., (A) 651
LI, F., *et al.*, (A) 140
LI, X.-Y., (O) 50
LI, Z., (A) 372
LIAV, A., (A) 155
LILLY, L., (A) 647
LIN, S.-S., (A) 513
LIN, Z., *et al.*, (A) 482
LINDHOLM-LEVY, P. J., (A) 376
LISICHENKO, G. M., (A) 160
LISSNER, C. R., (A) 511
LITVINOV, V. I., (A) 378, 513
LLOVET, R., (A) 355
LOCK, C. B., (A) 497
LOCKWOOD, D. N. J., (A) 669
LOCNISKAR, M., (A) 658
LOESCH, J., (A) 355
LONG, H. T., (A) 661
LOUIS, F. J., (A) 149
LOUIS, J.-P., (A) 149
LOVE, G. L., (A) 378
LOVE, J. M., (A) 490
LOWELL, G. H., (A) 514
LU, B., *et al.*, (A) 486
LUCAS, S., (A) 363
LUGER, T., (A) 496
LUGOSI, L., (A) 678
LYONS, N. F., (A) 493

MA, B., (A) 650
MA, H., (A) 506
MA, Y., (A) 379
MAC-MOUNE LAI, F., (A) 346
MACEDO, P. M., (O) 580
MACK, T. M., (A) 150
MACMORAN, J. W., (A) 374
MADARANG, M. G., (A) 491, 648
MADRIGAL, J. A., (A) 497
MAHADEVAN, P. R., (A) 144, 360, (O) 481, (A) 496
MAINE, N., (A) 666
MAJARIAN, W. R., (A) 514
MAKAREVICH, N. M., (A) 377
MALATY, R., (A) 147, 369, (O) 443, (A) 502
MALAVIYA, G. N., (A) 136, 486
MALENKO, A. F., (A) 513, 514
MALIK, S. K., (A) 485
MANDICH, D., (A) 682
MANDOCK, O., (A) 145, 358, 360
MANGHOUSH, E. A., (C) 110

MANGLANI, P. R., (A) 133
MANN, S. B. S., (A) 136
MANRIQUE MARTINEZ, P., (A) 671
MARGILETH, A. M., (A) 511
MARKOV, A. G., (A) 512
MARKS, S. C., JR., (O) 21
MAROLIA, J., (A) 360
MARTIN, L. N., (A) 147, 369, (O) 443
MATHAI, R., (O) 56
MATHUR, N. K., (A) 658
MATSUBARA, H., (A) 659
MATSUNO, Y., (A) 147
MATSUO, E., (A) 681
MATSUOKA, M., (A) 147, 687
MAUCH, H., (A) 671
MAYO, P., (A) 159
MAZON ZAMORA, D., (A) 377
MCADAM, K. P. W. J., (A) 658, 660
MCCASLAND, F. V., (A) 371
MCDERMOTT-LANCASTER, R. D., (A) 499
MCDOUGALL, A. C., (C) 101, (O) 302, (E) 603
MCELRATH, J., (A) 358
MCINTYRE, G., (A) 379
MCMANUS, I. C., (A) 669
MCNAIR, A. N., (A) 133
MCNEIL, M., (A) 368, 493, 683
MEEKER, H. C., (A) 360
MEENA, H. S., (A) 132
MEHRA, V., (A) 493, 682
MEHRA, Y. N., (A) 136
MEHTA, J., (O) 296
MEHTA, J. M., (A) 509, 650, 654, 667
MEHTA, L., (A) 140
MEHTA, Y. R., (A) 131
MELANCON-KAPLAN, J., (A) 493, 493
MELTZER, M. S., (A) 668
MENG, M., (A) 513
MENZEL, S., (A) 131
MERLIN, M., (A) 372
MESTER, L., (O) 481
MEYERS, W. M., (O) 61, (A) 147, (O) 302, (A) 361, 369, (O) 443, 537, (A) 667
MILLAN, J., (A) 354, 482
MINES, J. S., (A) 150
MINNIKIN, D. E., (A) 368
MIRANDA, C. F., (A) 660
MIRANDA, R. F., (A) 149
MIRSKY, R., (A) 364
MISHRA, B., (A) 486, 653, 659
MISHRA, S. D., (A) 653
MISRA, R. S., (A) 507, 659
MISSON, C. B., (A) 149
MISTRY, N. F., (C) 632
MITCHELL, M., (A) 159
MITCHISON, D. A., (A) 155
MITTAL, A., (A) 493
MITTAL, B. N., (A) 372, 504
MIYATA, Y., (A) 380, 499, 501
MIZUNO, K., (A) 147
MIZUNO, S., (A) 160
MOCK, B. A., (A) 668
MODLIN, R. L., (A) 344, 493, 493, 682, 688
MOHAGHEGHPOUR, N., (A) 679
MOHAMED, K. N., (C) 625
MOHAN, C., (A) 157
MONCADA, B., (A) 491
MONTREEWASUWAT, N., (A) 141
MOORE, M. B., (A) 158
MOR, N., (A) 665, 669
MOREAU, J. C., (A) 350
MORGENSTERN, J. P., (A) 497
MORI, T., (A) 380, 499
MORRISON, N. E., (A) 482
MOSS, C. W., (A) 378
MOWSZOWICZ, M., (A) 670
MRAVUNAC, M., (A) 136
MSHANA, R. N., (E) 314, (O) 422, (A) 494
MUDD, D. W., (A) 658
MUKHERJEE, A., (A) 361, 659
MUKHIJA, R. D., (A) 134, 349, 352, 485, 653
MUNN, M. W., (A) 679
MUNNO, I., (A) 361
MUNRO, C. S., (A) 361
MURTY, K. J. R., (A) 513
MUSTAFA, A. S., (O) 36, 265
MUTHUKKARUPPAN, V., (A) 141
MWANASANGEZI-BIN-MOUSSA, (A) 507

NAAFS, B., (A) 493
NACY, C. A., (A) 668
NADKARNI, N. J., (A) 649
NAGAI, S., (A) 144
NAGANO, J., (A) 667
NAIK, S. S., (A) 356
NAKAMURA, K., (A) 503, 504, 686
NAKATA, A., (A) 687
NARAYANAN, R. B., (A) 494, 655, 659, 660
NATARAJAN, M., (A) 660
NATH, I., (O) 401, (A) 493, 658
NATHAN, C. F., (A) 358
NATORI, T., (A) 147
NAUDILLON, Y., (A) 345
NAVALKAR, R. G., (A) 145, 358, 360
NAVARRETTE, C., (A) 363
NEELAN, P. N., (O) 223, (A) 487
NEGESSE, Y., (C) 329
NELSON, K. E., (O) 231, (A) 667
NEROT, C., (A) 135
NEUPANI, K., (A) 496
NEVES, R., (C) 302
NEWTON, C., (A) 158
NEYLAN, T. C., (O) 231
NGOM, A., (A) 350
NIGAM, P., (A) 352, 653
NIIYAMA, T., (A) 147
NILSEN, R., (E) 314
NISHIMURA, Y., (A) 682
NOGUEIRA, N., (A) 660
NOMAGUCHI, H., (A) 499, 687
NOORDEEN, S. K., (N) 122, (A) 361

Nunez, A., (O) 428
Nusrat, A., (A) 358
Nyawalo, J. O., (A) 346

O'Sullivan, J. F., (A) 348, 482, 485, 677
Obura, M., (A) 346
Ohashi, D. K., (O) 537
Ohkawa, S., (O) 61, 537
Okamura, N., (A) 501
Olivier, H. R., (A) 352, 352
Oltra, A., (O) 428
Onate Cuchet, J. M., (A) 671
Ong, B. H., (A) 652
Onozaki, K., (A) 684
Onwubalili, J. K., (A) 158
Oommen, P. K., (A) 487, 510
Orege, P. A., (A) 346
Orellana, M. A., (A) 515
Orme, I. M., (A) 160, 379, 670
Ortiz, M. C., (A) 357
Osawa, N., (A) 678
Osborne, L. J., (A) 663
Ostler, H. B., (A) 351
Ottenhoff, T. H. M., (A) 655
Ou, J., (A) 514
Owilli, O. M., (A) 363

Pabst, M. J., (A) 669, 670
Padhee, A., (C) 471
Pai, R. R., (A) 131
Paksoy, N., (A) 136, 495
Palmer, G. S., (A) 375
Palmer, L., (A) 158
Pan, Y., *et al.*, (A) 150
Pandey, S. S., (A) 486
Panja, R. K., (A) 488
Pannikar, V., (O) 418
Pao, C.-C., (A) 513
Papezova, E., (A) 511
Papida, S. S., (A) 513
Paramasivan, C. N., (A) 515
Parc, F., (A) 149
Parsad, C. E., (A) 513
Parthasarathy, R., (A) 158
Patarroyo, M. E., (A) 144
Patil, K. M., (A) 374
Patil, S. A., (O) 546
Patki, A. H., (A) 650
Pattyn, S. R., (C) 326, (A) 347, 499, 650
Pavithran, K., (A) 137, 487
Pearson, M., (A) 666
Pellegrino, N. M., (A) 361
Pemajayantha, V., (A) 141, 142, 362, 362, 362, 495
Perani, E., (A) 482
Perani, E. G., (O) 259
Petchclai, B., (O) 255
Pichet, C., (A) 482
Pieters, F. A. J. M., (O) 10, (A) 483
Pinto, M. R. M., (A) 141, 142, 362, 362, 362, 495
Pirmez, C., (A) 493
Pislaryuk, L. D., (A) 156
Plichart, R., (A) 504
Polimeno, G., (A) 361
Ponnighaus, I., (A) 666
Ponnighaus, J. M., (O) 243, 373, 408, (A) 666
Ponomareva, E. I., (A) 651
Popov, A., (A) 512
Porichha, D., (A) 142, (C) 628
Portaels, F., (A) 366, (C) 468, (O) 580, (A) 671
Porterfield, J. S., (A) 135
Porto, J. A., (A) 358
Posner, D. I., (A) 137
Pospelov, L. E., (A) 378, 513, 514
Postaire, E., (A) 500
Potar, M.-C., (A) 379
Potts, R. C., (O) 394
Poulter, L. W., (A) 361
Prabhakar, R., (A) 515
Praputpittaya, K., (A) 362
Prasad, H. V., (A) 487
Prilutsky, A. S., (A) 157
Prohit, S. D., (A) 131

Quismorio, F. P., Jr., (A) 682

Rada, E., (A) 363
Radaszkiewicz, T., (A) 496
Raghavia, M., (A) 483
Raheman, S. F., (A) 671
Rajan, M. A., (A) 487
Rajendran, N., (A) 137, 350
Rajendran, P., (A) 355
Rajwanshi, A., (A) 136
Ramachandran, A., (A) 487
Ramachandran, P., (A) 158
Ramakrishnan, K. R., (A) 485
Ramana, G., (A) 483
Ramanan, R., (A) 133
Ramanathan, U., (O) 1, (A) 132
Ramesh, V., (A) 507
Ramirez, A., (A) 349
Ramirez, C., (A) 144
Ramnarayan, K., (C) 471
Rampen, F. H. J., (A) 136
Ramu, G., (O) 1, 45, (A) 132, 136, 138, 368, 487, 653, 653, 655, 664, 664
Ranadive, S. N., (A) 511
Ranger, S., (A) 354
Rao, C. K., (A) 483
Rao, K. N., (A) 353, 653
Rao, K. S., (A) 487, 510
Rao, M., (A) 159
Rao, S., (A) 490
Rao, V. A., (A) 510
Rastogi, N., (A) 345, 357, 379
Ratledge, C., (A) 664
Ratnakar, C., (C) 464
Ravindranathan, O., (A) 654
Rawlinson, W. D., (A) 495

REA, T. H., (A) 150, 344, (O) 383, (A) 487, 493, 493, 682, 682, 688
REDDI, P. P., (O) 592
REES, A. D. M., (A) 359
REES, R. J. W., (A) 135, (C) 326, (A) 374, 515, 651
REIBNEGGER, G., (A) 142
REICHART, P., (A) 349
REMINGTON, J. S., (A) 515
REMY, J. C., (A) 345
RESNICK, M., (A) 665
RESOAGLI, E. H., (A) 669
REVANKAR, C. R., (A) 131, 133
REYES, O., (O) 302
RICHARD, J., (O) 238
ROBERTS, D. F., (A) 513
ROBERTS, P. O., (A) 660
ROBIN, Y., (A) 649
ROBINSON, E., (A) 650
ROBINSON, P., (A) 496
RODRIGUEZ, O., (A) 372
ROGOWITZ, L., (A) 647
ROJAS-ESPINOSA, O., (A) 363, (O) 428
ROMMEL, A., (A) 351
ROOK, G. A. W., (A) 153, 496
ROTHBARD, J. B., (A) 359
ROUX, J., (A) 504
ROY, B., (O) 574
RUIZ, P., (A) 154
RUNGRUANG, S., (A) 514
RUSSELL, D., (A) 138
RYZEN, E., (A) 487

SADHU, S. K., (A) 488
SADOFF, J. C., (A) 514
SADYKOV, A. S., (A) 514
SAHA, K., (A) 353, (O) 559, (A) 653
SAIKAWA, K., (A) 508
SAINI, A. S., (A) 651
SAITO, H., (A) 502, 514
SAITO, N., (A) 147
SALAFIA, A., (A) 483, (C) 625, 627
SALAZAR-GONZALEZ, J. F., (A) 491
SALGADO, J. L. F., (A) 660
SALGADO-NAVARRO, J., (A) 655
SALGAME, P., (A) 493
SAMB, A., (A) 354
SAMPAIO, E. P., (A) 660
SAMPATAVANICH, S., (O) 255
SAMPOONACHOT, P., (O) 255
SAMUEL, N. M., (A) 347, 363, 364, 483, 484, 496, 502
SAMUEL, S., (A) 347, 363, 483, 484, 496
SANCHEZ, A. L., (E) 66
SANCHEZ, J. L., (A) 489
SANCHEZ, R. M., (O) 291, (A) 501
SANDLER, B. B., (A) 160
SANE, S. B., (A) 509, 654
SANTHA, T., (A) 158
SARASWATHI, G., (A) 490
SARKARI, N. B. S., (A) 653
SARMA, G. R., (A) 158
SARNO, E. N., (A) 358, 660, 660
SAROJINI, P. A., (A) 654
SASAKI, N., (A) 681
SAXENA, A. K., (A) 351
SAYER, J., (A) 353
SCHALLER, K. F., (Ob) 324
SCHAUF, V., (O) 231, (A) 667
SCHECTER, G., (A) 509
SCHECTER, W. P., (A) 509
SCHEINBERG, M., (A) 355
SCHILL, H., (A) 149
SCHLICH, P., (O) 527
SCHMUTZHARD, E., (A) 142
SCHNIRER, F., (A) 500
SCHRIEBER, R. D., (A) 515
SCHRODER, K. H., (A) 501
SCHUBERT, G., (A) 647
SCHULLER-LEVIS, G., (A) 360
SCOGGIN, C. H., (A) 159
SCOLLARD, D. M., (O) 231, (A) 364, 667
SEGAWA, I., (A) 689
SEHGAL, V. N., (A) 142, 353, (O) 559
SELVAGANAPATHY, S., (A) 487
SELVAKUMAR, N., (A) 515
SEN, P. C., (A) 355
SENGUPTA, U., (O) 45, (A) 132, (O) 546, (A) 659
SEOW, C. S., (A) 652
SERIES, H., (A) 159
SERJEANTSON, S. W., (A) 495
SEROVA, L. D., (A) 513
SERSEN, E., (A) 360
SHAABAN, M. A., (A) 153
SHAH, D. H., (A) 356
SHAHAT, F. H., (C) 110
SHAHIDULLAH, M., (A) 131
SHANGLUO SANATORIUM, (A) 134
SHANKAR, P., (A) 360
SHANNON, E. J., (O) 274, (A) 365, (O) 422, (A) 493
SHARANGPANI, R. C., (A) 509
SHARMA, A. K., (A) 351
SHARMA, B. N., (A) 355
SHARMA, R. C., (A) 504
SHARMA, V. D., (A) 144, 146, 146, 664
SHARMA, V. K., (A) 488
SHCHERBINA, L. B., (A) 156
SHEFTEL, G., (A) 658
SHEIKH, N., (A) 159
SHEN, D., *et al.*, (A) 515
SHEN, W., *et al.*, (A) 484
SHENOY, S. D., (C) 471
SHETTY, V. P., (A) 138, 152, 152, (C) 619
SHI, S., *et al.*, (A) 158
SHIVANNAVAR, C. T., (A) 144, 146, 146, 664
SHIVRAJ, L., (O) 546
SHLOSAREK, M., (A) 377
SHOEMAKER, S. A., (A) 159
SHU, H., *et al.*, (A) 508
SHUKLA, V. K., (A) 648
SIBIRNAYA, R. I., (A) 668
SIBLEY, L. D., (A) 143, 660, 683

Siddalinga Swamy, M. K., (C) 464, (A) 487, 510
Siddiqui, Z., (A) 153
Silcox, V. A., (A) 378
Silva, A., (A) 372
Silva, M. T., (O) 580
Sim, H. C., (A) 342
Singapore Tuberculosis Service/British Medical Research Council, (A) 159
Singer, F. R., (A) 487
Singh, A., (A) 654
Singh, B. N., (A) 513
Singh, G., (A) 486, 488, 654
Singh, H., (A) 368, 664
Singh, J., (A) 654
Singh, K. K., (A) 485
Singh, M., (C) 110, (A) 488
Singh, N. B., (A) 134
Singh, V., (A) 651
Singhal, S. K., (A) 650
Sinha, S., (O) 45
Sirumban, P., (O) 223, (A) 351
Sivasubramanian, S., (A) 158
Skinsnes, O. K., (A) 681
Sliney, I. J., (A) 374
Small, C., (E) 66
Smeets, P., (C) 468
Smida, J., (O) 449
Smirnova, E. Y., (A) 161
Smith, T., (A) 667
Smith, W. C. S., (A) 138, 484, 651
Snapper, S. B., (A) 678
Snitinskaya, O. S., (A) 668
Somasundaram, P. R., (A) 158
Sorg, T. B., (A) 375
Sotillo Gago, I., (A) 489
Soudarssanane, M. B., (A) 483
Soudararajan, R., (A) 487
Sreevatsa, (O) 1, (A) 132, 484
Srinivas, C. R., (C) 109, 471, (A) 485
Srinivasa, D. K., (A) 483
Srinivasan, H., (A) 374, (O) 546, (A) 647
Srinivasan, T., (O) 296
Srivastava, G., (A) 142, 353, 486, 652
Srivastava, K., (A) 134
Sroat, D. A., (A) 353
Stackebrandt, E., (O) 449
Stallknecht, D. E., (A) 148
Stanfield, E., (A) 349
Stanford, J. L., (A) 153, 159, 359, 379, 669
Stanley, J. N. A., (A) 648
Steenbergen, G. J., (A) 648
Steiner, M., (A) 159
Steiner, P., (A) 159
Stemberger, H., (A) 496
Steven, L. M., (A) 648
Stewart, C., (A) 493
Stewart, G., (A) 683
Stewart, M., (A) 501
Stingl, P., (A) 353
Stokes, R. W., (A) 160
Storrs, E. E., (A) 515
Stuyvesant, W., (E) 66
Su, L., *et al.*, (A) 496
Suarez Moreno, O., (A) 371
Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) SWG, UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, (A) 347, 368, 484
Subowo, (A) 502
Sugiyama, K., (A) 682
Sullivan, K. H., (A) 375
Sundal, E., (A) 349
Suribabu, C. S. S., (A) 138
Suryawanshi, N., (O) 238
Suzuki, S., (A) 147
Suzuki, Y., (A) 380, 515
Sviridov, B. G., *et al.*, (A) 488
Swanson Beck, J., (O) 296, 394, (A) 651
Sweetser, D., (A) 661

Tada, K., (A) 667
Taieb, A., (A) 351
Takizawa, H., (A) 488
Talhari, A. C., (A) 373
Talhari, S., (A) 373
Talwar, G. P., (O) 592
Tan, T., (A) 652, 654
Tanaka, K. R., (A) 649
Tanji, O., (A) 500, 689
Tao, M., *et al.*, (A) 348
Tapia, F. J., (A) 656
Tarasov, A. S., (A) 160
Tare, S. P., (C) 121
Taylor, M. J., (A) 371
Tayoub, F., (A) 156
Tedla, T., (A) 505
Teferedegne, B., (O) 228
Terencio de las Aguas, J., (A) 349
Thangaraj, H., (O) 401
Thangaraj, I., (O) 401
Thomas, A., (A) 669
Thomas, D. A., (A) 150
Thomas, D. C., (A) 150
Thomas, I. M., (A) 651
Thomas, J. M., (A) 376
Thuan, A. T., (A) 661
Tiwari, V. D., (A) 488, 654
Togni, B., (A) 502
Tokairin, S., (A) 689
Tolson, T. A., (A) 355
Tomioka, H., (A) 502, 514
Torigian, V., (A) 682
Torrecila, M. A. A., (A) 373
Toyama, H., (A) 160
Trach, D. D., (A) 661
Tran Trao, V., (A) 661
Traore, M., (A) 350
Tripathy, S. P., (A) 158
Trowsdale, J., (A) 497

Trujillo, D., (A) 363
Truman, R. W., (A) 148
Trygg, C., (O) 537
Tsukamura, M., (A) 160, 380
Tsutsumi, S., (A) 676
Turak, V., (A) 670
Turk, J. L., (A) 141, 144, (O) 283
Tutakne, M. A., (A) 488, 654

Upleker, M. W., (O) 481
Urteaga-Ballon, O., (A) 365

Vachula, M., (A) 657
Vadiee, A. R., (O) 274, 422
Vaishnavi, C., (A) 503, 503
Valdivia Alvarez, J. A., (A) 377
Valencia, L. B., (A) 344, 489
Van Assendelft, A. H. W., (A) 134
Van Caekenberghe, D. L., (A) 499
Van Der Meyden, C. H., (A) 650
van Furth, R., (O) 552
van Rens, M. M., (A) 140
van Schooten, W., (A) 140
Vanaclocha Sebastian, F., (A) 671
Vanderveken, M., (A) 149
Vanlinden, F., (A) 154
Vasudeva, N. D., (A) 671
Vatter, A. E., (A) 155
Vasquez-Botet, M., (A) 489
Vega, R., (O) 428
Vellut, C. M., (A) 149
Vendeaud-Busquet, M., (A) 351
Venkatesan, K., (A) 368, 664
Venugopal, N., (A) 485
Verghese, S., (A) 144, (O) 283
Verhoeven, J. R., (A) 499
Vieira, L. M. M., (A) 660, 660
Vignale, R. A., (A) 670
Vignolly, B., (A) 351
Vladimirsky, M. A., (A) 512
Volc-Platzer, B., (A) 496

Wachter, H., (A) 142
Wade, S., (A) 657
Wagener, D. K., (A) 667
Wagner, S., (A) 671
Wallach, D., (A) 360
Wallner, S. J., (A) 368
Walsh, G. P., (O) 61, (N) 124, (A) 147, 369, (O) 443, (A) 511, (O) 537, (A) 667
Wang, H., (A) 371
Wang, L., *et al.*, (A) 508
Wang, Q., (A) 354
Wang, Y., (A) 354
Wang, Y. M., (A) 379
Wang, Z., *et al.*, (A) 348
Watson, J. D., (A) 490, 657
Wear, D. J., (A) 511
Weaver, C. W., (A) 657
Weiner, M. H., (A) 376
Weiss, E., (A) 656
Welbury, R. R., (A) 349
Wentzel, J., (A) 513
Wheeler, P. R., (A) 369, 369, 500, 664
Wiedermann, G., (A) 496
Wiker, H. G., (A) 144
Wilkinson, D., (A) 497
Williams, W., (A) 658
Wolf, R. H., (O) 61, (A) 147, 369, (O) 443, (A) 667
Woonink, F., (O) 10, (A) 483
Wright, E. P., (A) 661
Wu, Q., (A) 497
Wu, Q., *et al.*, (A) 497
Wu, Q.-X., (O) 50, (A) 491
Wu, S.-Y., (A) 513

Xiao, J., *et al.*, (A) 150
Xiong, D., *et al.*, (A) 373
Xu, S., *et al.*, (A) 498

Yakovleva, T. A., (A) 160
Yamada, T., (A) 380
Yan, L., (A) 374
Yande, R., (A) 136
Ye, G.-Y. (O) 50, (N) 637, 637
Ye. S., *et al.*, (A) 515
Yebra Sotillo, I., (A) 489
Yin, S., (A) 508
Yoder, L. J., (A) 355, (B) 644
Yogi, Y., (A) 503, 504, 686
Young, D. B., (A) 157, 359, 367, 661, 661, 665
Young, J. F., (A) 514
Young, M. R., (A) 375
Young, R. A., (A) 359, 661, 687
Young, S. M. M., (A) 493
Yurin, B. L., (A) 161

Zarco Olivo, C., (A) 671
Zeis, B. M., (A) 348, 348, 485
Zhang, G., *et al.*, (A) 152, 510
Zhang, X., (A) 510
Zhao, Z., *et al.*, (A) 485
Zheng, T., *et al.*, (A) 153
Zhou, D., *et al.*, (A) 489, 509
Zhu, W., *et al.*, (A) 662
Zimmerman, L. E., (O) 443
Zuidema, J., (O) 10, (A) 483
Zumla, A., (A) 658

SUBJECT INDEX

Original articles are indicated by (O), editorials (E), correspondence (C), new and notes (N), obituaries (Ob), reprinted articles (R), abstracts (A), and book reviews (B).

Absenteeism,
Absenteeism in leprosy patients in a rural area in Tamil Nadu. Raghavia, M., *et al.* ...(A) 483

Acid, fatty,
Analysis of mycolic acid cleavage products and cellular fatty acids of *Mycobacterium* species by capillary gas chromatography. Lambert, M. A., *et al.* ....(A) 378

Acid-fast,
Demonstration of acid-fast bacilli in skin biopsies from indeterminate leprosy cases, Alvarez-Mendoza, A., *et al.* ....(A) 655
[Fluorescent microscopy for the study of acid-fast bacilli in cutaneous tuberculosis.] Lazarova, A., *et al.* ....(A) 512
In vitro cultivation of an acid-fast nocardio-form chemoautotroph from mouse foot-pad-passaged strain of leprosy bacillus. Chakrabarty, A. N. and Dastidar, S. G. .....(A) 366

Acquired immunodeficiency syndrome (AIDS),
[AIDS and atypical mycobacteria.] Portaels, F. ....(A) 671
Immunological approach for control of *M. avium-intracellulare* infections in AIDS—an hypothesis. Deo, M. G. ....(E) 455
Leprosy in the acquired immunodeficiency syndrome. Lamfers, E. J. P., *et al.* .....(A) 136

Adenosine triphosphate (ATP),
In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index, and FDA-EB fluorescent staining in *M. leprae.* Katoch, V. M., *et al.* ....(A) 664
Metabolic studies on mycobacteria. V. A preliminary report on the ATP synthesis by mycobacteria including *M. leprae* by using different substrates. Katoch, V. M., *et al.* ....(A) 146

Africa,
All-Africa Leprosy and Rehabilitation Centre (ALERT) training courses for 1988. ....(N) 336
[Titrations of anti-BCG antibodies in healthy Africans and Africans with leprosy.] Agius, G., *et al.* ....(A) 354

Allergy,
Allergy and immunity in leprosy: are these concepts becoming obsolete? Corcos, M. G. ....(C) 106

American Samoa,
Hand deformity and sensory loss due to Hansen's disease in American Samoa. Brunel, W., *et al.* ....(A) 509

Anemia,
Case report: dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait. Lachant, N. A. and Tanaka, K. R. .....(A) 649

Ansamycin,
Comparison of *in vitro* antimycobacterial activities of ansamycin and rifampin. Tsukamura, M., *et al.* ....(A) 160
Two groups of *M. avium* complex strains determined according to the susceptibility to rifampicin and ansamycin. Tsukamura, M. .....(A) 380

Antibody(ies),
A patient with lepromatous leprosy and anticytoskeletal antibodies. Frey, F. L. P., *et al.* ....(A) 656

Analysis of the antigenic profile of *M. leprae*: cross-reactive and unique specificities of human and rabbit antibodies. Ehrenberg, J. P. and Gebre, N. ..... (A) 356
Antibodies to HIV-1 in sera from patients with mycobacterial infections. ShivRaj, L., *et al.* ..... (O) 546
Association of IgG and IgM antibodies to phenolic glycolipid-I antigen of *M. leprae* with disease parameters in multibacillary leprosy patients. Lyons, N. F., *et al.* ..... (A) 493
Comparison of synthetic antigens for detecting antibodies to phenolic glycolipid I in patients with leprosy and their household contacts. Chanteau, S., *et al.* ..... (A) 504
[Dependence of levels of antituberculous antibodies on HLA-DR genotype of patients suffering from tuberculosis.] Litvinov, V. I., *et al.* ..... (A) 378
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
[Enzyme immunoassay for specific antibodies in prophylactic examination of persons with posttuberculous lesions.] Markov, A. G., *et al.* ..... (A) 512
[Evaluation of blocking agents for ELISA in detection of leprosy antibody.] Wu, Q., *et al.* ..... (A) 497
Evaluation of inexpensive blocking agents for ELISA in the detection of antibody in leprosy. Douglas, J. T., *et al.* ..... (A) 491
In vitro synthesis of antimycobacterial antibodies with different specificities in various tissues of leprosy patients. Lai A Fat, R. F. M., *et al.* ..... (O) 552
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157
Serum antiphospholipid antibodies in leprosy. Quismorio, F. P., Jr. and Rea, T. H. ... (A) 682
The effects of chemotherapy on antibody levels in lepromatous patients. Douglas, J. T., *et al.* ..... (A) 648
[Titrations of anti-BCG antibodies in healthy Africans and Africans with leprosy.] Agius, G., *et al.* ..... (A) 354
Use of anti-*M. leprae* phenolic glycolipid-I antibody detection for early diagnosis and prognosis of leprosy. Agis, F., *et al.* ..... (O) 527
Viral challenge in leprosy: viraemia, interferon, and specific antibody production. Gelber, R. H., *et al.* ..... (A) 135

Antibodies, monoclonal,
[Characterization of mononuclear phagocytes in leprosy skin lesions: a monoclonal study.] Sarno, E. N., *et al.* ..... (A) 660
Human monoclonal antibodies to phenolic glycolipid-I derived from patients with leprosy, and production of specific anti-idiotypes. Locniskar, *et al.* ..... (A) 658
Immunopurification of radiolabeled antigens of *M. leprae* and *M. bovis* (bacillus Calmette-Guérin) with monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 139
Immunoreactivity of a 70 kD protein purified from *M. bovis* bacillus Calmette-Guérin by monoclonal antibody affinity chromatography. Britton, W. J., *et al.* ..... (A) 153
Monoclonal antibodies distinguish macrophages and epithelioid cells in sarcoidosis and leprosy. Munro, C. S., *et al.* ..... (A) 361
Most *M. leprae* carbohydrate-reactive monoclonal antibodies are directed by lipoarabinomannan. Gaylord, H., *et al.* ..... (A) 367
[Preparation of monoclonal antibodies to mycobacterial antigens.] Yurin, B. L. and Smirnova, E. Y. ..... (A) 161
Study of idiotypes expressed by monoclonal antibodies to the 35 kD and 12 kD antigens of *M. leprae*. Praputpittaya, K. and Ivanyi, J. ..... (A) 362

Antigen(s),
A passive hemagglutination test for leprosy using a synthetic disaccharide antigen. Petchclai, B., *et al.* ..... (O) 255
Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer; definition of DR2β gene products and antigen presentation to T cell clones from leprosy patients. Wilkinson, D., *et al.* ..... (A) 497
Analysis of the antigenic profile of *M. leprae*: cross-reactive and unique specificities of human and rabbit antibodies. Ehrenberg, J. P. and Gebre, N. ..... (A) 356
Antigenic proteins of *M. leprae*; complete sequence of the gene for the 18-kDa protein. Booth, R. J., *et al.* ..... (A) 490

[Antigens HLA and diverse forms and variants of pulmonary tuberculosis.] Sadykov, A. S., *et al.* ..... (A) 514
Antigens of *M. leprae* identified by immunoprecipitation with sera from leprosy and tuberculosis patients. Britton, W. J., *et al.* ..... (A) 491
Association of IgG and IgM antibodies to phenolic glycolipid-I antigen of *M. leprae* with disease parameters in multibacillary leprosy patients. Lyons, N. F., *et al.* ..... (A) 493
Cellular, humoral, and gamma interferon responses to *M. leprae* and BCG antigens in healthy individuals exposed to leprosy. Converse, P. J., *et al.* ..... (A) 656
Comparison of synthetic antigens for detecting antibodies to phenolic glycolipid I in patients with leprosy and their household contacts. Chanteau, S., *et al.* ..... (A) 504
Demonstration of *M. leprae* antigen in nerves of tuberculoid leprosy. Barros, U., *et al.* ..... (A) 138
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
Enzyme-linked immunosorbent assay using *M. tuberculosis* antigen 5 for the diagnosis of pulmonary tuberculosis in China. Ma, Y., *et al.* ..... (A) 379
Evaluation of a dual-antigen ELISA test for the serodiagnosis of tuberculosis. Raheman, S. F., *et al.* ..... (A) 671
Gamma interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Rada, E., *et al.* ..... (A) 363
Gamma interferon, but not *M. leprae,* induces major histocompatibility class II antigens on cultured rat Schwann cells. Samuel, N. M., *et al.* ..... (A) 364
Genetic control of murine T cell proliferative responses to *M. leprae.* V. Evidence for crossreactivity between host antigens and *M. leprae.* Harris, D. P., *et al.* ..... (A) 657
Haptenic oligosaccharides in antigenic variants of mycobacterial C-mycosides antagonize lipid receptor activity for mycobacteriophage D4 by masking a methylated rhamnose. Dhariwal, K. R., *et al.* ..... (A) 155
Heterologous expression of the 65-kilodalton antigen of *M. leprae* and murine T-cell responses to the gene product. Lamb, F. I., *et al.* ..... (A) 492
Human T cell proliferative responses to particulate microbial antigens are supported by populations enriched in dendritic cells. Mittal, A. and Nath, I. ..... (A) 493
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ..... (O) 265
Immunological effects of lepromin testing in Sri Lankan population groups. II. Effect of reactivity to a soluble protein antigen of *M. leprae.* Pinto, M. R. M., *et al.* ..... (A) 362
Immunological responsiveness to *M. leprae* and BCG antigens in 98 leprosy patients and their household contacts. Sarno, E. N., *et al.* ..... (A) 660
Immunopurification of radiolabeled antigens of *M. leprae* and *M. bovis* (bacillus Calmette-Guérin) with monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 139
Infection with live mycobacteria inhibits *in vitro* detection of Ia antigen on macrophages. Mshana, R. N., *et al.* ..... (A) 494
Isolation and characterization of large-molecular-size and hydrophobic protein antigens from the cell walls of *M. leprae.* Hunter, S. W., *et al.* ..... (A) 683
Isolation and characterization of the 36K antigen of *M. leprae.* de Wit, M. Y. L., *et al.* ..... (A) 140
Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Gaylord, H. and Brennan, P. J. ..... (A) 357
Localization and retention of mycobacterial antigen in lymph nodes of leprosy patients. Barros, U., *et al.* ..... (A) 354
Mapping T cell epitopes using recombinant antigens and synthetic peptides. Lamb, J. R., *et al.* ..... (A) 359
Mycobacterial antigen detection of immunohistochemistry in pulmonary tuberculosis. Humphrey, D. M. and Weiner, M. H. ..... (A) 376
Mycobacterial carbohydrate antigens for serological testing of patients with leprosy. Levis, W. R., *et al.* ..... (A) 360
Mycobacterial genes and antigens. Young, R. A. ..... (A) 687
Partial characterization of antigens from *M. leprae* evoking IgG and IgM antibodies in armadillos. Vadiee, A. R., *et al.* ..... (O) 274
Preparation and properties of antigen 60 from *M. bovis* BCG. Cocito, C. and Vanlinden, F. ..... (A) 154

[Preparation of monoclonal antibodies to mycobacterial antigens.] Yurin, B. L. and Smirnova, E. Y. ..... (A) 161
Purification and characterization of a 36 kDa antigen of *M. leprae.* de Wit, M. Y. L. and Klatser, P. R. ..... (A) 663
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157
Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Fine, P. E. M., *et al.* ..(O) 243
Serologic responses of *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ..... (O) 537
[Serological activity of semi-synthetic polysaccharide antigens of *M. leprae.*] Li, F., *et al.* ..... (A) 140
Soluble antigen of *M. leprae* coupled with liposomes elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae.* I. Reactivity to lepromin A. Pinto, M. R. M., *et al.* ..... (A) 141
... II. Reactivity to a soluble protein antigen. Pinto, M. R. M., *et al.* ..... (A) 362
... III. The post-lepromin test scar in healthy populations in Sri Lanka. Pinto, M. R. M., *et al.* ..... (A) 362
Studies on the antigenic specificity of *M. leprae.* I. Isoelectric and chromatofocusing separation. Ibegbu, C., *et al.* ..... (A) 145
... II. Immunological characterization. Mandock, O., *et al.* ..... (A) 360
... III. Further studies on immunological characterization. Kale, V., *et al.* ..... (A) 358
Study of idiotypes expressed by monoclonal antibodies to the 35 kD and 12 kD antigens of *M. leprae.* Praputpittaya, K. and Ivanyi, J. ..... (A) 362
[Study on relation between distribution of locus DR antigens of HLA system and tuberculosis in various populations.] Pospelov, L. E., *et al.* ..... (A) 513
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae.* Pemajayantha, V., *et al.* ..... (A) 495
Three types of response to mycobacterial antigens. Lockwood, D. N. J., *et al.* ..... (A) 669
Twenty years observation of lepromin reaction (Mitsuda antigen) in leprosy patients. Takizawa, H. and Kobayashi, S. ..... (A) 488

Armadillo(s),

Analysis of deoxyribonucleic acids from armadillo-derived mycobacteria. De Kesel, M., *et al.* ..... (A) 366
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., *et al.* ..... (A) 150
Armadillo IgG and IgM antibody responses to phenolic glycolipid-I during experimental infection with *M. leprae.* Vadiee, A. R., *et al.* ..... (O) 422
Corneal changes in nine-banded armadillos with leprosy. Malaty, R. and Togni, B. .... (A) 502
In vitro cultivation of a chemoautotrophic nocardioform bacterium from armadillo tissue infected with leprosy bacillus. Dastidar, S. G., *et al.* ..... (A) 366
[Langerhans' cells in the armadillo.] Gimenez, M. F., *et al.* ..... (A) 669
Lepromatous meningoencephalitis in the nine-banded armadillo (*Dasypus novemcinctus*). Job, C. K., *et al.* ..... (O) 291
Leprosy in armadillos (*Dasypus novemcinctus*) from Texas. Clark, K. A., *et al.* ..... (A) 371
Multiplication of armadillo-derived *M. leprae* in murine dissociated Schwann cell cultures. Antia, N. H., *et al.* ..... (C) 632
Our experience with breeding of nine-banded armadillos (*Dasypus novemcinctus*) in captivity. Job, C. K., *et al.* ..... (A) 501
Partial characterization of antigens from *M. leprae* evoking IgG and IgM antibodies in armadillos. Vadiee, A. R., *et al.* ..... (O) 274
Partial nucleotide sequences of 16S ribosomal RNA isolated from armadillo-grown *M. leprae.* Estrada-G., I. C. E., *et al.* ..... (A) 663
[Phagocytic syndrome in lepromatous leprosy patients and in armadillos infected with Hansen's bacillus.] Urteaga-Ballon, O. ..... (A) 365
Superdelayed parturition in armadillos: a new mammalian survival strategy. Storrs, E. E., *et al.* ..... (A) 515

Surveillance for naturally acquired leprosy in a nine-banded armadillo population. Stallknecht, D. E., et al. ..... (A) 148

Asia,
2nd Asian Dermatological Congress. ..... (N) 638
WHO Regional Committee for South-East Asia Report. ..... (N) 339

Assay(s), (see also ELISA),
[Acid-base and gas assay in the blood of leprosy cases.] He, H. ..... (A) 350
[Assay of foot and foot pad technique for the multiplication of *M. leprae* in different mouse lines existing in Cuba.] Suarez Moreno, O., *et al.* ..... (A) 371
Assay of testosterone, FSH and LH in serum and spermogram in leprosy patients. Singh, J., *et al.* ..... (A) 654
Metabolic studies on mycobacteria. IV. Assay of isocitrate lyase and malate synthase activity in *M. leprae.* Bharadwaj, V. P., *et al.* ..... (A) 144
Microbiological assay versus spectrophotometry for determination of rifampicin in urine. George, J., *et al.* ..... (A) 649

Australia,
The serological response to the phenolic glycolipid of *M. leprae* in Australian and Nepali leprosy patients. Britton, W. J., *et al.* ..... (A) 490

B663 (see Clofazimine)

Bacilli,
Auramine staining in detecting small number of bacilli in skin smears. Bhatia, V. N., *et al.* ..... (A) 662
Cellular peripheral parts of the "so-called" leprosy bacilli in comparison with avian tuberculous mycobacterium and other microorganisms *in vitro* and/or *in vivo.* Hirata, T. and Chyugun, M. ..... (A) 681
Demonstration of acid-fast bacilli in skin biopsies from indeterminate leprosy cases. Alvarez-Mendoza, A., *et al.* ..... (A) 655
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
Endothelial cell bacillation in lepromatous leprosy: a case report. Mukherjee, A. and Meyers, W. M. ..... (A) 361
Excretion of viable tubercle bacilli by *Blatta orientalis* (the oriental cockroach) following ingestion of heat-fixed sputum smears: a laboratory investigation. Allen, B. W. ..... (A) 365
Experimental inoculation with leprosy bacillus in various hybrid mice (continued): results of CD-1 (ICR) hybrid nude mice. Nakamura, K. and Yogi, Y. ..... (A) 686
[Fluorescent microscopy for the study of acid-fast bacilli in cutaneous tuberculosis.] Lazarova, A., *et al.* ..... (A) 512
In vitro cultivation of a chemoautotrophic nocardioform bacterium from armadillo tissue infected with leprosy bacillus. Dastidar, S. G., *et al.* ..... (A) 366
In vitro cultivation of an acid-fast nocardio-form chemoautotroph from mouse foot-pad-passaged strain of leprosy bacillus. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 366
[Joint experience with phage typing and identification of tubercle bacilli isolated in the USSR and CSSR.] Khomenko, A. G., *et al.* ..... (A) 377
Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Gaylord, H. and Brennan, P. J. ..... (A) 357
[Phagocytic syndrome in lepromatous leprosy patients and in armadillos infected with Hansen's bacillus.] Urteaga-Ballon, O. ..... (A) 365
[Use of biseptol for preventing rifampin resistance development in tubercle bacilli.] Dolzhansky, V. M. ..... (A) 668

Bacterial index (BI),
[Effect of MDT regimen on bacillus index for 2 years in 317 multibacillary leprosy patients.] Tao, M., *et al.* ..... (A) 348
Skin smears and bacterial index in multiple drug therapy. Agrawal, M. N. and Porichha, D. ..... (C) 628
Skin smears and the bacterial index (BI) in multiple drug therapy leprosy control programs: an unsatisfactory and potentially hazardous state of affairs. Georgiev, G. D. and McDougall, A. C. ..... (C) 101

Bacteriology,
Cat-scratch disease; isolation and culture of the bacterial agent. English, C. K. *et al.* ...(A) 511
Clinical, bacteriological and histopathological assessment of multibacillary leprosy cases after 1 and 2 years' multidrug therapy; preliminary communication. McNair, A. N., *et al.* ...(A) 133
[Liquid chromatography contribution towards new bacteriological analysis.] Postaire, E., *et al.* ...(A) 500
Renal involvement in *M. leprae* infected mice; histopathological, bacteriological and immunofluorescence study. Vaishnavi, C., *et al.* ...(A) 503

BCG (bacille Calmette-Guérin),
BCG vaccination in leprosy. Noordeen, S. K. ...(A) 361
Cellular, humoral, and gamma interferon responses to *M. leprae* and BCG antigens in healthy individuals exposed to leprosy. Converse, P. J., *et al.* ...(A) 656
Evidence for a biphasic memory T-cell response to high dose BCG vaccination in mice. Orme, I. M. ...(A) 670
Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved *M. leprae* and live BCG. Meyers, W. M., *et al.* ...(O) 302
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; an *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ...(A) 657
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ...(O) 265
Immunological responsiveness to *M. leprae* and BCG antigens in 98 leprosy patients and their household contacts. Sarno, E. N., *et al.* ...(A) 660
Immunopurification of radiolabeled antigens of *M. leprae* and *M. bovis* (bacillus Calmette-Guérin) with monoclonal antibodies. Britton, W. J., *et al.* ...(A) 139
Immunoreactivity of a 70 kD protein purified from *M. bovis* bacillus Calmette-Guérin by monoclonal antibody affinity chromatography. Britton, W. J., *et al.* ...(A) 153
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ...(A) 656
M. bovis BCG-induced protection against cutaneous and systemic *Leishmania major* infections in mice. Fortier, A. H., *et al.* ...(A) 668
MPB59, a widely crossreacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ...(A) 144
Preparation and properties of antigen 60 from *M. bovis* BCG. Cocito, C. and Vanlinden, F. ...(A) 154
Protective effect of BCG in Ahmednagar, India. Stanford, J. L., *et al.* ...(A) 159
Recombinant interleukin-2 limits the replication of *M. lepraemurium* and *M. bovis* BCG in mice. Jeevan, A. and Asherson, G. L. ...(A) 492
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ...(A) 157
The dynamics of infection following BCG and *M. tuberculosis* challenge in T-cell-deficient mice. Orme, I. M. ...(A) 379
The Ity/Lsh/Bcg gene significantly affects mouse resistance to *M. lepraemurium.* Brown, I. N. and Glynn, A. A. ...(A) 370
The lack of therapeutic effects in mice of the combined gamma-irradiated *M. leprae* and viable BCG against *M. leprae* infection. Saito, H., *et al.* ...(A) 502
[Titrations of anti-BCG antibodies in healthy Africans and Africans with leprosy.] Agius, G., *et al.* ...(A) 354
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ...(A) 153
Vaccination of borderline tuberculoid leprosy patients with BCG plus killed *M. leprae.* Samuel, N. M., *et al.* ...(A) 496

Belgium,
Dr. Albert Dubois Quinquennial Prize for Tropical Pathology. ...(N) 473

Beta-glucuronidase,
In vitro binding of beta-glucuronidase to a mycobacterium HI-75. Matsuo, E., *et al.* ...(A) 681

Biopsy,
[A comparison of skin scraping and skin biopsy in mouse foot experiments with *M. leprae.*] Wang, H. ..... (A) 371
Demonstration of acid-fast bacilli in skin biopsies from indeterminate leprosy cases. Alvarez-Mendoza, A., *et al.* ..... (A) 655
Detection of mycobacterial lipids in skin biopsies from leprosy patients. Venkatsean, K., *et al.* ..... (A) 368
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (O) 56
Effect of shipment of skin-biopsy specimens to a distant laboratory on viability of *M. leprae.* Baras, M. and Levy, L. ..... (C) 115
Unmyelinated nerve fibres in leprosy. A qualitative and quantitative study of sural nerve biopsies in 2 cases of lepromatous leprosy. Gibbels, E., *et al.* ..... (A) 656

Blood,
[Acid-base and gas assay in the blood of leprosy cases.] He, H. ..... (A) 350
Blood flow velocity in cutaneous lesions of leprosy. Agusni, I., *et al.* ..... (O) 394

Bone,
Bone loss in limbs with decreased or absent sensation: ten year follow-up of the hands in leprosy. MacMoran, J. W. and Brand, P. W. ..... (A) 374
Erythema nodosum leprosum reaction of leprosy causing the double stripe sign on bone scan; case report. Datz, F. L. ..... (A) 134
Facies leprosa: resorption of maxillary anterior alveolar bone and the anterior nasal spine in patients with lepromatous leprosy in Mali. Marks, S. C., Jr. and Grossetete, G. ..... (O) 21

Book reviews,
A Trial to Compare Serodiagnostic Test for Leprosy by the International Cooperative Team for Evaluating Serological Tests in Leprosy. ..... (B) 644
Annual Report of the Director General 1985–86, Indian Council of Medical Research. ..... (B) 127
Clinical Leprosy (Illustrated Second Edition) by V. N. Sehgal. Yoder, L. J. ..... (B) 644
Dermatology in Five Continents; Proceedings of the XVII World Congress of Dermatology. C. E. Orfanos, R. Stadler and H. Gollnick, eds. ..... (B) 479
Early Surgery for Hansen's Neuritis; an Illustrated Manual by S. Renzo and C. Panciera. Enna, C. D. ..... (B) 129
Laboratory Aspects of Leprosy; a Technical Manual for Smear Personnel by B. Devasundaram and C. J. G. Chacko. Hastings, R. C. ..... (B) 479
Leprosy; Basic Information and Management by A. C. McDougall and S. J. Yawalkar. Hastings, R. C. ..... (B) 128
Leprosy for Medical Practitioners and Paramedical Workers by R. H. Thangaraj and S. J. Yawalkar. Hastings, R. C. ..... (B) 129
Manual of the National Leprosy Tuberculosis Programme for the Clinical Officer Tuberculosis and Leprosy. ..... (B) 128
Mycobacteria and Human Disease by J. M. Grange. ..... (B) 479
Proceedings of the Indo–U.K. Symposium on Leprosy, Agra, April 7–10, 1986. Hastings, R. C. ..... (B) 129
Studies on Leprosy by Bombay Leprosy Project 1976–1986. Hastings, R. C. ..... (B) 645

Borderline leprosy,
A borderline leprosy lesion on the palate: a case report. Mishra, B., *et al.* ..... (A) 486
A comparative study of testicular involvement in lepromatous and borderline lepromatous leprosy. Rea, T. H. ..... (O) 383
A follow up study of borderline tuberculoid leprosy under sulphone monotherapy. Ramu, G. and Desikan, K. V. ..... (A) 653
A large hypoanesthetic patch in borderline tuberculoid leprosy. Mohamed, K. N. ..... (C) 625
Comedones induced by coconut oil in a borderline tuberculoid lesion. Srinivas, C. R., *et al.* ..... (C) 471
LDH profile in an unusual case of borderline leprosy in reaction associated with portal hypertension. Prasad, H. V., *et al.* ..... (A) 487
T and B cells in borderline (BB) leprosy. Biggins, T., *et al.* ..... (A) 655

Type 1 (reversal) lepra reaction in borderline leprosy with unusual clinical presentation—a case report. Kar, H. K., *et al.* ..... (A) 351
Vaccination of borderline tuberculoid leprosy patients with BCG plus killed *M. leprae.* Samuel, N. M., *et al.* ..... (A) 496

Brazil,
A study of leprosy and other skin diseases in school children in the state of Amazonas, Brazil. Talhari, S., *et al.* ..... (A) 373
I Congress of the Association of Former Students of Professor Azulay. ..... (N) 637
VI World Congress of Dermatology ..... (N) 335
[The epidemiology and control of leprosy in Brazil.] Goncalves, A. ..... (A) 372

Caribbean,
Detection of major genes for susceptibility to leprosy and its subtypes in a Caribbean island: Desirade Island. Abel, L. and Demenais, F. ..... (A) 665

Cell(s), (see also specific cells),
A component of *M. leprae* as immunomodulating agent for immune deficient cells of leprosy patients. Robinson, P. and Mahadevan, P. R. ..... (A) 496
[Cellular anergy in lepromatous leprosy.] Rojas-Espinosa, O. ..... (A) 363
Cellular peripheral parts of the "so-called" leprosy bacilli in comparison with avian tuberculous mycobacterium and other microorganisms *in vitro* and/or *in vivo.* Hirata, T. and Chyugun, M. ..... (A) 681
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Kaplan, G., *et al.* ..... (A) 358
Cellular, humoral, and gamma interferon responses to *M. leprae* and BCG antigens in healthy individuals exposed to leprosy. Converse, P. J., *et al.* ..... (A) 656
Demonstration that the galactosyl and arabinosyl residues in the cell-wall arabinogalactan of *M. leprae* and *M. tuberculosis* are furanoid. McNeil, M., *et al.* ..... (A) 368
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kaplan, G., *et al.* ..... (A) 658
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; an *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ..... (A) 657
Immunological significance of *M. leprae* cell walls. Mehra, V., *et al.* ..... (A) 682
Immunological significance of *M. leprae* cell walls. Melancon-Kaplan, J., *et al.* ..... (A) 493
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ..... (A) 141
Isolation and characterization of large-molecular-size and hydrophobic protein antigens from the cell walls of *M. leprae.* Hunter, S. W., *et al.* ..... (A) 683
Mast cells in histoid lepromatous lesions. Kumar, R. ..... (A) 492
[Study on cell culture of *M. leprae.* (II). Effect of temperature on viability of *M. lepraemurium.*] Ye, S., *et al.* ..... (A) 515

Cells, B,
T and B cells in borderline (BB) leprosy. Biggins, T., *et al.* ..... (A) 655

Cells, endothelial,
Alkaline phosphatase activity in peripheral nerves and endothelial cell cultures in leprosy. Mehta, L., *et al.* ..... (A) 140
Endothelial cell bacillation in lepromatous leprosy: a case report. Mukherjee, A. and Myers, W. M. ..... (A) 361

Cells, epithelioid,
Epithelioid and polygonal cells in histoid leprosy. Porichha, D. and Bhatia, V. N. ..... (A) 142
Epithelioid cell granuloma induction in the guinea pig by haptenated *M. leprae.* Verghese, S., *et al.* ..... (A) 144
Monoclonal antibodies distinguish macrophages and epithelioid cells in sarcoidosis and leprosy. Munro, C. S., *et al.* ..... (A) 361

Cells, Langerhans',
CD1 positive epidermal Langerhans cells in indeterminate leprosy. Narayanan, R. B., *et al.* ..... (A) 660
[Langerhans' cells in the armadillo.] Gimenez, M. F., *et al.* ..... (A) 669

Cells, Schwann,
Gamma interferon, but not *M. leprae,* induces major histocompatibility class II antigens on cultured rat Schwann cells. Samuel, N. M., *et al.* ..... (A) 364
Multiplication of armadillo-derived *M. leprae* in murine dissociated Schwann cell cultures. Antia, N. H., *et al.* ..... (C) 632
Ultrastructure of human foetal Schwann cells in tissue culture infected with *M. leprae.* Samuel, N. M., *et al.* ..... (A) 502

Cells, T,
A novel approach in the identification of T-cell epitopes in *M. tuberculosis* using human T-lymphocyte clones. Lamb, J. R. and Young, D. B. ..... (A) 157
Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer; definition of DR2β gene products an antigen presentation to T cell clones from leprosy patients. Wilkinson, D., *et al.* ..... (A) 497
Evidence for a biphasic memory T-cell response to high dose BCG vaccination in mice. Orme, I. M. ..... (A) 670
Genetic control of murine T cell proliferative responses to *M. leprae.* V. Evidence for crossreactivity between host antigens and *M. leprae.* Harris, D. P., *et al.* ..... (A) 657
Heterologous expression of the 65-kilodalton antigen of *M. leprae* and murine T-cell responses to the gene product. Lamb, F. I., *et al.* ..... (A) 492
Human T cell proliferative responses to particulate microbial antigens are supported by populations enriched in dendritic cells. Mittal, A. and Nath, I. ..... (A) 493
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ..... (O) 265
M. leprae-reactive T-cell clones isolated from polar lepromatous and tuberculoid leprosy patients. Launois, P., *et al.* ..... (A) 360
Mapping T cell epitopes using recombinant antigens and synthetic peptides. Lamb, J. R., *et al.* ..... (A) 359
Regulatory interactions between macrophages and *M. lepraemurium*-specific T-cell activation. Brett, S. J. ..... (A) 370
T and B cells in borderline (BB) leprosy. Biggins, T., *et al.* ..... (A) 655
The dynamics of infection following BCG and *M. tuberculosis* challenge in T-cell-deficient mice. Orme, I. M. ..... (A) 379

Cell-mediated immunity (CMI),
Cell-mediated immunity in tuberculoid leprosy—a study of T lymphocyte population by "E" rosette technique. Behra, R. N., *et al.* ..... (A) 355
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kaplan, G., *et al.* ..... (A) 658
Epidermal changes in reactional leprosy: keratinocyte Ia expression as an indicator of cell-mediated immune responses. Thangaraj, H., *et al.* ..... (O) 401
Evaluation of urinary neopterin—a marker of cell-mediated immune response—in patients with leprosy. Schmutzhard, E., *et al.* ..... (A) 142
Evidence of cell-mediated immune contrasuppression in lepromatous leprosy: modulation of a putative T contrasuppressor cell subset. Gonzalez-Amaro, R., *et al.* ..... (A) 491
Role of lymphokines in the regulation of cell-mediated immunity in leprosy. Kaplan, G. and Cohn, Z. A. ..... (A) 685

Chemotherapy, (see also **Therapy**),
Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan: results 18 months after completion of treatment (Lahore Tuberculosis Study). Aziz, A., *et al.* ..... (A) 510
Combined chemotherapy of multibacillary leprosy patients. Samuel, N. M., *et al.* ..... (A) 483
[Dynamics of the excretion of bacterial and ultramicro forms of *M. tuberculosis* by patients with pulmonary tuberculosis in the process of chemotherapy.] Golyshevskaya, V. I., *et al.* ..... (A) 512
Immunostimulation with an allied mycobacterium and DDS chemotherapy in lepromatous leprosy. Chaudhury, S., *et al.* ..... (A) 356
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Dickinson, J. M. ..... (A) 156

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Dickinson, J. M. ..... (A) 156
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore TB Service/BMRC ... (A) 159
[Quadruple twice monthly supervised chemotherapy for 72 paucibacillary patients in French Guyana.] Jamet, P. and Robin, Y. ..... (A) 649
[Study of the pathologic changes of posterior tibial nerve in arrested leprosy patients: to compare the combined chemotherapy with DDS treatment.] Zhu, W., *et al.* ..... (A) 662
The effects of chemotherapy on antibody levels in lepromatous patients. Douglas, J. T., *et al.* ..... (A) 648
The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Cree, I. A., *et al.* ..... (A) 651
The variability of *M. tuberculosis* in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Khomenko, A. G. ..... (A) 377
Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy. Castells, A., *et al.* ..... (A) 349
Treatment regimens in paucibacillary leprosy. Jopling, W. H. ..... (C) 104

Children,
A study of leprosy and other skin diseases in school children in the state of Amazonas, Brazil. Talhari, S., *et al.* ..... (A) 373
[Clinical analysis of 70 cases of leprosy in children.] Chen, L., *et al.* ..... (A) 651
[Informative value of liquid-crystalline thermography of reaction of Mantoux test in estimation of tuberculosis activity in children and adolescents.] Donets, O. T., *et al.* ..... (A) 156
Primary dapsone resistance in multibacillary leprosy among Nepalese children. Samuel, N. M., *et al.* ..... (A) 347
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of *M. tuberculosis* to rifampin. Steiner, P., *et al.* ..... (A) 159
Pure neural leprosy in a child; a case report. Arora, S. K. and Mukhija, R. D. ..... (A) 349
Study on prevention of leprosy. 2. Chemoprophylaxis trial for leprosy household contact children. Saikawa, K. ..... (A) 508
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ..... (A) 153

China, People's Republic of,
[Analysis of 71 cases of relapsed leprosy in Lufeng County, Guangdong.] Wang, Q. ... (A) 354
[Analysis of all cases of newly detected leprosy in the years 1983–1985 in Shandong Province.] Pan, Y., *et al.* ..... (A) 150
[Clinical analysis of 969 leprosy patients in Jiangqu Hospital of Tibet.] Jiangqu Hospital ..... (A) 149
[Effect of leprosy control in Baoying County, Jiangsu Province.] Bian, T., *et al.* ..... (A) 148
Enzyme-linked immunosorbent assay using *M. tuberculosis* antigen 5 for the diagnosis of pulmonary tuberculosis in China. Ma, Y., *et al.* ..... (A) 379
[Epidemiological survey of leprosy in a Gangzi Autonomous County, Sichuan Province.] Xiong, D., *et al.* ..... (A) 373
[General situation of leprosy control in Anhui Province.] Wang, L., *et al.* ..... (A) 508
[General situation of leprosy control in the area of the Qiang nationality in Sichuan Province.] Xiao, J., *et al.* ..... (A) 150
[Leprosy control in the city of Fuzhou.] Fu, Z., *et al.* ..... (A) 148
Manual of multidrug therapy published. Ye, G.-Y. ..... (N) 637
Prevention and control of leprosy in China and some of its problems today. Ma, H. .. (A) 506
[Review of research on the ancient history of leprosy in China.] Fang, D. ..... (A) 481
Scientific/educational film "Leprosy" produced in Shanghai. Ye, G.-Y. ..... (N) 637
[Survey of eye diseases in leprosy patients in Huiyang Prefecture, Guangdong Province.] Lu, B., *et al.* ..... (A) 486
[Treatment of multibacillary leprosy with MDT for half a year.] Shangluo Sanatorium ..... (A) 134

Chromatography,
Analysis of mycolic acid cleavage products and cellular fatty acids of *Mycobacterium* species by capillary gas chromatography. Lambert, M. A., *et al.* ..... (A) 378

Immunoreactivity of a 70 kD protein purified from *M. bovis* bacillus Calmette-Guérin by monoclonal antibody affinity chromatography. Britton, W. J., *et al.* ....(A) 153
[Liquid chromatography contribution towards new bacteriological analysis.] Postaire, E., *et al.* ....(A) 500

Chromosome(s),
Chromosome aberrations and sister chromatid exchanges (SCEs) in peripheral blood lymphocyte cultures of untreated patients. D'Souza, D. and Thomas, I. M. ....(A) 651
Restriction fragment analysis of chromosomal DNA defines different strains of *M. tuberculosis*. Shoemaker, S. A., *et al.* ....(A) 159

Ciprofloxacin,
Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* and *M. avium* complex. Heifets, L. B. and Lindholm-Levy, P. J. ....(A) 376

Classification,
[Classification of *M. tuberculosis* by phage-type markers in Havana City Province.] Jimenez Misas, C. A., *et al.* ....(A) 377
Leprous neuritis, classification of leprosy, and multidrug therapy. Negesse, Y. ....(C) 329
[On some problems in the classification of leprosy.] Meng, M. ....(A) 513

Clinic(s),
Operational efficiency of leprosy clinics: a time-motion study. Kumar, A., *et al.* ....(A) 351

Clinical,
A clinician's experience in managing patients with Hansen's disease. Dann, F. J. ....(A) 350
A multicentre evaluation of a questionnaire to assess ability in the diagnosis of leprosy. Smith, W. C. S. ....(A) 139
Adenosine deaminase activity in leprosy (a preliminary study). Chaudhary, S. G., *et al.* ....(A) 651
Auditory brainstem evoked potentials in leprosy. Bartel, P. R., *et al.* ....(A) 650
Autoaggressive hanseniasis. Azulay, R. D. ....(A) 349
[Clinical analysis of 70 cases of leprosy in children.] Chen, L., *et al.* ....(A) 651
[Clinical analysis of 969 leprosy patients in Jiangqu Hospital of Tibet.] Jiangqu Hospital ....(A) 149
Clinical and laboratory studies of inflammatory polyarthritis in patients with leprosy in Papua New Guinea. Atkin, S. L., *et al.* ....(A) 349
Clinical and seroepidemiological application of *M. leprae*-specific gelatin particle agglutination test (MLPA) for leprosy. Izumi, S., *et al.* ....(A) 682
[Clinical effect of multidrug therapy regimen.] Wang, Z., *et al.* ....(A) 348
Clinical Leprosy (Illustrated Second Edition) by V. N. Sehgal. Yoder, L. J. ....(B) 644
Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan: results 18 months after completion of treatment (Lahore Tuberculosis Study). Aziz, A., *et al.* ....(A) 510
Clinical, bacteriological and histopathological assessment of multibacillary leprosy cases after 1 and 2 years' multidrug therapy; preliminary communication. McNair, A. N., *et al.* ....(A) 133
Evaluation of the clinical and histopathological findings in indeterminate leprosy. Paksoy, N. ....(A) 136
Healing time in untreated paucibacillary leprosy: a cross-sectional study. Sirumban, P., *et al.* ....(O) 223
Hypothesis: leprosy and the sun. Britton, S. ....(A) 139
Illness beliefs of leprosy patients: use of medical anthropology in clinical practice. Neylan, T. C., *et al.* ....(O) 231
Indeterminate leprosy: a clinical and histopathological evaluation. Paksoy, N. ....(A) 495
Leprosy. Russell, D. ....(A) 138
Leprosy with pellagroid features (a case report). Singh, G., *et al.* ....(A) 488
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore TB Service/BMRC ..(A) 159
Manual of the National Leprosy Tuberculosis Programme for the Clinical Officer Tuberculosis and Leprosy. ....(B) 128
Mycolic acid analysis for clinical identification of *M. avium* and related mycobacteria. Lévy-Frèbault, V., *et al.* ....(A) 378

Palmo-plantar lesions in paucibacillary leprosy—unusual clinical expressions. Rajendran, N. ..... (A) 137
Reactional states in the nasal mucosa: a clinical and histopathological study. Job, A. and Chacko, C. J. G. ..... (O) 523
Sparing of leprosy macule in ampicillin hypersensitivity rash. Pavithran, K. ..... (A) 487
[Study on the factors relating to morbidity and mortality in leprosy patients.] Zhou, D., *et al.* ..... (A) 509
The associated diseases with leprosy. Singh, M., *et al.* ..... (A) 488
The detection of mycobacterial DNA sequences in uncultured clinical specimens with cloned *M. tuberculosis* DNA as probes. Pao, C.-C., *et al.* ..... (A) 513
Type 1 (reversal) lepra reaction in borderline leprosy with unusual clinical presentation—a case report. Kar, H. K., *et al.* ..... (A) 351

Clofazimine,
[A peculiar cause of small bowel segmental narrowing: clofazimine enteritis.] Hassan, M., *et al.* ..... (A) 132
Clofazimine analogues active against a clofazimine-resistant organism. O'Sullivan, J. F., *et al.* ..... (A) 482
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ..... (A) 348
[Effects of treatment of multibacillary leprosy with RFD, B663, and DDS.] Chen, L., *et al.* ..... (A) 481
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patient in Nigeria. Pieters, F. A. J. M., *et al.* ..... (A) 483
Inhibition of mononuclear leukocyte transformation *in vitro* by dihydrophenazines in comparison to clofazimine. Zeis, B. M., *et al.* ..... (A) 485
Lamprene (clofazimine) and its side effects. Salafia, A., and Kharkar, R. D. ..... (A) 483
More about clofazimine—3 years' experience and review of literature. Kumar, B., *et al.* ..... (A) 133
Studies of clofazimine resistance in mycobacteria: is the inability to isolate drug-resistant mutants related to its mode of action? David, H. L., *et al.* ..... (A) 345
The effect of ten phenazine-derivatives in comparison to clofazimine on the production of prostaglandin E2 by polymorphonuclear leucocytes. Zeis, B. M., *et al.* ..... (A) 348
The killing of *M. leprae* in mice by various dietary concentrations of clofazimine and ethionamide. Gelber, R. H. ..... (A) 370
[Treatment of multibacillary leprosy cases with B663, RFP and DDS for one year.] Chen, J., *et al.* ..... (A) 345

Congresses,
Dermatology in Five Continents; Proceedings of the XVII World Congress of Dermatology. C. E. Orfanos, R. Stadler and H. Gollnick, eds. ..... (B) 479
I Congress of the Association of Former Students of Professor Azulay. ..... (N) 637
2nd Asian Dermatological Congress ..... (N) 638
VI World Congress of Dermatology. ..... (N) 335
13th International Leprosy Congress, program information. ..... (N) 124

Control of leprosy,
A broader scope of leprosy control. Feenstra, P. and Tedla, T. ..... (A) 505
Blister calendar packs for the implementation of multiple drug therapy in DANIDA-assisted leprosy control projects in India. Georgiev, G. D. and Kielstrup, R. W. ..... (A) 346
Blister calendar packs—potential for improvement in the supply and utilization of multiple drug therapy in leprosy control programs. Georgiev, G. D. and McDougall, A. C. ..... (E) 603
[Effect of leprosy control in Baoying County, Jiangsu Province.] (China) Bian, T., *et al.* ..... (A) 148
[General situation of leprosy control in Anhui Province.] (China) Wang, L., *et al.* ..... (A) 508
[General situation of leprosy control in the area of the Qiang nationality in Sichuan Province.] (China) Xiao, J., *et al.* ..... (A) 150
Human behavioural research applied to the leprosy programme of Sarawak, Malaysia. Chen, P. C. Y. ..... (A) 342

Leprosy control by a people's program: "A new concept in technology transfer." Antia, N. H. ..... (A) 342
[Leprosy control in the city of Fuzhou.] (China) Fu, Z., *et al.* ..... (A) 148
Prevention and control of leprosy in China and some of its problems today. Ma, H. ..... (A) 506
[Program for the eradication of leprosy; practical aspects.] Leguizamon, O. R. ..... (A) 133
Psycho-social and environmental factors in triad model for the management of control programme: focus on leprosy. Valencia, L. B. ..... (A) 344
Skin smears and the bacterial index (BI) in multiple drug therapy leprosy control programs: an unsatisfactory and potentially hazardous state of affairs. Georgiev, G. D. and McDougall, A. C. ..... (C) 101
[Socio-psychological factors in leprosy control.] Zhang, X. ..... (A) 510
Studies on Leprosy by Bombay Leprosy Project 1976–1986. ..... (B) 645
[The epidemiology and control of leprosy in Brazil.] Goncalves, A. ..... (A) 372
[The management target of leprosy control.] Yin, S. ..... (A) 508
What does distance matter? Leprosy control in west Nepal. Pearson, M. ..... (A) 666

Cuba,
[Assay of foot pad technique for the multiplication of *M. leprae* in different mouse lines existing in Cuba.] Saurez Moreno, O., *et al.* ..... (A) 371
[Classification of *M. tuberculosis* by phage-type markers in Havana City Province.] Jimenez Misas, C. A., *et al.* ..... (A) 377

Cultivation,
Factors affecting growth of the metabolically competent but microbe-dependent *M. leprae* (?); indications for *in vitro* cultivation in a multifactorial medium. Kato, L. ..... (A) 145
In vitro activity of five new quinolones against cultivable mycobacteria. Pattyn, S. R., *et al.* ..... (A) 499
In vitro cultivation of a chemoautotrophic nocardioform bacterium from armadillo tissue infected with leprosy bacillus. Dastidar, S. G., *et al.* ..... (A) 366
In vitro cultivation of an acid-fast nocardio-form chemoautotroph from mouse foot-pad-passaged strain of leprosy bacillus. Chakrabarty, A. N. and Dastidar, S. G. ..... (A) 366

Cutaneous,
Blood flow velocity in cutaneous lesions of leprosy. Agusni, I., *et al.* ..... (O) 394
[Cutaneous granuloma due to *M. vaccae.*] Mowszowicz, M., *et al.* ..... (A) 670
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (C) 56
[Fluorescent microscopy for the study of acid-fast bacilli in cutaneous tuberculosis.] Lazarova, A., *et al.* ..... (A) 512
Gamma interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Rada, E., *et al.* ..... (A) 363
M. bovis BCG-induced protection against cutaneous and systemic *Leishmania major* infections in mice. Fortier, A. H., *et al.* ..... (A) 668
[Observation on the therapeutic effect of 60 cases of cutaneous diseases treated with thalidomide.] Shen, D., *et al.* ..... (A) 515
Primary hyperpigmented cutaneous lesions in tuberculoid leprosy. Chattopadhyay, S. P. and Gupta, C. M. ..... (A) 651
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ..... (A) 501

Damien-Dutton Society,
Hermann Kober 1988 Damien-Dutton Award winner. ..... (N) 636
W. Felton Ross 1987 Damien-Dutton Award winner. ..... (N) 119

Dapsone (DDS),
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin followed by 1 year of daily dapsone with 10 weekly doses of rifampicin. Pattyn, S. R., *et al.* ..... (A) 347
A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone. Pieters, F. A. J. M., *et al.* ..... (O) 10
A follow up study of borderline tuberculoid leprosy under sulphone monotherapy. Ramu, G. and Desikan, K. V. ..... (A) 653

Are hypersensitivity reactions to dapsone becoming more frequent? Smith, W. C. S. ..(A) 484
Case report: dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait. Lachant, N. A. and Tanaka, K. R. ..(A) 649
Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. Subcommittee on Clinical ... ..(A) 484
Cytogenetic effect of dapsone, an antileprotic drug, in the mouse *in vivo* system. Roy, B. and Das, R. K. ..(O) 574
Dapsone susceptibility of *M. leprae* isolated before 1977. Ji, B., *et al.* ..(C) 326
Dapsone syndrome—a case report. Khare, A. K., *et al.* ..(A) 132
[Effects of treatment of multibacillary leprosy with RFD, B663, and DDS.] Chen, L., *et al.* ..(A) 481
Immunostimulation with an allied mycobacterium and DDS chemotherapy in lepromatous leprosy. Chaudhury, S., *et al.* ..(A) 356
Infectivity of secondary dapsone-resistant cases. Jesudasan, K., *et al.* ..(O) 418
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patient in Nigeria. Pieters, F. A. J. M., *et al.* ..(A) 483
Long-term prothionamide compliance: study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Ellard, G. A., *et al.* ..(A) 648
[*M. leprae* resistance against dapsone and rifampicin; results of a survey carried out in the Cap-Verde region (Senegal).] Grosset, J., *et al.* ..(A) 482
Paucibacillary primary dapsone resistance—a case report. Deenabandhu, A. and Kothandapani, V. G. ..(A) 647
Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy. Garg, S. K., *et al.* ..(A) 648
Photodermatitis provoked by dapsone: a case report. Joseph, M. S. ..(A) 346
Primary dapsone resistance in Bamako and Chingleput: final report. Subcommittee on Clinical ... ..(A) 368
Primary dapsone resistance in multibacillary leprosy among Nepalese children. Samuel, N. M., *et al.* ..(A) 347
Primary drug resistance to both rifampicin and dapsone in a paucibacillary leprosy patient. Koranne, R. V. and Srivastava, G. ..(A) 652
Secondary and primary dapsone resistant leprosy: an analysis of 199 patients from St. Thomas Hospital and Leprosy Project, Chettupattu, South India. Aschhoff, M., *et al.* ..(A) 647
[Study of the pathologic changes of posterior tibial nerve in arrested leprosy patients: to compare the combined chemotherapy with DDS treatment.] Zhu, W., *et al.* ..(A) 662
Suicide with dapsone. Singhal, S. K. ..(A) 650
[Treatment of multibacillary leprosy cases with B663, RFP and DDS for one year.] Chen, J., *et al.* ..(A) 345
Treatment of paucibacillary leprosy patients with dapsone and rifampin. Samuel, N. M., *et al.* ..(A) 484

Deformity(ies),
Hand deformity and sensory loss due to Hansen's disease in American Samoa. Brunel, W., *et al.* ..(A) 509
[Investigation of 225 leprosy patients with deformity and disability.] Yan, L. ..(A) 374
Leprosy deformities. I. An epidemiological study in a rural area of Rajasthan. (India) Mishra, B., *et al.* ..(A) 653
[Treatment of neuralgia and prevention of deformity with endoneurolysis.] Guo, C., *et al.* ..(A) 152

Deoxyfructoserotonin,
Effect of deoxyfructoserotonin (DFS) on lepromatous leprosy. Antia, N. H., *et al.* ..(O) 481

Dermal,
Effect of supernatants of dermal leprosy granulomas on lymphocyte morphology and function. Narayanan, R. B., *et al.* ..(A) 659
Thalidomide and exfoliative dermatitis. Salafia, A. and Kharkar, R. D. ..(C) 625

Dermatology,
Dermatology in Five Continents; Proceedings of the XVII World Congress of Dermatology. C. E. Orfanos, R. Stadler and H. Gollnick, eds. ..(B) 479

Hawaii Dermatology Society to hold international symposium. ....(N) 123
International Society of Dermatology 1988 meeting notice. ....(N) 340
Second Asian Dermatological Congress. ....(N) 638
VI World Congress of Dermatology. ....(N) 335

DNA,
A species-specific DNA probe as a candidate for diagnosis of leprosy. Clark-Curtiss, J. E. ....(A) 679
Analysis of deoxyribonucleic acids from armadillo-derived mycobacteria. De Kesel, M., *et al.* ....(A) 366
Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer; definition of DR2β gene products and antigen presentation to T cell clones from leprosy patients. Wilkinson, D., *et al.* ....(A) 497
Distinction of *M. tuberculosis* from other mycobacteria through DNA hybridization. Bhattacharya, S., *et al.* ....(A) 511
DNA methylation in leprosy-associated bacteria: *M. leprae* and *Corynebacterium tuberculostearicum*. Hottat, F., *et al.* ....(A) 367
Repetitive DNA sequence of *M. tuberculosis*: analysis of differential hybridization pattern with other mycobacteria. Reddi, P. P., *et al.* ....(O) 592
Restriction fragment analysis of chromosomal DNA defines different strains of *M. tuberculosis*. Shoemaker, S. A., *et al.* ....(A) 159
The detection of mycobacterial DNA sequences in uncultured clinical specimens with cloned *M. tuberculosis* DNA as probes. Pao, C.-C., *et al.* ....(A) 513

Drugs, (see also specific drugs),
A rapid method for viability and drug sensitivity of *M. leprae* cultured in macrophages and using fluorescein diacetate. Bhagria, A. and Mahadevan, P. R. ....(A) 144
Blister calendar packs for the implementation of multiple drug therapy in DANIDA-assisted leprosy control projects in India. Georgiev, G. D. and Kielstrup, R. W. ....(A) 346
Blister calendar packs—potential for improvement in the supply and utilization of multiple drug therapy in leprosy control programs. Georgiev, G. D. and McDougall, A. C. ....(E) 603
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ....(A) 348
Cytogenetic effect of dapsone, an antileprotic drug, in the mouse *in vivo* system. Roy, B. and Das, R. K. ....(O) 574
Drug interaction during multidrug regimens for treatment of leprosy. George, J., *et al.* ....(A) 482
Drugs against leprosy. Rao, C. K. ....(A) 483
[Effect of three drug therapy of leprosy.] Gao, Q., *et al.* ....(A) 482
[Experimental study on effect of antituberculosis drugs and certain pathogenetic agents on host immunological reactions.] Belyakova, O. I., *et al.* ....(A) 668
"Flu" syndrome on once monthly rifampicin. Patki, A. H., *et al.* ....(A) 650
Gonadal involvement in leprosy—study of gynaecomastia, testicular and epididymal involvement and therapeutic efficacy of indigenous drugs. Nigam, P., *et al.* ....(A) 352
Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: ultrastructure and drug-susceptibility studies. Rastogi, N., *et al.* ....(A) 379
Long-term prothionamide compliance: study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Ellard, G. A., *et al.* ....(A) 648
Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy. Garg, S. K., *et al.* ....(A) 648
Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Boerrigter, G., *et al.* ....(O) 408
Primary drug resistance to both rifampicin and dapsone in a paucibacillary leprosy patient. Koranne, R. V. and Srivastava, G. ....(A) 652
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of *M. tuberculosis* to rifampin. Steiner, P., *et al.* ....(A) 159
Screening of drug resistant strains of *M. leprae* in lepromatous leprosy patients under multidrug treatment. Sreevatsa, *et al.* ....(A) 484

[Short-course therapy of patients with pulmonary tuberculosis by antituberculous drugs and levamisole.] Feureisl, R. and Papezova, E. ..... (A) 511
Skin smears and bacterial index in multiple drug therapy. Agrawal, M. N. and Porichha, D. ..... (C) 628
Skin smears and the bacterial index (BI) in multiple drug therapy leprosy control programs: an unsatisfactory and potentially hazardous state of affairs. Georgiev, G. D. and McDougall, A. C. ..... (C) 101
Studies of clofazimine resistance in mycobacteria: is the inability to isolate drug-resistant mutants related to its mode of action? David, H. L., *et al.* ..... (A) 345

Electron microscopy, (see also Ultrastructure),
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. ..... (A) 501

ELISA (enzyme-linked immunosorbent assay) tests,
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
[Enzyme immunoassay for specific antibodies in prophylactic examination of persons with posttuberculous lesions.] Markov, A. G., *et al.* ..... (A) 512
Enzyme-linked immunosorbent assay using *M. tuberculosis* antigen 5 for the diagnosis of pulmonary tuberculosis in China. Ma, Y., *et al.* ..... (A) 379
Evaluation of a dual-antigen ELISA test for the serodiagnosis of tuberculosis. Raheman, S. F., *et al.* ..... (A) 671
[Evaluation of blocking agents for ELISA in detection of leprosy antibody.] Wu, Q., *et al.* ..... (A) 497
Evaluation of inexpensive blocking agents for ELISA in the detection of antibody in leprosy. Douglas, J. T., *et al.* ..... (A) 491
Serodiagnosis of leprosy with PGL-I using ELISA technique. Dandekar, S. R., *et al.* ..... (A) 356
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157
Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Fine, P. E. M., *et al.* ..... (O) 243

Enzymes,
Enzymes for purine synthesis and scavenging in pathogenic mycobacteria and their distribution in *M. leprae*. Wheeler, P. R. ..... (A) 369
Metabolic studies on mycobacteria. III. Demonstration of key enzymes of TCA cycles in *M. leprae*. Katoch, V. M., *et al.* ..... (A) 146

Epidemiology,
A sample survey: one objective method of evaluating leprosy prevalence in an endemic area. Merlin, M., *et al.* ..... (A) 372
Epidemiological study of leprosy in Malwani suburb of Bombay. Chaturvedi, R. M. ..... (A) 666
[Epidemiological survey of leprosy in a Gangzi Autonomous County, Sichuan Province.] Xiong, D., *et al.* ..... (A) 373
Leprosy as a zoonosis; an update. Walsh, G. P., *et al.* ..... (A) 667
Leprosy deformities. I. An epidemiological study in a rural area of Rajasthan. Mishra, B., *et al.* ..... (A) 653
New postgraduate fellowships in epidemiology. ..... (N) 641
[Role of various mycobacterial species in epidemiology of tuberculosis.] Tarasov, A. S., *et al.* ..... (A) 160
[The epidemiology and control of leprosy in Brazil.] Goncalves, A. ..... (A) 372
[The history and epidemiology of leprosy in the province of Almeria.] Miranda, R. F. and Fernandez, R. M. G. ..... (A) 149
The Lepra Evaluation Project (LEP), an epidemiological study of leprosy in north Malawi. II. Prevalence rates. Ponnighaus, J. M., *et al.* ..... (A) 666
Transmission of leprosy. Job, C. K. ..... (A) 147

Erythema nodosum leprosum (ENL),
An attempt to induce a histological ENL symptom in *M. leprae* infected nude mice. Subowo. ..... (A) 502

Coexistent leprosy and lupus erythematosus. Posner, D. I. and Guill, M. A., III .....(A) 137
[Effectiveness of plasma exchanges in a leprotic erythema nodosum.] Fain, O., *et al.* ..(A) 486
Erythema nodosum leprosum. Vazquez-Botet, M. and Sanchez, J. L. .....(A) 489
Erythema nodosum leprosum in Singapore. Giam, Y. C., *et al.* .....(A) 652
Erythema nodosum leprosum reaction of leprosy causing the double stripe sign on bone scan; case report. Datz, F. L. .....(A) 134
Simultaneous upgrading reaction and erythema nodosum leprosum in a patient with lepromatous leprosy. Job, C. K., *et al.* .....(O) 437
[Thalidomide in the treatment of 50 cases (60 treatments) of lupus erythematosus.] Shi, S., *et al.* .....(A) 158

Ethionamide,
The killing of *M. leprae* in mice by various dietary concentrations of clofazimine and ethionamide. Gelber, R. H. .....(A) 370

Ethiopia,
All-Africa Leprosy and Rehabilitation Centre (ALERT) training courses for 1988. ....(N) 336
Leprosy and tuberculosis in the Blue Nile Valley of western Ethiopia. Gundersen, S. G. .....(A) 148

Experimental leprosy,
Effect of ofloxacin and minocycline on experimental leprosy. Kohsaka, K. and Ito, T. .....(A) 678
Experimental leprosy in African green monkeys (*Cercopithecus aethiops*): a model for polyneuritic leprosy. Baskin, G. B., *et al.* .....(A) 369
On search for new antileprous compounds and their enhancement with immunostimulants in experimental leprosy. Tsutsumi, S. and Gidoh, M. .....(A) 676
Role of immune complexes in alteration of lymphocyte subpopulation numbers and functions in experimental leprosy. Vaishnavi, C., *et al.* .....(A) 503
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* .....(O) 537

Eye(s),
[A report on correcting lagophthalmos in 26 leprosy patients with transplantation of a fascicle of the temporalis.] Zheng, T., *et al.* .....(A) 153
Cataract extraction in leprosy patients. Rao, V. A. and Kawatra, V. K. .....(A) 510
Cataract surgery on leprosy patients. Suryawashi, N. and Richard, J. .....(O) 238
Corneal changes in nine-banded armadillos with leprosy. Malaty, R. and Togni, B. ....(A) 502
Defining the magnitude of ocular complications from leprosy: problems of methodology. Courtright, P. D. .....(O) 556
Histopathological changes in the eyes of mangabey monkeys with lepromatous leprosy. Malaty, R., *et al.* .....(O) 443
Keratoconjunctivitis sicca in leprosy. Hodges, E. J., *et al.* .....(A) 351
Ocular leprosy. Sroat, D. A. .....(A) 353
Ocular lesions in Hansen's (leprosy). Gnandoss, A. S. and Rajendran, N. .....(A) 350
[Survey of eye diseases in leprosy patients in Huiyang Prefecture, Guangdong Province.] Lu, B., *et al.* .....(A) 486
WHO 1987 Symposium on Ocular Leprosy. .....(N) 477

Family(ies),
A family with histoid leprosy. Singh, M., *et al.* .....(C) 110
[Analysis of new cases in the families of 131 leprosy patients.] Gao, S. .....(A) 505
[Eight cases of leprosy in one family.] Li, Z. .....(A) 372
Impact of leprosy on family and intimate relationships. Ashmalla, L. .....(A) 371
Leprosy and immunity: genetics and immune function in multiple case families. Rawlinson, W. D., *et al.* .....(A) 495
Segregation analysis of leprosy in families in northern Thailand, Wagener, D. K., *et al.* .....(A) 667

FLA-ABS test,
Seroepidemiological studies in subsided cases of multi- and paucibacillary types of leprosy using FLA-ABS test. Bharadwaj, V. P., *et al.* .....(A) 138

Foot,
Management of tarsal disintegration (T.D.) in leprosy. Kulkarni, V. N., *et al.* ....(A) 509
Measurement of pressure under leprotic feet using a barograph. Patil, K. M. and Srinivasan, H. ....(A) 374
Neuroarthropathy of the foot in leprosy. Horibe, S., *et al.* ....(A) 667
Primary involvement of sole in leprosy (a case report). Aggarwal, S. K., *et al.* ....(A) 485
Restoration of plantar sweat secretion in the feet of leprosy patients. Rao, K. S., *et al.* ....(A) 510

Foot pads,
[A comparison of skin scraping and skin biopsy in mouse foot pad experiments with *M. leprae.*] Wang, H. ....(A) 371
[Antileprosy effect of RFD (R77-3) in the mouse foot pad technique.] Lin, Z., *et al.* ....(A) 482
[Assay of foot pad technique for the multiplication of *M. leprae* in different mouse lines existing in Cuba.] Suarez Moreno, O., *et al.* ....(A) 371
In vitro cultivation of an acid-fast nocardio-form chemoautotroph from mouse foot-pad-passaged strain of leprosy bacillus. Chakrabarty, A. N. and Dastidar, S. G. ....(A) 366
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ....(A) 501

France,
4th International Colloquium on the Mycobacteria. ....(N) 120

Genetics,
Association HLA and other genetic markers in South Indian patients with pulmonary tuberculosis. Papida, S. S., *et al.* ....(A) 513
Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., *et al.* ....(A) 678
Evidence for genetic divergence in ribosomal RNA genes in mycobacteria. Cox, R. A. and Katoch, V. M. ....(A) 154
Genetic control of murine T cell proliferative responses to *M. leprae.* V. Evidence for crossreactivity between host antigens and *M. leprae.* Harris, D. P., *et al.* ....(A) 657
Leprosy and immunity: genetics and immune function in multiple case families. Rawlinson, W. D., *et al.* ....(A) 495
Molecular-genetic evidence for the relationship of *M. leprae* to slow-growing pathogenic mycobacteria. Smida, J., *et al.* ....(O) 449
The Ity/Lsh/Bcg gene significantly affects mouse resistance to *M. lepraemurium.* Brown, I. N. and Glynn, A. A. ....(A) 370

Germany,
DM 307 million in donations for the GLRA. ....(N) 638
Hermann Kober 1988 Damien-Dutton Award winner. ....(N) 636

Granuloma(s),
Comparative histology of skin and nerve granulomas in leprosy patients. Mukherjee, A. and Misra, R. S. ....(A) 659
[Cutaneous granuloma due to *M. vaccae.*] Mowszowicz, M., *et al.* ....(A) 670
Effect of supernatants of dermal leprosy granulomas on lymphocyte morphology and function. Narayanan, R. B., *et al.* ....(A) 659
Epithelioid cell granuloma induction in the guinea pig by haptenated *M. leprae.* Verghese, S., *et al.* ....(A) 144
Immunopathology of leprosy granulomas—current status: a review. Narayanan, R. B. ....(A) 494
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ....(A) 141
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ....(A) 656
Nerve damage induced by mycobacterial granulomas in guinea pig sciatic nerves. Cowley, S. A., *et al.* ....(O) 283
Proteolytic and anti-proteolytic regulation in granulomatous tissue reaction. Izaki, S., *et al.* ....(A) 689
Renal granuloma and mesangial proliferative glomerulonephritis in leprosy. Al-Mohaya, S. A., *et al.* ....(O) 599

Guadeloupe,
Contribution of relapses to total infection sources of leprosy in Guadeloupe. Cartel, J. L., *et al.* ..... (A) 345

Guyana, French,
[Quadruple twice monthly supervised chemotherapy for 72 paucibacillary patients in French Guyana.] Jamet, P. and Robin, Y. ..... (A) 649

Hand(s),
Bone loss in limbs with decreased or absent sensation: ten year follow-up of the hands in leprosy. MacMoran, J. W. and Brand, P. W. ..... (A) 374
Common Vocational Training Project for the Handicapped (CVTPH). (India) Amritmahal, A. and Mehta, J. M. ..... (A) 667
Correction of claw fingers in leprosy by the Brand four-tailed tendon graft operation. Kadir, A. H. A. ..... (A) 668
Hand deformity and sensory loss due to Hansen's disease in American Samoa. Brunel, W., *et al.* ..... (A) 509

Hawaii,
Challenging the stigma: Hawaii's role in dispelling the myths of leprosy. Law, A. S. ..... (A) 343
Hawaii Dermatology Society to hold international symposium. ..... (N) 123
Hui Hoa Aloha—the Hansen's Disease Association. Char, D. F. B. ..... (A) 342
Progress in the serology of leprosy at the University of Hawaii. Douglas, J. T. ..... (A) 356

Heiser Program, The,
The Heiser Program for Research in Leprosy 1989. ..... (N) 478

Histoid leprosy,
A family with histoid leprosy. Singh, M., *et al.* ..... (C) 110
Epithelioid and polygonal cells in histoid leprosy. Porichha, D. and Bhatia, V. N. ..... (A) 142
Histoid leprosy in Singapore. Giam, Y. C. and Seow, C. S. ..... (A) 652
Histoid leprosy—a histopathological reappraisal. Sehgal, V. N., *et al.* ..... (A) 142
Mast cells in histoid lepromatous lesions. Kumar, R. ..... (A) 492

Histology,
An attempt to induce a histological ENL symptom in *M. leprae* infected nude mice. Subowo. ..... (A) 502
Comparative histology of skin and nerve granulomas in leprosy patients. Mukherjee, A. and Misra, R. S. ..... (A) 659
Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved *M. leprae* and live BCG. Meyers, W. M., *et al.* ..... (O) 302
Reproducibility of histology in leprosy lesions. Cree, I. A., *et al.* ..... (O) 296
Short term combination therapy for paucibacillary leprosy—histological evaluation & follow-up study. Kumar, B., *et al.* ..... (A) 132

Histopathology,
Auramine staining in histopathology sections. Bhatia, V. N., *et al.* ..... (A) 490
Clinical, bacteriological and histopathological assessment of multibacillary leprosy cases after 1 and 2 years' multidrug therapy; preliminary communication. McNair, A. N., *et al.* ..... (A) 133
Evaluation of the clinical and histopathological findings in indeterminate leprosy. Paksoy, N. ..... (A) 136
Histoid leprosy—a histopathological reappraisal. Sehgal, V. N., *et al.* ..... (A) 142
Histopathological changes in the eyes of mangabey monkeys with lepromatous leprosy. Malaty, R., *et al.* ..... (O) 443
Indeterminate leprosy: a clinical and histopathological evaluation. Paksoy, N. ..... (A) 495
Reactional states in the nasal mucosa: a clinical and histopathological study. Job, A. and Chacko, C. J. G. ..... (O) 523
Renal involvement in *M. leprae* infected mice; histopathological, bacteriological and immunofluorescence study. Vaishnavi, C., *et al.* ..... (A) 503

History of leprosy,
[Historical reflections on leprosy with regard to some military medical aspects.] Schubert, G. and Rogowitz, L. ..... (A) 647

Leprosy: the long hard road. Lechat, M. F. ..... (A) 481
[Review of research on the ancient history of leprosy in China.] Fang, D. ..... (A) 481
[The history and epidemiology of leprosy in the province of Almeria.] (Spain) Miranda, R. F. and Fernandez, R. M. G. ..... (A) 149

HLA,
Analysis of HLA-DR glycoproteins by DNA-mediated gene transfer; definition of DR2β gene products and antigen presentation to T cell clones from leprosy patients. Wilkinson, D., *et al.* ..... (A) 497
[Antigens HLA and diverse forms and variants of pulmonary tuberculosis.] Sadykov, A. S., *et al.* ..... (A) 514
Association HLA and other genetic markers in South Indian patients with pulmonary tuberculosis. Papida, S. S., *et al.* ..... (A) 513
[Dependence of levels of antituberculous antibodies on HLA-DR genotype of patients suffering from tuberculosis.] Litvinov, V. I., *et al.* ..... (A) 378
[Study on relation between distribution of locus DR antigens of HLA system and tuberculosis in various populations.] Pospelov, L. E., *et al.* ..... (A) 513
Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Gorodezky, C., *et al.* ..(A) 372

Hypersensitivity,
Are hypersensitivity reactions to dapsone becoming more frequent? Smith, W. C. S. ..(A) 484
Soluble antigen of *M. leprae* coupled with liposomes elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45
Sparing of leprosy macule in ampicillin hypersensitivity rash. Pavithran, K. ..... (A) 487
The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Cree, I. A., *et al.* ..... (A) 651

ICRC bacilli,
Immunogenic "subunit" of the ICRC antileprosy vaccine. Chirmule, N. B., *et al.* .....(O) 27

Immune complexes,
Role of immune complexes in alteration of lymphocyte subpopulation numbers and functions in experimental leprosy. Vaishnavi, C., *et al.* ..... (A) 503
Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions. Chakrabarty, A. K., *et al.* ..... (O) 559

Immune responses,
Epidermal changes in reactional leprosy: keratinocyte Ia expression as an indicator of cell-mediated immune responses. Thangaraj, H., *et al.* ..... (O) 401
Immunoblotting and the immune response to leprosy. Young, D. B. ..... (A) 661

Immunoglobulins,
Armadillo IgG and IgM antibody responses to phenolic glycolipid-I during experimental infection with *M. leprae.* Vadiee, A. R., *et al.* ..... (O) 422
Association of IgG and IgM antibodies to phenolic glycolipid-I antigen of *M. leprae* with disease parameters in multibacillary leprosy patients. Lyons, N. F., *et al.* .....(A) 493
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
Partial characterization of antigens from *M. leprae* evoking IgG and IgM antibodies in armadillos. Vadiee, A. R., *et al.* ..... (O) 274
Patterns of immunoglobulins in the serum of leprosy patients. Choudhary, M. S., *et al.* ..... (A) 134
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157

Immunology,
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ..... (A) 348
[Determination of immune function in leprosy patients.] Su, L., *et al.* ..... (A) 496
[Experimental study on effect of antituberculosis drugs and certain pathogenetic agents on host immunological reactions.] Belyakova, O. I., *et al.* ..... (A) 668

Immunologic unresponsiveness in leprosy is mediated by modulation of E-receptor. Muthukkaruppan, V., *et al.* ..... (A) 141
[Immunological analysis of leprosy.] Matsubara, H. ..... (A) 659
Immunological approach for control of *M. avium-intracellulare* infections in AIDS—an hypothesis. Deo, M. G. ..... (E) 455
Immunological effects of lepromin testing in Sri Lankan population groups. I. Effects of repeated lepromin testing. Pinto, M. R. M., *et al.* ..... (A) 142
... II. Effect of reactivity to a soluble protein antigen of *M. leprae.* Pinto, M. R. M., *et al.* ..... (A) 362
[Immunological reactivity of patients with various levels of tuberculosis activity.] Gudz, E. A. and Prilutsky, A. S. ..... (A) 157
Immunological responsiveness to *M. leprae* and BCG antigens in 98 leprosy patients and their household contacts. Sarno, E. N., *et al.* ..... (A) 660
Immunological significance of *M. leprae* cell walls. Mehra, V., *et al.* ..... (A) 682
Immunological significance of *M. leprae* cell walls. Melancon-Kaplan, J., *et al.* ..... (A) 493
Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Gaylord, H. and Brennan, P. J. ..... (A) 357
Leprosy: the immunologist and the patient. Mshana, R. N. and Nilsen, R. ..... (E) 314
Progress in the immunology of the mycobacterioses. Rook, G. A. W. ..... (A) 496
Robert White Fellowships in Immunology. (U.K.) ..... (N) 341
Studies on the antigenic specificity of *M. leprae.* II. Immunological characterization. Mandock, O., *et al.* ..... (A) 360
... III. Further studies on immunological characterization. Kale, V., *et al.* ..... (A) 358

Indeterminate leprosy,

CD1 positive epidermal Langerhans cells in indeterminate leprosy. Narayanan, R. B., *et al.* ..... (A) 660
Comparative study of lepromin reaction in indeterminate leprosy and controls. Ravindranathan, O. and Sarojini, P. A. ..... (A) 654
Demonstration of acid-fast bacilli in skin biopsies from indeterminate leprosy cases. Alvarez-Mendoza, A., *et al.* ..... (A) 655
Evaluation of the clinical and histopathological findings in indeterminate leprosy. Paksoy, N. ..... (A) 136
Indeterminate leprosy. A passing phase in the evolution of leprosy. Sehgal, V. N. and Srivastava, G. ..... (A) 353
Indeterminate leprosy: a clinical and histopathological evaluation. Paksoy, N. ..... (A) 495

India,

A survey on proportion of multibacillary cases of leprosy in Himachal Pradesh. Dharmshaktu, N. S., *et al.* ..... (A) 504
Absenteeism in leprosy patients in a rural area in Tamil Nadu. Raghavia, M., *et al.* ..... (A) 483
AHM opens new office in Pune. ..... (N) 335
Annual Report of the Director General 1985–86, Indian Council of Medical Research. ..... (B) 127
Association HLA and other genetic markers in South Indian patients with pulmonary tuberculosis. Papida, S. S., *et al.* ..... (A) 513
Blister calendar packs for the implementation of multiple drug therapy in DANIDA-assisted leprosy control projects in India. Georgiev, G. D. and Kielstrup, R. W. ..... (A) 346
Common Vocational Training Project for the Handicapped (CVTPH). Amritmahal, A. and Mehta, J. M. ..... (A) 667
Current status of National Leprosy Eradication Programme in India. Mittal, B. N. ..... (A) 372
Epidemiological study of leprosy in Malwani suburb of Bombay. Chaturvedi, R. M. ..... (A) 666
Government of India 1987 National Awards. ..... (N) 473
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Parthasarathy, R., *et al.* ..... (A) 158
Leprosy deformities. I. An epidemiological study in a rural area of Rajasthan. Mishra, B., *et al.* ..... (A) 653
Leprosy in the Union Territory of Delhi. Misra, R. S. and Ramesh, V. ..... (A) 507
Long-term prothionamide compliance: study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Ellard, G. A., *et al.* ..... (A) 648
Multidrug therapy. ..... (N) 120

Mycobacteriocin typing of *M. tuberculosis* isolated from patients in south India. Selvakumar, N., *et al.* ..... (A) 515
National Seminar on Social Science Research on Leprosy. Tare, S. P. ..... (C) 121
New director of JALMA. ..... (N) 121
New director of SLR&TC, Karigiri. ..... (N) 121
New IAL officers elected. ..... (N) 335
Persisting *M. leprae* among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical ... . (A) 347
Primary dapsone resistance in Bamako and Chingleput: final report. Subcommittee on Clinical ... . (A) 368
Proceedings of the National Seminar on Social Science Research on Leprosy. ..... (N) 473
Protective effect of BCG in Ahmednagar, India. Stanford, J. L., *et al.* ..... (A) 159
Secondary and primary dapsone resistant leprosy: an analysis of 199 patients from St. Thomas Hospital and Leprosy Project, Chettupattu, South India. Aschhoff, M., *et al.* ..... (A) 647
36th Annual Report 1986–1987 Gandhi Memorial Leprosy Foundation. ..... (N) 338

Indonesia,
A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Kardjito, T., *et al.* ..... (A) 359

Inoculation,
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. ..... (A) 501
Experimental inoculation with leprosy bacillus in various hybrid mice (continued): results of CD-1 (ICR) hybrid nude mice. Nakamura, K. and Yogi, Y. ..... (A) 686
Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved *M. leprae* and live BCG. Meyers, W. M., *et al.* ..... (O) 302
Inoculation of *M. leprae* into beige mice. Kohsaka, K., *et al.* ..... (A) 501
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ..... (A) 656
The experimental inoculation with *M. leprae* in the congenitally asplenic mouse. Yogi, Y. and Nakamura, K. ..... (A) 504
The nude mouse as an experimental lepromatous leprosy model (continued): the lepromatoid lesions in mystacial vibrissae located site of injection. Yogi, Y. and Nakamura, K. ..... (A) 503
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ..... (A) 501

Interferon,
A study of the effects of intradermal administration of recombinant gamma interferon in lepromatous leprosy patients. Samuel, N. M., *et al.* ..... (A) 363
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Kaplan, G., *et al.* ..... (A) 358
Cellular, humoral, and gamma interferon responses to *M. leprae* and BCG antigens in healthy individuals exposed to leprosy. Converse, P. J., *et al.* ..... (A) 656
Defective intralesional interferon-gamma activity in patients with lepromatous leprosy. Volc-Platzer, B., *et al.* ..... (A) 496
Gamma interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Rada, E., *et al.* ..... (A) 363
Gamma interferon, but not *M. leprae*, induces major histocompatibility class II antigens on cultured rat Schwann cells. Samuel, N. M., *et al.* ..... (A) 364
Induction of macrophage unresponsiveness to interferon-gamma by *M. leprae* constituents. Krahenbuhl, J. L., *et al.* ..... (A) 683
Induction of unresponsiveness to gamma interferon in macrophages infected with *M. leprae*. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 660
Interferon-gamma; the major mediator of resistance against *Toxoplasma gondii*. Suzuki, Y., *et al.* ..... (A) 515
Viral challenge in leprosy: viraemia, interferon, and specific antibody production. Gelber, R. H., *et al.* ..... (A) 135

Interleukin(s),
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ..... (A) 141
Recombinant interleukin-2 limits the replication of *M. lepraemurium* and *M. bovis* BCG in mice. Jeevan, A. and Asherson, G. L. ..... (A) 492

International Journal of Leprosy (IJL),
Index to Volume 55, 1987. ..... (—) 163
Reviewers. ..... (—) 692
Statement of Financial Condition ..... (—) 517
Statement of Ownership, Management and Circulation ..... (—) 694
The 1987 Journal—a continuing perspective. Hastings, R. C. ..... (E) 82

Isoniazid,
Long-term prothionamide compliance: study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Ellard, G. A., *et al.* ..(A) 648

Japan,
Changes at National Institute for Leprosy Research. ..... (N) 339
Twenty-Third Joint Leprosy Research Conference, Nara, Japan, 27 and 29 July 1988. ..... (—) 673

Kidney(s),
Acute renal failure following rifampicin. Rajan, M. A., *et al.* ..... (A) 487
Renal failure and haemolysis caused by rifampicin. Van Assendelft, A. H. W. ..... (A) 134
Renal granuloma and mesangial proliferative glomerulonephritis in leprosy. Al-Mohaya, S. A., *et al.* ..... (O) 599
Renal involvement in *M. leprae* infected mice; histopathological, bacteriological and immunofluorescence study. Vaishnavi, C., *et al.* ..... (A) 503

Korea,
Leprosy in the Democratic People's Republic of Korea. Lechat, M. F. ..... (N) 122
Present status and future of leprosy in Korea. Kim, D.-I. ..... (A) 505
WHO Regional Committee for South-East Asia Report. ..... (N) 339

Kuwait,
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ..... (A) 153

Leishmaniasis,
Gamma interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Rada, E., *et al.* ..... (A) 363
M. bovis BCG-induced protection against cutaneous and systemic *Leishmania major* infections in mice. Fortier, A. H., *et al.* ..... (A) 668

Lepromatous leprosy,
[A case of lepromatous leprosy.] Butov, Y. S., *et al.* ..... (A) 651
A comparative study of testicular involvement in lepromatous and borderline lepromatous leprosy. Rea, T. H. ..... (O) 383
A patient with lepromatous leprosy and anticytoskeletal antibodies. Frey, F. L. P., *et al.* ..... (A) 656
A study of the effects of intradermal administration of recombinant gamma interferon in lepromatous leprosy patients. Samuel, N. M., *et al.* ..... (A) 363
Armadillo exposure among Mexican-born patients with lepromatous leprosy. Thomas, D. A., *et al.* ..... (A) 150
[Cellular anergy in lepromatous leprosy] Rojas-Espinosa, O. ..... (A) 363
Cellular responses to the intradermal injection of recombinant human gamma-interferon in lepromatous leprosy patients. Kaplan, G., *et al.* ..... (A) 358
Defective intralesional interferon-gamma activity in patients with lepromatous leprosy. Volc-Platzer, B., *et al.* ..... (A) 496
Effect of deoxyfructoserotonin (DFS) on lepromatous leprosy. Antia, N. H., *et al.* ..... (O) 481

Effects of a synthetic extract (thymopentin) on the immune system of lepromatous leprosy patients. Munno, I., *et al.* ..... (A) 361
Endothelial cell bacillation in lepromatous leprosy: a case report. Mukherjee, A. and Meyers, W. M. ..... (A) 361
Evidence of cell-mediated immune contrasuppression in lepromatous leprosy: modulation of a putative T contrasuppressor cell subset. Gonzalez-Amaro, R., *et al.* ..... (A) 491
Facies leprosa: resorption of maxillary anterior alveolar bone and the anterior nasal spine in patients with lepromatous leprosy in Mali. Marks, S. C., Jr. and Grossetete, G. ..... (O) 21
Histiocytic lymphoma simulating lepromatous leprosy—a case report. Balachandran, C., *et al.* ..... (A) 485
Histopathological changes in the eyes of mangabey monkeys with lepromatous leprosy. Malaty, R., *et al.* ..... (O) 443
Immunostimulation with an allied mycobacterium and DDS chemotherapy in lepromatous leprosy. Chaudhury, S., *et al.* ..... (A) 356
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ..... (A) 656
M. leprae-reactive T-cell clones isolated from polar lepromatous and tuberculoid leprosy patients. Launois, P., *et al.* ..... (A) 360
Mast cells in histoid lepromatous lesions. Kumar, R. ..... (A) 492
Nontuberculous mycobacterial skin infection resembling lepromatous leprosy. Love, G. L. ..... (A) 378
[Phagocytic syndrome in lepromatous leprosy patients and in armadillos infected with Hansen's bacillus.] Urteaga-Ballon, O. ..... (A) 365
Scalp lesion in a lepromatous patient—case report. Malaviya, G. N., *et al.* ..... (A) 136
Screening of drug resistant strains of *M. leprae* in lepromatous leprosy patients under multidrug treatment. Sreevatsa, *et al.* ..... (A) 484
Severe reactional state in lepromatous leprosy simulating Sweet's syndrome. Kuo, T.-T. and Chan, H.-L. ..... (A) 652
Simultaneous upgrading reaction and erythema nodosum leprosum in a patient with lepromatous leprosy. Job, C. K., *et al.* ..... (O) 437
The effects of chemotherapy on antibody levels in lepromatous patients. Douglas, J. T., *et al.* ..... (A) 648
The nude mouse as an experimental lepromatous leprosy model (continued): the lepromatoid lesions in mystacial vibrissae located site of injection. Yogi, Y. and Nakamura, K. ..... (A) 503
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ..... (A) 501
Thymopentin treatment in patients with chemotherapy-resistant lepromatous leprosy. Castells, A., *et al.* ..... (A) 349
Transitory macrophage activation in the granulomatous lesions of *M. lepraemurium*-induced lepromatoid leprosy in the mouse. Rojas-Espinosa, O., *et al.* ..... (O) 428
[Treatment of patients with temporomandibular joint pathology developing in lepromatous leprosy.] Sviridov, B. G., *et al.* ..... (A) 488
Undernutrition and lepromatous leprosy. III: Micronutrients and their transport proteins. Rao, K. N., *et al.* ..... (A) 353
... Serum vitamin A and E levels in leprosy spectrum. Rao, K. N. and Saha, K. ..... (A) 653
Unmyelinated nerve fibres in leprosy. A qualitative and quantitative study of sural nerve biopsies in 2 cases of lepromatous leprosy. Gibbels, E., *et al.* ..... (A) 656

Lepromin,
Arthus-like phenomenon and lepromin A—a case report. Salafia, A. and Kharkar, R. D. ..... (C) 627
Comparative study of lepromin reaction in indeterminate leprosy and controls. Ravindranathan, O. and Sarojini, P. A. ..... (A) 654
Immunological effects of lepromin testing in Sri Lankan population groups. I. Effects of repeated lepromin testing. Pinto, M. R. M., *et al.* ..... (A) 142
... II. Effect of reactivity to a soluble protein antigen of *M. leprae*. Pinto, M. R. M., *et al.* ..... (A) 362
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae*. I. Reactivity to lepromin A. Pinto, M. R. M., *et al.* ..... (A) 141

... III. The post-lepromin test scar in healthy populations in Sri Lanka. Pinto, M. R. M., *et al.* ....(A) 362
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae*. Pemajayantha, V., *et al.* ....(A) 495
Twenty years observation of lepromin reaction (Mitsuda antigen) in leprosy patients. Takizawa, H. and Kobayashi, S. ....(A) 488
Vaccination of human volunteers with heat-killed *M. leprae*: local responses in relation to the interpretation of the lepromin reaction. Gill, H. K., *et al.* ....(O) 36

Lesions,
A borderline leprosy lesion on the palate: a case report. Mishra, B., *et al.* ....(A) 486
A review of immunopathologic studies of human leprosy lesions *in situ*. Scollard, D. M. ....(A) 364
Blood flow velocity in cutaneous lesions of leprosy. Agusni, I., *et al.* ....(O) 394
[Characterization of mononuclear phagocytes in leprosy skin lesions: a monoclonal study.] Sarno, E. N., *et al.* ....(A) 660
Comedones induced by coconut oil in a borderline tuberculoid lesion. Srinivas, C. R., *et al.* ....(C) 471
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. ....(A) 501
[Enzyme immunoassay for specific antibodies in prophylactic examination of persons with posttuberculous lesions.] Markov, A. G., *et al.* ....(A) 512
Learning from lesions: patterns of tissue inflammation in leprosy. Modlin, R. L., *et al.* ....(A) 493
Lesional modulation of peripheral monocyte leucotactic responsiveness in leprosy. Campbell, P. B., *et al.* ....(A) 355
Mast cells in histoid lepromatous lesions. Kumar, R. ....(A) 492
Ocular lesions in Hansen's (leprosy). Gnanadoss, A. S. and Rajendran, N. ....(A) 350
Palmo-plantar lesions in paucibacillary leprosy—unusual clinical expressions. Rajendran, N. ....(A) 137
Photoactivated topical 8-methoxypsoralen in repigmentation of a tuberculoid leprosy lesion. Srinivas, C. R. ....(C) 109
Primary hyperpigmented cutaneous lesions in tuberculoid leprosy. Chattopadhyay, S. P. and Gupta, C. M. ....(A) 651
Reproducibility of histology in leprosy lesions. Cree, I. A., *et al.* ....(O) 296
Scalp lesion in a lepromatous patient—case report. Malaviya, G. N., *et al.* ....(A) 136
The nude mouse as an experimental lepromatous leprosy model (continued): the lepromatoid lesions in mystacial vibrissae located site of injection. Yogi, Y. and Nakamura, K. ....(A) 503
Transitory macrophage activation in the granulomatous lesions of *M. lepraemurium*-induced lepromatoid leprosy in the mouse. Rojas-Espinosa, O., *et al.* ....(O) 428

Leukocyte(s),
Inhibition of mononuclear leukocyte transformation *in vitro* by dihydrophenazines in comparison to clofazimine. Zeis, B. M., *et al.* ....(A) 485
Lesional modulation of peripheral monocyte leucotactic responsiveness in leprosy. Campbell, P. B., *et al.* ....(A) 355
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ....(A) 656
The effect of ten phenazine-derivatives in comparison to clofazimine on the production of prostaglandin E2 by polymorphonuclear leucocytes. Zeis, B. M., *et al.* ....(A) 348

Levamisole,
[Short-course therapy of patients with pulmonary tuberculosis by antituberculous drugs and levamisole.] Feureisl, R. and Papezova, E. ....(A) 511

Lipid,
Detection of mycobacterial lipids in skin biopsies from leprosy patients. Venkatesan, K., *et al.* ....(A) 368
Haptenic oligosaccharides in antigenic variants of mycobacterial C-mycosides antagonize lipid receptor activity for mycobacteriophage D4 by masking a methylated rhamnose. Dhariwal, K. R., *et al.* ....(A) 155

Use of carbon sources for lipid biosynthesis of *M. leprae*: a comparison with other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 664

Liposome,
Effect of protamine and rifampin liposomes on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 678
Soluble antigen of *M. leprae* coupled with liposomes elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45

Liver,
Leprosy, liver and jaundice. Kumar, B., *et al.* ..... (A) 136

Lupus,
Coexistent leprosy and lupus erythematosus. Posner, D. I. and Guill, M. A., III ..... (A) 137
Comparison between autoantibodies in malaria and leprosy with lupus. Bonfa, E., *et al.* ..... (A) 355
Lupus and lepros. Grange, J. M. ..... (C) 111
[Thalidomide in the treatment of 50 cases (60 treatments) of lupus erythematosus.] Shi, S., *et al.* ..... (A) 158

Lymph node(s),
[Fine needle aspiration of lymph nodes; study of 50 leprosy patients.] Latapi-Contreras, F., *et al.* ..... (A) 652
Localization and retention of mycobacterial antigen in lymph nodes of leprosy patients. Barros, U., *et al.* ..... (A) 354

Lymphocyte(s),
A novel approach in the identification of T-cell epitopes in *M. tuberculosis* using human T-lymphocyte clones. Lamb, J. R. and Young, D. B. ..... (A) 157
Cell-mediated immunity in tuberculoid leprosy—a study of T lymphocyte population by "E" rosette technique. Behra, R. N., *et al.* ..... (A) 355
Chromosome aberrations and sister chromatid exchanges (SCEs) in peripheral blood lymphocyte cultures of untreated patients. D'Souza, D. and Thomas, I. M. ..... (A) 651
Effect of supernatants of dermal leprosy granulomas on lymphyocyte morphology and function. Narayanan, R. B., *et al.* ..... (A) 659
Evidence that the Mitsuda reaction of *M. leprae* can be mediated by lymphocytes responsive to *M. tuberculosis*. Roberts, P. O., *et al.* ..... (A) 660
Responses to *M. leprae* by lymphocytes from new and old leprosy: role of exogenous lymphokines. Tran Trao, V., *et al.* ..... (A) 661
Role of immune complexes in alteration of lymphocyte subpopulation numbers and functions in experimental leprosy. Vaishnavi, C., *et al.* ..... (A) 503
Role of lymphokines in the regulation of cell-mediated immunity in leprosy. Kaplan, G. and Cohn, Z. A. ..... (A) 685
T4 lymphopenia in human tuberculosis. Onwubalili, J. K., *et al.* ..... (A) 158

Macrophage(s),
A rapid method for viability and drug sensitivity of *M. leprae* cultured in macrophages and using fluorescein diacetate. Bhagria, A. and Mahadevan, P. R. ..... (A) 144
Effect of protamine and rifampin liposomes on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 678
Induction of macrophage unresponsiveness to interferon-gamma by *M. leprae* constituents. Krahenbuhl, J. L., *et al.* ..... (A) 683
Induction of unresponsiveness to gamma interferon in macrophages infected with *M. leprae*. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 660
Infection with live mycobacteria inhibits *in vitro* detection of Ia antigen on macrophages. Mshana, R. N., *et al.* ..... (A) 494
Inhibition of macrophage priming by sulfatide from *M. tuberculosis*. Pabst, M. J., *et al.* ..... (A) 670
Inhibition of phagosome-lysosome fusion in macrophages by certain mycobacteria can be explained by inhibition of lysosomal movements observed after phagocytosis. D'Arcy Hart, P., *et al.* ..... (A) 375
Interaction of *M. lepraemurium* with resident peritoneal macrophages; phagocytosis and stimulation of the oxidative burst. Brett, S. J. and Butler, R. ..... (A) 375

Intracellular fate of *M. leprae* in normal and activated mouse macrophages. Sibley, L. D., *et al.* ..... (A) 143
M. lepraemurium activates macrophages but fails to trigger release of superoxide anion. Mor, N., *et al.* ..... (A) 669
Macrophage activation after phagocytosis of *M. lepraemurium* and *M. avium in vitro*. Fukutomi, Y., *et al.* ..... (A) 684
Monoclonal antibodies distinguish macrophages and epithelioid cells in sarcoidosis and leprosy. Munro, C. S., *et al.* ..... (A) 361
Regulatory interactions between macrophages and *M. lepraemurium*-specific T-cell activation. Brett, S. J. ..... (A) 370
Superoxide production from macrophages of leprosy patients after stimulation with *M. leprae*. Marolia, J. and Mahadevan, P. R. ..... (A) 360
The phagocytic activity of macrophages correlates with the RT1.B-restricted immune response to *M. lepraemurium* in the rat. Natori, T., *et al.* ..... (A) 147
Transitory macrophage activation in the granulomatous lesions of *M. lepraemurium*-induced lepromatoid leprosy in the mouse. Rojas-Espinosa, O., *et al.* ..... (O) 428

Malaria,
Comparison between autoantibodies in malaria and leprosy with lupus. Bonfa, E., *et al.* ..... (A) 355
Oral *Salmonella typhimurium* vaccine expressing circumsporozoite protein protects against malaria. Sadoff, J. C., *et al.* ..... (A) 514

Malawi,
Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Boerrigter, G., *et al.* ..... (O) 408
Seroepidemiological studies of leprosy in northern Malawi based on an enzyme-linked immunosorbent assay using synthetic glycoconjugate antigen. Fine, P. E. M., *et al.* ..... (O) 243
The Lepra Evaluation Project (LEP) in northern Malawi. I: Methods. Ponnighaus, J. M., *et al.* ..... (A) 373
The Lepra Evaluation Project (LEP), an epidemiological study of leprosy in north Malawi. II. Prevalence rates. Ponnighaus, J. M., *et al.* ..... (A) 666

Malaysia,
Human behavioural research applied to the leprosy control programme of Sarawak, Malaysia. Chen, P. C. Y. ..... (A) 342
The development of culture-specific health education packages to increase case-finding of leprosy in Sarawak. Chen, P. C. Y. and Sim, H. C. ..... (A) 342

Mali,
Facies leprosa: resorption of maxillary anterior alveolar bone and the anterior nasal spine in patients with lepromatous leprosy in Mali. Marks, S. C., Jr. and Grossetete, G. ..... (O) 21
Persisting *M. leprae* among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical ... . (A) 347
Primary dapsone resistance in Bamako and Chingleput: final report. Subcommittee on Clinical ... . (A) 368

Metabolism,
Biophysical optima for metabolism of *M. leprae*. Franzblau, S. G. and Harris, E. B. ... (A) 663
Factors affecting growth of the metabolically competent but microbe-dependent *M. leprae* (?); indications for *in vitro* cultivation in a multifactorial medium. Kato, L. .. (A) 145
Metabolic studies in mycobacteria. III. Demonstration of key enzymes of TCA cycles in *M. leprae*. Katoch, V. M., *et al.* ..... (A) 146
... IV. Assay of isocitrate lyase and malate synthase activity in *M. leprae*. Bharadwaj, V. P., *et al.* ..... (A) 144
... V. A preliminary report on the ATP synthesis by mycobacteria including *M. leprae* by using different substrates. Katoch, V. M., *et al.* ..... (A) 146
Rapid *in vitro* metabolic screen for antileprosy compounds. Franzblau, S. G. and Hastings, R. C. ..... (A) 367

Mice,
Activity of minocycline in *M. leprae*-infected mice. Gelber, R. H. ..... (A) 147
Activity of ofloxacin against *M. leprae* in the mouse. Grosset, J. H., *et al.* ..... (O) 259

Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. Subcommittee on Clinical ... (A) 484
Cytogenetic effect of dapsone, an antileprotic drug, in the mouse *in vivo* system. Roy, B. and Das, R. K. (O) 574
Evidence for a biphasic memory T-cell response to high dose BCG vaccination in mice. Orme, I. M. (A) 670
Haemophagocytosis and other haematological aspects of *M. lepraemurium* disease of mice. Resnick, M., *et al.* (A) 665
Inoculation of *M. leprae* into beige mice. Kohsaka, K., *et al.* (A) 501
M. bovis BCG-induced protection against cutaneous and systemic *Leishmania major* infections in mice. Fortier, A. H., *et al.* (A) 668
Recombinant interleukin-2 limits the replication of *M. lepraemurium* and *M. bovis* BCG in mice. Jeevan, A. and Asherson, G. L. (A) 492
Renal involvement in *M. leprae* infected mice; histopathological, bacteriological and immunofluorescence study. Vaishnavi, C., *et al.* (A) 503
Role of mononuclear phagocytes in expression of resistance and susceptibility to *M. avium* infections in mice. Stokes, R. W., *et al.* (A) 160
The dynamics of infection following BCG and *M. tuberculosis* challenge in T-cell-deficient mice. Orme, I. M. (A) 379
The experimental inoculation with *M. leprae* in the congenitally asplenic mouse. Yogi, Y. and Nakamura, K. (A) 504
The Ity/Lsh/Bcg gene significantly affects mouse resistance to *M. lepraemurium*. Brown, I. N. and Glynn, A. A. (A) 370
The killing of *M. leprae* in mice by various dietary concentrations of clofazimine and ethionamide. Gelber, R. H. (A) 370
The lack of therapeutic effects in mice of the combined gamma-irradiated *M. leprae* and viable BCG against *M. leprae* infection. Saito, H., *et al.* (A) 502
Transitory macrophage activation in the granulomatous lesions of *M. lepraemurium*-induced lepromatoid leprosy in the mouse. Rojas-Espinosa, O., *et al.* (O) 428

Mice, nude,
Adoptively transferred reactivity to *M. leprae* in nude mice infected with *M. leprae*. Shannon, E. J., *et al.* (A) 365
An attempt to induce a histological ENL symptom in *M. leprae* infected nude mice. Subowo (A) 502
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. (A) 501
Experimental inoculation with leprosy bacillus in various hybrid mice (continued): results of CD-1 (ICR) hybrid nude mice. Nakamura, K. and Yogi, Y. (A) 686
Further observations on the breeding and rearing of BALB/C nude (nu-nu) mice under normal laboratory conditions. Rungruang, S. (A) 514
The nude mouse as an experimental lepromatous leprosy model (continued): the lepromatoid lesions in mystacial vibrissae located site of injection. Yogi, Y. and Nakamura, K. (A) 503
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* (A) 501

Microbiology,
Microbiological assay versus spectrophotometry for determination of rifampicin in urine. George, J., *et al.* (A) 649
[Microbiology of leprosy.] Cocito, C., *et al.* (A) 366
Repeated isolation of Nocardia like organisms from multibacillary cases of leprosy. Chakrabarty, A. N., *et al.* (A) 498

Microscopy,
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. (A) 501
[Fluorescent microscopy for the study of acid-fast bacilli in cutaneous tuberculosis.] Lazarova, A., *et al.* (A) 512
Ultracytochemical and light microscopic histochemical studies in murine leprosy. Bharadwaj, V. P., *et al.* (A) 500

Minocycline,
Activity of minocycline in *M. leprae*-infected mice. Gelber, R. H. ..... (A) 147
Effect of ofloxacin and minocycline on experimental leprosy. Kohsaka, K. and Ito, T. ..... (A) 678

Mitsuda, reaction,
Evidence that the Mitsuda reaction to *M. leprae* can be mediated by lymphocytes responsive to *M. tuberculosis*. Roberts, P. O., *et al.* ..... (A) 660
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae*. Pemajayantha, V., *et al.* ..... (A) 495
Twenty years observation of lepromin reaction (Mitsuda antigen) in leprosy patients. Takizawa, H. and Kobayashi, S. ..... (A) 488

Monkey(s),
A second sooty mangabey monkey with naturally acquired leprosy: first reported possible monkey-to-monkey transmission. Gormus, B. J., *et al.* ..... (O) 61
Experimental leprosy in African green monkeys (*Cercopithecus aethiops*): a model for polyneuritic leprosy. Baskin, G. B., *et al.* ..... (A) 369
Histopathological changes in the eyes of mangabey monkeys with lepromatous leprosy. Malaty, R., *et al.* ..... (O) 443
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ..... (O) 537

Multidrug therapy (MDT),
A computer simulation of the effect of multidrug therapy on the incidence of leprosy. Lechat, M. F., *et al.* ..... (A) 149
[Clinical effect of multidrug therapy regimen.] Wang, Z., *et al.* ..... (A) 348
Clinical, bacteriological and histopathological assessment of multibacillary leprosy cases after 1 and 2 years' multidrug therapy; preliminary communication. McNair, A. N., *et al.* ..... (A) 133
Drug interaction during multidrug regimens for treatment of leprosy. George, J., *et al.* ..... (A) 482
[Effect of MDT regimen on bacillus index for 2 years in 317 multibacillary leprosy patients.] Tao, M., *et al.* ..... (A) 348
Evaluation of two regimens of multidrug therapy in multibacillary leprosy (a preliminary report). Grugni, A., *et al.* ..... (A) 649
Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy. Katoch, K., *et al.* ..... (A) 132
Follow-up study of paucibacillary leprosy on multidrug regimen. Ramanan, R., *et al.* ..... (A) 133
Leprous neuritis, classification of leprosy, and multidrug therapy. Negesse, Y. ..... (C) 329
Manual of multidrug therapy published. (China) Ye, G.-Y. ..... (N) 637
Multidrug therapy in hospitalised leprosy cases. Tiwari, V. D., *et al.* ..... (A) 654
[Multidrug therapy of multibacillary leprosy for one year.] Shen, W., *et al.* ..... (A) 484
Multidrug therapy. (India) ..... (N) 120
[Pathologic changes in multibacillary leprosy after two years of treatment with MDT.] Ma, B. ..... (A) 650
Screening of drug resistant strains of *M. leprae* in lepromatous leprosy patients under multidrug treatment. Sreevatsa, *et al.* ..... (A) 484
Short-course multidrug therapy for leprosy patients in western Kenya. Preliminary communication. Orege, P. A., *et al.* ..... (A) 346
Three years' assessment of multidrug therapy in multibacillary cases. Ganapati, R., *et al.* ..... (A) 131
[Treatment of multibacillary leprosy with MDT for half a year.] (China) Shangluo Sanatorium ..... (A) 134

Murine,
Effect of protamine and rifampin liposomes on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 678
Genetic control of murine T cell proliferative responses to *M. leprae*. V. Evidence for crossreactivity between host antigens and *M. leprae*. Harris, D. P., *et al.* ..... (A) 657
Heterologous expression of the 65-kilodalton antigen of *M. leprae* and murine T-cell responses to the gene product. Lamb, F. I., *et al.* ..... (A) 492

Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: ultrastructure and drug-susceptibility studies. Rastogi, N., *et al.* ....(A) 379
Multiplication of armadillo-derived *M. leprae* in murine dissociated Schwann cell cultures. Antia, N. H., *et al.* ....(C) 632
Ultracytochemical and light microscopic histochemical studies in murine leprosy. Bharadwaj, V. P., *et al.* ....(A) 500

Mycobacteria, (see also individual species),
[AIDS and atypical mycobacteria.] Portaels, F. ....(A) 671
Analysis of deoxyribonucleic acids from armadillo-derived mycobacteria. De Kesel, M., *et al.* ....(A) 366
Analysis of mycolic acid cleavage products and cellular fatty acids of *Mycobacterium* species by capillary gas chromatography. Lambert, M. A., *et al.* ....(A) 378
Antibodies to HIV-1 in sera from patients with mycobacterial infections. ShivRaj, L., *et al.* ....(O) 546
Biosynthesis and scavenging of purines by pathogenic mycobacteria including *M. leprae.* Wheeler, P. R. ....(A) 369
Detection of mycobacterial lipids in skin biopsies from leprosy patients. Venkatesan, K., *et al.* ....(A) 368
Development of genetic systems for the mycobacteria. Jacobs, W. R., Jr., *et al.* ....(A) 678
Distinction of *M. tuberculosis* from other mycobacteria through DNA hybridization. Bhattacharya, S., *et al.* ....(A) 511
Distribution of phthiocerol diester, phenolic mycosides and related compounds in mycobacteria. Daffé, M. and Laneelle, M. A. ....(A) 662
Effects of freezing and thawing on the viability and the ultrastructure of *in vivo* grown mycobacteria. Portaels, F., *et al.* ....(O) 580
Enzymes for purine synthesis and scavenging in pathogenic mycobacteria and their distribution in *M. leprae.* Wheeler, P. R. ....(A) 369
Evidence for genetic divergence in ribosomal RNA genes in mycobacteria. Cox, R. A. and Katoch, V. M. ....(A) 154
4th International Colloquium on the Mycobacteria. ....(N) 120
Haptenic oligosaccharides in antigenic variants of mycobacterial C-mycosides antagonize lipid receptor activity for mycobacteriophage D4 by masking a methylated rhamnose. Dhariwal, K. R., *et al.* ....(A) 155
In vitro activity of five new guinolones against cultivable mycobacteria. Pattyn, S. R., *et al.* ....(A) 499
In vitro activity of new rifamycins against rifampicin-resistant *M. tuberculosis* and MAIS-complex mycobacteria. Dickinson, J. M. and Mitchison, D. A. ....(A) 155
In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index, and FDA-EB fluorescent staining in *M. leprae.* Katoch, V. M., *et al.* ....(A) 664
Infection with live mycobacteria inhibits *in vitro* detection of Ia antigen on macrophages. Mshana, R. N., *et al.* ....(A) 494
Inhibition of phagosome-lysosome fusion in macrophages by certain mycobacteria can be explained by inhibition of lysosomal movements observed after phagocytosis. D'Arcy Hart, P., *et al.* ....(A) 375
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ....(A) 141
Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774; ultrastructure and drug-susceptibility studies. Rastogi, N., *et al.* ....(A) 379
Isolation of mycobacteria from healthy persons' stools. Portaels, F., *et al.* ....(C) 468
Localization and retention of mycobacterial antigen in lymph nodes of leprosy patients. Barros, U., *et al.* ....(A) 354
Metabolic studies on mycobacteria. III. Demonstration of key enzymes of TCA cycles in *M. leprae.* Katoch, V. M., *et al.* ....(A) 146
... IV. Assay of isocitrate lyase and malate synthase activity in *M. leprae.* Bharadwaj, V. P., *et al.* ....(A) 144
... V. A preliminary report on the ATP synthesis by mycobacteria including *M. leprae* by using different substrates. Katoch, V. M., *et al.* ....(A) 146
Molecular-genetic evidence for the relationship of *M. leprae* to slow-growing pathogenic mycobacteria. Smida, J., *et al.* ....(O) 449

Mycobacteria and Human Disease by J. M. Grange. ..... (B) 479
Mycobacterial antigen detection of immunohistochemistry in pulmonary tuberculosis. Humphrey, D. M. and Weiner, M. H. ..... (A) 376
Mycobacterial carbohydrate antigens for serological testing of patients with leprosy. Levis, W. R., *et al.* ..... (A) 360
Mycobacterial genes and antigens. Young, R. A. ..... (A) 687
Mycolic acid analysis for clinical identification of *M. avium* and related mycobacteria. Lévy-Frèbault, V., *et al.* ..... (A) 378
Nerve damage induced by mycobacterial granulomas in guinea pig sciatic nerves. Cowley, S. A., *et al.* ..... (O) 283
[New method for the determination of the virulence of nontuberculous mycobacteria and faintly virulent *M. tuberculosis.*] Brudnaya, Y. E., *et al.* ..... (A) 511
Nontuberculous mycobacterial skin infection resembling lepromatous leprosy. Love, G. L. ..... (A) 378
[Preparation of monoclonal antibodies to mycobacterial antigens.] Yurin, B. L. and Smirnova, E. Y. ..... (A) 161
Psychrophilic mycobacteria in *M. leprae*-infected tissues. Kato, L. ..... (C) 631
Repetitive DNA sequence of *M. tuberculosis*: analysis of differential hybridization pattern with other mycobacteria. Reddi, P. P., *et al.* ..... (O) 592
[Role of various mycobacterial species in epidemiology of tuberculosis.] Tarasov, A. S., *et al.* ..... (A) 160
Seroreactivity against the *M. leprae* phenolic glycolipid I in mycobacteria-infected or stimulated groups of individuals. Gonzalez-Abreu, E. and Gonzalez, A. ..... (A) 140
Studies of clofazimine resistance in mycobacteria: is the inability to isolate drug-resistant mutants related to its mode of action? David, H. L., *et al.* ..... (A) 345
The detection of mycobacterial DNA sequences in uncultured clinical specimens with cloned *M. tuberculosis* DNA as probes. Pao, C.-C., *et al.* ..... (A) 513
Three types of response to mycobacterial antigens. Lockwood, D. N. J., *et al.* ..... (A) 669
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ..... (A) 153
Use of carbon sources for lipid biosynthesis of *M. leprae*: a comparison with other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 664

Mycobacterium avium,

Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* and *M. avium* complex. Heifets, L. B. and Lindholm-Levy, P. J. ..... (A) 376
Comparative *in vitro* activities of ampicillin, BMY 28142, and imipenem against *M. avium* complex. Cynamon, M. H., *et al.* ..... (A) 375
Macrophage activation after phagocytosis of *M. lepraemurium* and *M. avium in vitro.* Fukutomi, Y., *et al.* ..... (A) 684
Mycolic acid analysis for clinical identification of *M. avium* and related mycobacteria. Lévy-Frèbault, V., *et al.* ..... (A) 378
Role of mononuclear phagocytes in expression of resistance and susceptibility to *M. avium* infections in mice. Stokes, R. W., *et al.* ..... (A) 160
Susceptibilities of transparent, opaque, and rough colonial variants of *M. avium* complex to various fatty acids. Saito, H. and Tomioka, H. ..... (A) 514
Taxonomic differences between *M. avium* and *M. intracellulare* elucidated in man by skin tests with three new tuberculins. McIntyre, G., *et al.* ..... (A) 379
Two groups of *M. avium* complex strains determined according to the susceptibility to rifampicin and ansamycin. Tsukamura, M. ..... (A) 380

Mycobacterium avium-intracellulare,

Analysis of plasmids in *M. avium-intracellulare* isolates from persons with acquired immunodeficiency syndrome. Crawford, J. T. and Bates, J. H. ..... (A) 154
Immunological approach for control of *M. avium-intracellulare* infections in AIDS—an hypothesis. Deo, M. G. ..... (E) 455

Mycobacterium bovis,

Determination of the D and L configuration of phenolic glycolipids of *M. leprae* and *M. bovis.* Fujiwara, T. ..... (C) 112
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; and *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ..... (A) 657

Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ..... (O) 265
Immunopurification of radiolabeled antigens of *M. leprae* and *M. bovis* (bacillus Calmette-Guérin) with monoclonal antibodies. Britton, W. J., *et al.* ..... (A) 139
Immunoreactivity of a 70 kD protein purified from *M. bovis* bacillus Calmette-Guérin by monoclonal antibody affinity chromatography. Britton, W. J., *et al.* ..... (A) 153
M. bovis BCG-induced protection against cutaneous and systemic *Leishmania major* infections in mice. Fortier, A. H., *et al.* ..... (A) 668
MPB59, a widely crossreacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 144
Preparation and properties of antigen 60 from *M. bovis* BCG. Cocito, C. and Vanlinden, F. ..... (A) 154
Recombinant interleukin-2 limits the replication of *M. lepraemurium* and *M. bovis* BCG in mice. Jeevan, A. and Asherson, G. L. ..... (A) 492

Mycobacterium chelonei,
M. chelonei and abscess formation in soft tissues. Hanson, P. J. V., *et al.* ..... (A) 376
[Sporotricoid infection due to *M. chelonei.*] Zarco Olivo, C., *et al.* ..... (A) 671

Mycobacterium gordonae,
Chronic keratitis caused by *M. gordonae.* Moore, M. B., *et al.* ..... (A) 158

Mycobacterium intracellulare,
Taxonomic differences between *M. avium* and *M. intracellulare* elucidated in man by skin tests with three new tuberculins. McIntyre, G., *et al.* ..... (A) 379
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ..... (A) 501

Mycobacterium leprae,
[A comparison of skin scraping and skin biopsy in mouse foot pad experiments with *M. leprae.*] Wang, H. ..... (A) 371
A component of *M. leprae* as immunomodulating agent for immune deficient cells of leprosy patients. Robinson, P. and Mahadevan, P. R. ..... (A) 496
A rapid method for viability and drug sensitivity of *M. leprae* cultured in macrophages and using fluorescein diacetate. Bhagria, A. and Mahadevan, P. R. ..... (A) 144
[A study of subclinical infection with *M. leprae.* (I). The infection rate among household contacts of leprosy patients and the detection of population at high risk of infection.] Shu, H., *et al.* ..... (A) 508
Activity of minocycline in *M. leprae*-infected mice. Gelber, R. H. ..... (A) 147
Activity of ofloxacin against *M. leprae* in the mouse. Grosset, J. H., *et al.* ..... (O) 259
Adoptively transferred reactivity to *M. leprae* in nude mice infected with *M. leprae.* Shannon, E. J., *et al.* ..... (A) 365
An attempt to induce a histological ENL symptom in *M. leprae* infected nude mice. Subowo ..... (A) 502
Analysis of the antigenic profile of *M. leprae*: cross-reactive and unique specificities of human and rabbit antibodies. Ehrenberg, J. P. and Gebre, N. ..... (A) 356
Antigenic proteins of *M. leprae*; complete sequence of the gene for the 18-kDa protein. Booth, R. J., *et al.* ..... (A) 490
Antigens of *M. leprae* identified by immunoprecipitation with sera from leprosy and tuberculosis patients. Britton, W. J., *et al.* ..... (A) 491
Armadillo IgG and IgM antibody responses to phenolic glycolipid-I during experimental infection with *M. leprae.* Vadiee, A. R., *et al.* ..... (O) 422
[Assay of foot pad technique for the multiplication of *M. leprae* in different mouse lines existing in Cuba.] Suarez Moreno, O., *et al.* ..... (A) 371
Association of IgG and IgM antibodies to phenolic glycolipid-I antigen of *M. leprae* with disease parameters in multibacillary leprosy patients. Lyons, N. F., *et al.* ..... (A) 493
Axenic incorporation of [U-14C]palmitic acid into the phenolic glycolipid-I of *M. leprae.* Franzblau, S. G., *et al.* ..... (A) 499
Biophysical optima for metabolism of *M. leprae.* Franzblau, S. G. and Harris, E. B. ..... (A) 663
Biosynthesis and scavenging of purines by pathogenic mycobacteria including *M. leprae.* Wheeler, P. R. ..... (A) 369

Cellular, humoral, and gamma interferon responses to *M. leprae* and BCG antigens in healthy individuals exposed to leprosy. Converse, P. J., *et al.* ....(A) 656
Characteristics of the multiplication of dapsone-resistant strains of *M. leprae* in mice. Subcommittee on Clinical ... .(A) 484
Chemical synthesis of the trisaccharide unit of the species-specific phenolic glycolipid from *M. leprae.* Fujiwara, T., *et al.* ....(A) 145
Clinical and seroepidemiological application of *M. leprae*-specific gelatin particle agglutination test (MLPA) for leprosy. Izumi, S., *et al.* ....(A) 682
Dapsone susceptibility of *M. leprae* isolated before 1977. Ji, B., *et al.* ....(C) 326
Demonstration of *M. leprae* antigen in nerves of tuberculoid leprosy. Barros, U., *et al.* ....(A) 138
Demonstration that the galactosyl and arabinosyl residues in the cell-wall arabinogalactan of *M. leprae* and *M. tuberculosis* are furanoid. McNeil, M., *et al.* ....(A) 368
Determination of the D and L configuration of phenolic glycolipids of *M. leprae* and *M. bovis.* Fujiwara, T. ....(C) 112
DNA methylation in leprosy-associated bacteria: *M. leprae* and *Corynebacterium tuberculostearicum.* Hottat, F., *et al.* ....(A) 367
Effect of protamine and rifampin liposomes on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ....(A) 678
Effect of shipment of skin-biopsy specimens to a distant laboratory on viability of *M. leprae.* Baras, M. and Levy, L. ....(C) 115
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kaplan, G., *et al.* ....(A) 658
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. ....(A) 501
Enzymes for purine synthesis and scavenging in pathogenic mycobacteria and their distribution in *M. leprae.* Wheeler, P. R. ....(A) 369
Epithelioid cell granuloma induction in the guinea pig by haptenated *M. leprae.* Verghese, S., *et al.* ....(A) 144
Evidence that the Mitsuda reaction to *M. leprae* can be mediated by lymphocytes responsive to *M. tuberculosis.* Roberts, P. O., *et al.* ....(A) 660
Exact definition of species-specific and cross-reactive epitopes of the 65-kilodalton protein of *M. leprae* using synthetic peptides. Anderson, D. C., *et al.* ....(A) 655
Factors affecting growth of the metabolically competent but microbe-dependent *M. leprae* (?); indications for *in vitro* cultivation in a multifactorial medium. Kato, L. ..(A) 145
Gamma interferon, but not *M. leprae,* induces major histocompatibility class II antigens on cultured rat Schwann cells. Samuel, N. M., *et al.* ....(A) 364
Genetic control of murine T cell proliferative responses to *M. leprae.* V. Evidence for crossreactivity between host antigens and *M. leprae.* Harris, D. P., *et al.* ....(A) 657
Heterologous expression of the 65-kilodalton antigen of *M. leprae* and murine T-cell responses to the gene product. Lamb, F. I., *et al.* ....(A) 492
Histologic responses in sixty multibacillary leprosy patients inoculated with autoclaved *M. leprae* and live BCG. Meyers, W. M., *et al.* ....(O) 302
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; an *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ....(A) 657
Identification of a major immunostimulating protein from *M. leprae.* Mohagheghpour, N., *et al.* ....(A) 679
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ....(O) 265
Immunological effects of lepromin testing in Sri Lankan population groups. II. Effect of reactivity to a soluble protein antigen of *M. leprae.* Pinto, M. R. M., *et al.* ....(A) 362
Immunological responsiveness to *M. leprae* and BCG antigens in 98 leprosy patients and their household contacts. Sarno, E. N., *et al.* ....(A) 660
Immunological significance of *M. leprae* cell walls. Mehra, V., *et al.* ....(A) 682
Immunological significance of *M. leprae* cell walls. Melancon-Kaplan, J., *et al.* ....(A) 493
Immunopurification of radiolabeled antigens of *M. leprae* and *M. bovis* (bacillus Calmette-Guérin) with monoclonal antibodies. Britton, W. J., *et al.* ....(A) 139
In vitro activity of selected phenazines, fluoroquinolones, oxazolidinones and macrolides

against *M. leprae*: identification of potential antileprosy agents. Franzblau, S. G., *et al.* ..... (A) 677
In vitro effect of *M. leprae* suspensions on the polymorphonuclear neutrophil function of hanseniasis patients to *Candida albicans* and *C. pseudotropicalis*. Fliess, E. L., *et al.* ..... (A) 357
In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index, and FDA-EB fluorescent staining in *M. leprae*. Katoch, V. M., *et al.* ..... (A) 664
Induction of macrophage unresponsiveness to interferon-gamma by *M. leprae* constituents. Krahenbuhl, J. L., *et al.* ..... (A) 683
Induction of unresponsiveness to gamma interferon in macrophages infected with *M. leprae*. Sibley, L. D. and Krahenbuhl, J. L. ..... (A) 660
Inhibition of phenolic glycolipid-I synthesis in extracellular *M. leprae* as an indicator of antimicrobial activity. Harris, E. B., *et al.* ..... (O) 588
Inoculation of *M. leprae* into beige mice. Kohsaka, K., *et al.* ..... (A) 501
Intracellular fate of *M. leprae* in normal and activated mouse macrophages. Sibley, L. D., *et al.* ..... (A) 143
Isolation and characterization of large-molecular-size and hydrophobic protein antigens from the cell walls of *M. leprae*. Hunter, S. W., *et al.* ..... (A) 683
Isolation and characterization of the 36K antigen of *M. leprae*. de Wit, M. Y. L., *et al.* ..... (A) 140
Leukocyte subsets in the granulomatous response produced after inoculation with *M. leprae*-BCG in lepromatous patients. Gross, A., *et al.* ..... (A) 656
Limited *in vitro* multiplication of *M. leprae*. Dhople, A. M., *et al.* ..... (A) 663
[*M. leprae* resistance against dapsone and rifampicin; results of a survey carried out in the Cap-Verde region (Senegal).] Grosset, J., *et al.* ..... (A) 482
M. leprae surface components intervene in the early phagosome-lysosome fusion inhibition event. Frehel, C. and Rastogi, N. ..... (A) 357
M. leprae-reactive T-cell clones isolated from polar lepromatous and tuberculoid leprosy patients. Launois, P., *et al.* ..... (A) 360
Measurement of hypoxanthine incorporation in purified suspensions of *M. leprae*: a suitable method to screen for anti-leprosy agents. Wheeler, P. R. ..... (A) 500
Metabolic studies on mycobacteria. III. Demonstration of key enzymes of TCA cycles in *M. leprae*. Katoch, V. M., *et al.* ..... (A) 146
... IV. Assay of isocitrate lyase and malate synthase activity in *M. leprae*. Bharadwaj, V. P., *et al.* ..... (A) 144
... V. A preliminary report on the ATP synthesis by mycobacteria including *M. leprae* by using different substrates. Katoch, V. M., *et al.* ..... (A) 146
Molecular-genetic evidence for the relationship of *M. leprae* to slow-growing pathogenic mycobacteria. Smida, J., *et al.* ..... (O) 449
Most *M. leprae* carbohydrate-reactive monoclonal antibodies are directed by lipoarabinomannan. Gaylord, H., *et al.* ..... (A) 367
Multiplication of armadillo-derived *M. leprae* in murine dissociated Schwann cell cultures. Antia, N. H., *et al.* ..... (C) 632
Oxidation of palmitic acid by *M. leprae* in an axenic medium. Franzblau, S. G. ..... (A) 498
Partial characterization of antigens from *M. leprae* evoking IgG and IgM antibodies in armadillos. Vadiee, A. R., *et al.* ..... (O) 274
Partial nucleotide sequences of 16S ribosomal RNA isolated from armadillo-grown *M. leprae*. Estrada-G., I. C. E., *et al.* ..... (A) 663
Persisting *M. leprae* among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical ... . (A) 347
Psychrophilic mycobacteria in *M. leprae*-infected tissues. Kato, L. ..... (C) 631
Purification and characterization of a 36 kDa antigen of *M. leprae*. de Wit, M. Y. L. and Klatser, P. R. ..... (A) 663
Purification of 65-kDa protein of *M. leprae* in *Escherichia coli*. Nomaguchi, H., *et al.* ..... (A) 687
Renal involvement in *M. leprae* infected mice; histopathological, bacteriological and immunofluorescence study. Vaishnavi, C., *et al.* ..... (A) 503
Responses to *M. leprae* by lymphocytes from new and old leprosy: role of exogenous lymphokines. Tran Trao, V., *et al.* ..... (A) 661

Rifampicin-resistant strains of *M. leprae* may have reduced virulence. McDermott-Lancaster, R. D. and Hilson, G. R. F. ..... (A) 499
Screening of drug resistant strains of *M. leprae* in lepromatous leprosy patients under multidrug treatment. Sreevatsa, *et al.* ..... (A) 484
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ..... (O) 537
[Serological activity of semi-synthetic polysaccharide antigens of *M. leprae*.] Li, F., *et al.* ..... (A) 140
Seroreactivity against the *M. leprae* phenolic glycolipid I in mycobacteria-infected or stimulated groups of individuals. Gonzalez-Abreu, E. and Gonzalez, A. ..... (A) 140
Soluble antigen of *M. leprae* coupled with liposomes elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae*. I. Reactivity to lepromin A. Pinto, M. R. M., *et al.* ..... (A) 141
... II. Reactivity to a soluble protein antigen. Pinto, M. R. M., *et al.* ..... (A) 362
... III. The post-lepromin test scar in healthy populations in Sri Lanka. Pinto, M. R. M., *et al.* ..... (A) 362
Studies on the antigenic specificity of *M. leprae*. I. Isoelectric and chromatofocusing separation. Ibegbu, C., *et al.* ..... (A) 145
... II. Immunological characterization. Mandock, O., *et al.* ..... (A) 360
... III. Further studies on immunological characterization. Kale, V., *et al.* ..... (A) 358
Study of idiotypes expressed by monoclonal antibodies to the 35 kD and 12 kD antigens of *M. leprae*. Praputpittaya, K. and Ivanyi, J. ..... (A) 362
[Study on cell culture of *M. leprae*. (II). Effect of temperature on viability of *M. lepraemurium*.] Ye, S., *et al.* ..... (A) 515
Superoxide production from macrophages of leprosy patients after stimulation with *M. leprae*. Marolia, J. and Mahadevan, P. R. ..... (A) 360
The experimental inoculation with *M. leprae* in the congenitally asplenic mouse. Yogi, Y. and Nakamura, K. ..... (A) 504
The killing of *M. leprae* in mice by various dietary concentrations of clofazimine and ethionamide. Gelber, R. H. ..... (A) 370
The lack of therapeutic effects in mice of the combined gamma-irradiated *M. leprae* and viable BCG against *M. leprae* infection. Saito, H., *et al.* ..... (A) 502
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae*. Pemajayantha, V., *et al.* ..... (A) 495
The serological response to the phenolic glycolipid of *M. leprae* in Australian and Nepali leprosy patients. Britton, W. J., *et al.* ..... (A) 490
The simultaneous inoculation of *M. leprae* and *M. intracellulare* into nude mice: development of cutaneous leproma and acceleration of foot swelling. Kazda, J., *et al.* ..... (A) 501
Ultrastructure of human foetal Schwann cells in tissue culture infected with *M. leprae*. Samuel, N. M., *et al.* ..... (A) 502
Use of anti-*M. leprae* phenolic glycolipid-I antibody detection for early diagnosis and prognosis of leprosy. Agis, F., *et al.* ..... (O) 527
Use of carbon sources for lipid biosynthesis of *M. leprae*: a comparison with other pathogenic mycobacteria. Wheeler, P. R. and Ratledge, C. ..... (A) 664
Vaccination of borderline tuberculoid leprosy patients with BCG plus killed *M. leprae*. Samuel, N. M., *et al.* ..... (A) 496
Vaccination of human volunteers with heat-killed *M. leprae*: local responses in relation to the interpretation of the lepromin reaction. Gill, H. K., *et al.* ..... (O) 36

Mycobacterium lepraemurium,
Analysis of mycolic acids and various carbon-chain-lengths' fatty acids in *M. lepraemurium* originated from rough and smooth colonies grown on Ogawa's yolk media. Kusaka, T., *et al.* ..... (A) 499
Haemophagocytosis and other haematological aspects of *M. lepraemurium* disease of mice. Resnick, M., *et al.* ..... (A) 665
Interactions of *M. lepraemurium* with resident peritoneal macrophages; phagocytosis and stimulation of the oxidative burst. Brett, S. J. and Butler, R. ..... (A) 375
M. lepraemurium activates macrophages but fails to trigger release of superoxide anion. Mor, N., *et al.* ..... (A) 669

Macrophage activation after phagocytosis of *M. lepraemurium* and *M. avium in vitro.* Fukutomi, Y., *et al.* ..... (A) 684
Recombinant interleukin-2 limits the replication of *M. lepraemurium* and *M. bovis* BCG in mice. Jeevan, A. and Asherson, G. L. ..... (A) 492
Regulatory interactions between macrophages and *M. lepraemurium*-specific T-cell activation. Brett, S. J. ..... (A) 370
[Study on cell culture of *M. leprae.* (II). Effect of temperature on viability of *M. lepraemurium.*] Ye, S., *et al.* ..... (A) 515
The Ity/Lsh/Bcg gene significantly affects mouse resistance to *M. lepraemurium.* Brown, I. N. and Glynn, A. A. ..... (A) 370
The phagocytic activity of macrophages correlates with the RT1.B-restricted immune response to *M. lepraemurium* in the rat. Natori, T., *et al.* ..... (A) 147
Transitory macrophage activation in the granulomatous lesions of *M. lepraemurium*-induced lepromatoid leprosy in the mouse. Rojas-Espinosa, O., *et al.* ..... (O) 428

Mycobacterium tuberculosis,
A novel approach in the identification of T-cell epitopes in *M. tuberculosis* using human T-lymphocyte clones. Lamb, J. R. and Young, D. B. ..... (A) 157
Bacteriophage typing of *M. tuberculosis* cultures from incidents of suspected laboratory cross-contamination. Jones, W. D., Jr. ..... (A) 512
Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* and *M. avium* complex. Heifets, L. B. and Lindholm-Levy, P. J. ..... (A) 376
[Classification of *M. tuberculosis* by phage-type markers in Havana City Province.] (Cuba) Jimenez Misas, C. A., *et al.* ..... (A) 377
Demonstration that the galactosyl and arabinosyl residues in the cell-wall arabinogalactan of *M. leprae* and *M. tuberculosis* are furanoid. McNeil, M., *et al.* ..... (A) 368
Distinction of *M. tuberculosis* from other mycobacteria through DNA hybridization. Bhattacharya, S., *et al.* ..... (A) 511
[Dynamics of the excretion of bacterial and ultramicro forms of *M. tuberculosis* by patients with pulmonary tuberculosis in the process of chemotherapy.] Golyshevskaya, V. I., *et al.* ..... (A) 512
Enzyme-linked immunosorbent assay using *M. tuberculosis* antigen 5 for the diagnosis of pulmonary tuberculosis in China. Ma, Y., *et al.* ..... (A) 379
Evidence that the Mitsuda reaction to *M. leprae* can be mediated by lymphocytes responsive to *M. tuberculosis.* Roberts, P. O., *et al.* ..... (A) 660
In vitro activity of new rifamycins against rifampicin-resistant *M. tuberculosis* and MAIS-complex mycobacteria. Dickinson, J. M. and Mitchison, D. A. ..... (A) 155
In vitro susceptibility of *M. tuberculosis* to a new macrolide antibiotic: RU-28965. Casal, M., *et al.* ..... (A) 154
Inhibition of macrophage priming by sulfatide from *M. tuberculosis.* Pabst, M. J., *et al.* ..... (A) 670
Mycobacteriocin typing of *M. tuberculosis* isolated from patients in south India. Selvakumar, N., *et al.* ..... (A) 515
[New method for the determination of the virulence of nontuberculous mycobacteria and faintly virulent *M. tuberculosis.*] Brudnaya, Y. E., *et al.* ..... (A) 511
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of *M. tuberculosis* to rifampin. Steiner, P., *et al.* ..... (A) 159
Repetitive DNA sequence of *M. tuberculosis*: analysis of differential hybridization pattern with other mycobacteria. Reddi, P. P., *et al.* ..... (O) 592
Restriction fragment analysis of chromosomal DNA defines different strains of *M. tuberculosis.* Shoemaker, S. A., *et al.* ..... (A) 159
Structure of the major triglycosyl phenol-phthiocerol of *M. tuberculosis* (strain Canetti). Daffé, M., *et al.* ..... (A) 155
The detection of mycobacterial DNA sequences in uncultured clinical specimens with cloned *M. tuberculosis* DNA as probes. Pao, C.-C., *et al.* ..... (A) 513
The dynamics of infection following BCG and *M. tuberculosis* challenge in T-cell-deficient mice. Orme, I. M. ..... (A) 379
The variability of *M. tuberculosis* in patients with cavitary pulmonary tuberculosis in the course of chemotherapy. Khomenko, A. G. ..... (A) 377

Mycobacterium vaccae,
[Cutaneous granuloma due to *M. vaccae.*] Mowszowicz, M., *et al.* ..... (A) 670

Mycobacterium w,
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ..... (O) 265

Nepal,
Primary dapsone resistance in multibacillary leprosy among Nepalese children. Samuel, N. M., *et al.* ..... (A) 347
The serological response to the phenolic glycolipid of *M. leprae* in Australian and Nepali leprosy patients. Britton, W. J., *et al.* ..... (A) 490
What does distance matter? Leprosy control in west Nepal. Pearson, M. ..... (A) 666

Nerve(s),
Alkaline phosphatase activity in peripheral nerves and endothelial cell cultures in leprosy. Mehta, L., *et al.* ..... (A) 140
Comparative histology of skin and nerve granulomas in leprosy patients. Mukherjee, A. and Misra, R. S. ..... (A) 659
Correlating Semmes-Weinstein monofilament mappings with sensory nerve conduction parameters in Hansen's disease patients: an update. Breger, D. ..... (A) 151
Demonstration of *M. leprae* antigen in nerves of tuberculoid leprosy. Barros, U., *et al.* ..... (A) 138
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (O) 56
Eighth nerve evaluation in leprosy. Mann, S. B. S., *et al.* ..... (A) 136
[Electron microscopic findings of the peripheral nerve lesions of nude mouse inoculated with *M. leprae*—perineural lesion.] Fukunishi, Y. ..... (A) 501
[Long-term results of surgical decompression of the posterior tibial nerve in neuropathy of Hansen's disease.] Chaise, F. and Boucher, P. ..... (A) 374
Nerve damage in leprosy. Shetty, V. P. and Antia, N. H. ..... (C) 619
Nerve damage induced by mycobacterial granulomas in guinea pig sciatic nerves. Cowley, S. A., *et al.* ..... (O) 283
Phrenic nerve conduction in leprosy. Dhand, U. K., *et al.* ..... (O) 389
Promotion of research on leprosy reactions and nerve damage. Engers, H. and Ji, B. ..... (N) 641
Pure neural leprosy in a child: a case report. Arora, S. K. and Mukhija, R. D. ..... (A) 349
[Remote results of decompression of posterior tibial nerve to prevent plantar ulcers and their recurrences.] Boucher, P. and Hirzel, C. ..... (A) 151
Sporotrichoid nerve abscess. Guha, P. K., *et al.* ..... (A) 486
[Study of the pathologic changes of posterior tibial nerve in arrested leprosy patients: to compare the combined chemotherapy with DDS treatment.] Zhu, W., *et al.* ..... (A) 662
[Treatment of neuralgia and prevention of deformity with endoneurolysis.] Guo, C., *et al.* ..... (A) 152
Unmyelinated nerve fibres in leprosy. A qualitative and quantitative study of sural nerve biopsies in 2 cases of lepromatous leprosy. Gibbels, E., *et al.* ..... (A) 656

Netherlands, The,
Fourth Immunodermatology Symposium notice. Bos, J. D. ..... (N) 339

Neuritis,
Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. Jacob, M. and Mathai, R. ..... (O) 56
Early Surgery for Hansen's Neuritis; an Illustrated Manual by S. Renzo and C. Panciera. Enna, C. D. ..... (B) 129
Field detection of early neuritis in leprosy. Fritschi, E. P. ..... (A) 151
Leprous neuritis, classification of leprosy, and multidrug therapy. Negesse, Y. ..... (C) 329

Neuropathy,
Autonomic neuropathy in leprosy. Ramachandran, A. and Neelan, P. N. ..... (A) 487
[Electromyography; a valuable method for the early diagnosis of the peripheral neuropathy of leprosy.] Yebra Sotillo, I., *et al.* ..... (A) 489
Leprosy presenting as peripheral neuropathy. Hale, W. A. ..... (A) 647
[Long-term results of surgical decompression of the posterior tibial nerve in neuropathy of Hansen's disease.] Chaise, F. and Boucher, P. ..... (A) 374
Myelin changes in leprous neuropathy. Jacobs, J. M., *et al.* ..... (A) 152

Teased fibre studies in leprous neuropathy. Jacobs, J. M., *et al.* ..... (A) 152
Thalidomide neuropathy: an electrophysiologic study. Lagueny, A., *et al.* ..... (A) 351

Nigeria,
A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone. Pieters, F. A. J. M., *et al.* ..... (O) 10
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patient in Nigeria. Pieters, F. A. J. M., *et al.* ..... (A) 483

Nose,
Facies leprosa: resorption of maxillary anterior alveolar bone and the anterior nasal spine in patients with lepromatous leprosy in Mali. Marks, S. C., Jr. and Grossetete, G. ..... (O) 21
Reactional states in the nasal mucosa: a clinical and histopathological study. Job, A. and Chacko, C. J. G. ..... (O) 523

Nutrition,
Nutrition in leprosy: a review. Foster, R. L., *et al.* ..... (E) 66
Undernutrition and lepromatous leprosy. III: Micronutrients and their transport proteins. Rao, K. N., *et al.* ..... (A) 353

Obituaries,
Bopp, Clovis. ..... (Ob) 323
Klingmüller, Georg. ..... (Ob) 324
Madarang, Monina G. ..... (Ob) 325

Ofloxacin,
Activity of ofloxacin against *M. leprae* in the mouse. Grosset, J. H., *et al.* ..... (O) 259
Bacteriostatic and bactericidal activity of ciprofloxacin and ofloxacin against *M. tuberculosis* and *M. avium* complex. Heifets, L. B. and Lindholm-Levy, P. J. ..... (A) 376
Effect of ofloxacin and minocycline on experimental leprosy. Kohsaka, K. and Ito, T. ..... (A) 678

Pakistan,
Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan: results 18 months after completion of treatment (Lahore Tuberculosis Study). Aziz, A., *et al.* ..... (A) 510

Papua New Guinea,
Clinical and laboratory studies of inflammatory polyarthritis in patients with leprosy in Papua New Guinea. Atkin, S. L., *et al.* ..... (A) 349
Use of phenolic glycolipid 1 for serodiagnosis of leprosy in a high prevalence village in Papua New Guinea. Baumgart, K., *et al.* ..... (A) 490

Pathology,
Adenosine deaminase activity in leprosy (a preliminary study). Chaudhary, S. G., *et al.* ..... (A) 651
Dr. Albert Dubois Quinquennial Prize for Tropical Pathology. ..... (N) 473
Male gonads in leprosy—a clinico-pathological study. Nigam, P., *et al.* ..... (A) 653
[Pathologic changes in multibacillary leprosy after two years of treatment with MDT.] Ma, B. ..... (A) 650
Pathology seminar at Carville. ..... (N) 123
[Study of the pathologic changes of posterior tibial nerve in arrested leprosy patients: to compare the combined chemotherapy with DDS treatment.] Zhu, W., *et al.* ..... (A) 662
[Treatment of patients temporomandibular joint pathology developing in lepromatous leprosy.] Sviridov, B. G., *et al.* ..... (A) 488

Phagocytes,
[Characterization of mononuclear phagocytes in leprosy skin lesions: a monoclonal study.] Sarno, E. N., *et al.* ..... (A) 660
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; an *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ..... (A) 657
Inhibition of phagosome-lysosome fusion in macrophages by certain mycobacteria can be explained by inhibition of lysosomal movements observed after phagocytosis. D'Arcy Hart, P., *et al.* ..... (A) 375

Interactions of *M. lepraemurium* with resident peritoneal macrophages; phagocytosis and stimulation of the oxidative burst. Brett, S. J. and Butler, R. ....(A) 375
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ....(A) 141
Macrophage activation after phagocytosis of *M. lepraemurium* and *M. avium in vitro.* Fukutomi, Y., *et al.* ....(A) 684
[Phagocytic syndrome in lepromatous leprosy patients and in armadillos infected with Hansen's bacillus.] Urteaga-Ballon, O. ....(A) 365
Role of mononuclear phagocytes in expression of resistance and susceptibility to *M. avium* infections in mice. Stokes, R. W., *et al.* ....(A) 160
The phagocytic activity of macrophages correlates with the RT1.B-restricted immune response to *M. lepraemurium* in the rat. Natori, T., *et al.* ....(A) 147

Pharmacokinetics,
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patient in Nigeria. Pieters, F. A. J. M., *et al.* ....(A) 483
Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy. Garg, S. K., *et al.* ....(A) 648

Phenolic glycolipid,
Armadillo IgG and IgM antibody responses to phenolic glycolipid-I during experimental infection with *M. leprae.* Vadiee, A. R., *et al.* ....(O) 422
Association of IgG and IgM antibodies to phenolic glycolipid-I antigen of *M. leprae* with disease parameters in multibacillary leprosy patients. Lyons, N. F., *et al.* ....(A) 493
Axenic incorporation of [U-14C] palmitic acid into the phenolic glycolipid-I of *M. leprae.* Franzblau, S. G., *et al.* ....(A) 499
Chemical synthesis of the trisaccharide unit of the species-specific phenolic glycolipid from *M. leprae.* Fujiwara, T., *et al.* ....(A) 145
Comparison of synthetic antigens for detecting antibodies to phenolic glycolipid I in patients with leprosy and their household contacts. Chanteau, S., *et al.* ....(A) 504
Determination of the D and L configuration of phenolic glycolipids of *M. leprae* and *M. bovis.* Fujiwara, T. ....(C) 112
Human monoclonal antibodies to phenolic glycolipid-I derived from patients with leprosy, and production of specific anti-idiotypes. Locniskar, M., *et al.* ....(A) 658
Inhibition of phenolic glycolipid-I synthesis in extracellular *M. leprae* as an indicator of antimicrobial activity. Harris, E. B., *et al.* ....(O) 588
Serodiagnosis of leprosy with PGL-I using ELISA technique. Dandekar, S. R., *et al.* ..(A) 356
Serologic responses to *M. leprae*-specific phenolic glycolipid-I antigen in sooty mangabey monkeys with experimental leprosy. Gormus, B. J., *et al.* ....(O) 537
Seroreactivity against the *M. leprae* phenolic glycolipid I in mycobacteria-infected or stimulated groups of individuals. Gonzalez-Abreu, E. and Gonzalez, A. ....(A) 140
[Study on serological property of synthetic glycoconjugates containing the immunodominant epitope of PG-I.] Wu, Q., *et al.* ....(A) 497
Synthesis of the neoglycoconjugates of phenolic glycolipid-related trisaccharides for the serodiagnosis of leprosy. Fujiwara, T. and Izumi, S. ....(A) 367
The serological response to the phenolic glycolipid of *M. leprae* in Australian and Nepali leprosy patients. Britton, W. J., *et al.* ....(A) 490
Use of anti-*M. leprae* phenolic glycolipid-I antibody detection for early diagnosis and prognosis of leprosy. Agis, F., *et al.* ....(O) 527
Use of phenolic glycolipid 1 for serodiagnosis of leprosy in a high prevalence village in Papua New Guinea. Baumgart, K., *et al.* ....(A) 490

Philippines, The,
Knowledge, beliefs and attitudes on leprosy in Iloilo City proper, Philippines. Gerochi, L. N. ....(A) 151

Phytohemagglutinin,
[Effect of treating leprosy with PHA in a short term.] Xu, S., *et al.* ....(A) 498

Pregnancy,
[Leprosy and pregnancy.] Correa, P., *et al.* ....(A) 350

Prostaglandin,
Clofazimine-mediated stimulation of prostaglandin synthesis and free radical production as novel mechanisms of drug-induced immunosuppression. Zeis, B. M. and Anderson, R. ..... (A) 348
Interleukin 1 and prostaglandin production by cells of the mononuclear phagocyte system isolated from mycobacterial granuloma. Montreewasuwat, N., *et al.* ..... (A) 141
The effect of ten phenazine-derivatives in comparison to clofazimine on the production of prostaglandin E2 by polymorphonuclear leucocytes. Zeis, B. M., *et al.* ..... (A) 348

Protein(s),
Antigenic proteins of *M. leprae*; complete sequence of the gene for the 18-kDa protein. Booth, R. J., *et al.* ..... (A) 490
Exact definition of species-specific and cross-reactive epitopes of the 65-kilodalton protein of *M. leprae* using synthetic peptides. Anderson, D. C., *et al.* ..... (A) 655
Identification of a major immunostimulating protein from *M. leprae.* Mohagheghpour, N., *et al.* ..... (A) 679
Immunological effects of lepromin testing in Sri Lankan population groups. II. Effect of reactivity to a soluble protein antigen of *M. leprae.* Pinto, M. R. M., *et al.* ..... (A) 362
Immunoreactivity of a 70 kD protein purified from *M. bovis* bacillus Calmette-Guérin by monoclonal antibody affinity chromatography. Britton, W. J., *et al.* ..... (A) 153
Isolation and characterization of large-molecular-size and hydrophobic protein antigens from the cell walls of *M. leprae.* Hunter, S. W., *et al.* ..... (A) 683
MPB59, a widely crossreacting protein of *M. bovis* BCG. Wiker, H. G., *et al.* ..... (A) 144
Purification of 65-kDa protein of *M. leprae* in *Escherichia coli.* Nomaguchi, H., *et al.* ..... (A) 687
Stress proteins are immune targets in leprosy and tuberculosis. Young, D., *et al.* ..... (A) 661
Stress-induced proteins and the immune response to leprosy. Young, D. B. ..... (A) 665
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae.* II. Reactivity to a soluble protein antigen. Pinto, M. R. M., *et al.* ..... (A) 362
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae.* Pemajayantha, V., *et al.* ..... (A) 495

Prothionamide,
Long-term prothionamide compliance; study carried out in India using a combined formulation containing prothionamide, dapsone and isoniazid. Ellard, G. A., *et al.* ..(A) 648

Psychosocial,
Leprosy—as seen by the patients. Valencia, L. B. ..... (A) 489
[On suicide among leprosy patients.] Zhou, D., *et al.* ..... (A) 489
Psychiatric aspects of Hansen's disease (leprosy). Olivier, H. R. ..... (A) 352
Sixty years of psychiatry at Carville. Olivier, H. R. ..... (A) 352

Purine(s),
Biosynthesis and scavenging of purines by pathogenic mycobacteria including *M. leprae.* Wheeler, P. R. ..... (A) 369
Enzymes for purine synthesis and scavenging in pathogenic mycobacteria and their distribution in *M. leprae.* Wheeler, P. E. ..... (A) 369

Radioimmunoassay,
[Determination of SIgA in the tears of leprosy patients by radioimmunoassay.] He, H., *et al.* ..... (A) 350

Rapa,
[Last offensive of leprosy in the South Pacific Ocean: the outbreak of Rapa (1922–1950).] Louis, F. J., *et al.* ..... (A) 149

Rat(s),
Gamma interferon, but not *M. leprae,* induces major histocompatibility class II antigens on cultured rat Schwann cells. Samuel, N. M., *et al.* ..... (A) 364
The phagocytic activity of macrophages correlates with the RT1.B-restricted immune responses to *M. lepraemurium* in the rat. Natori, T., *et al.* ..... (A) 147

Reaction, leprosy,
Epidermal changes in reactional leprosy: keratinocyte Ia expression as an indicator of cell-mediated immune responses. Thangaraj, H., *et al.* ..... (O) 401

Erythema nodosum leprosum reaction of leprosy causing the double stripe sign on bone scan; case report. Datz, F. L. ..... (A) 134
Hypercalcaemia and elevated 1,25-dihydroxy-vitamin D3 levels in a patient with multibacillary leprosy and a type 1 leprosy reaction. Fraser, A. G., *et al.* ..... (A) 135
LDH profile in an unusual case of leprosy in reaction associated with portal hypertension. Prasad, H. V., *et al.* ..... (A) 487
Promotion of research on leprosy reactions and nerve damage. Engers, H. and Ji, B. ..(N) 641
Reactional states in the nasal mucosa: a clinical and histopathological study. Job, A. and Chacko, C. J. G. ..... (O) 523
Severe reactional state in lepromatous leprosy simulating Sweet's syndrome. Kuo, T.-T. and Chan, H.-L. ..... (A) 652
Simultaneous upgrading reaction and erythema nodosum leprosum in a patient with lepromatous leprosy. Job, C. K., *et al.* ..... (O) 437
Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions. Chakrabarty, A. K., *et al.* ..... (O) 559
Type 1 (reversal) lepra reaction in borderline leprosy with unusual clinical presentation—a case report. Kar, H. K., *et al.* ..... (A) 351

Rehabilitation,
All-Africa Leprosy and Rehabilitation Centre (ALERT) training courses for 1988. ....(N) 336

Relapse(s),
[Analysis of 130 cases of relapsed leprosy.] Zhao, Z., *et al.* ..... (A) 485
[Analysis of 71 cases of relapsed leprosy in Lufeng County, Guangdong.] (China) Wang, Q. ..... (A) 354
Contribution of relapses to total infection sources of leprosy in Guadeloupe. Cartel, J. L., *et al.* ..... (A) 345
Relapse in Hansen's disease. Kunz, K. ..... (A) 351
The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. Pattyn, S. R., *et al.* ..... (A) 650

Rifampin,
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin followed by 1 year of daily dapsone with 10 weekly doses of rifampicin. Pattyn, S. R., *et al.* ..... (A) 347
Acute renal failure following rifampicin. Rajan, M. A., *et al.* ..... (A) 487
Comparison of *in vitro* antimycobacterial activities of ansamycin and rifampin. Tsukamura, M., *et al.* ..... (A) 160
Effect of protamine and rifampin liposomes on *M. leprae* in murine macrophages. Osawa, N. and Akiyama, T. ..... (A) 678
"Flu" syndrome on once monthly rifampicin. Patki, A. H., *et al.* ..... (A) 650
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. Parthasarathy, R., *et al.* ..... (A) 158
In vitro activity of new rifamycins against rifampicin-resistant *M. tuberculosis* and MAIS-complex mycobacteria. Dickinson, J. M. and Mitchison, D. A. ..... (A) 155
Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patient in Nigeria. Pieters, F. A. J. M., *et al.* ..... (A) 483
[*M. leprae* resistance against dapsone and rifampicin; results of a survey carried out in the Cap-Verde region (Senegal).] Grosset, J., *et al.* ..... (A) 482
Microbiological assay versus spectrophotometry for determination of rifampicin in urine. George, J., *et al.* ..... (A) 649
Papillary necrosis associated with rifampicin therapy. Mac-Moune Lai, F., *et al.* ..... (A) 346
Primary drug resistance to both rifampicin and dapsone in a paucibacillary leprosy patient. Koranne, R. V. and Srivastava, G. ..... (A) 652
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of *M. tuberculosis* to rifampin. Steiner, P., *et al.* ..... (A) 159
Renal failure and haemolysis caused by rifampicin. Van Assendelft, A. H. W. ..... (A) 134
Rifampicin-resistant strains of *M. leprae* may have reduced virulence. McDermott-Lancaster, R. D. and Hilson, G. R. F. ..... (A) 499
Serum and urinary rifampicin and hepatic toxicity. Gupta, P. R., *et al.* ..... (A) 131

The incubation time of relapses after treatment of multibacillary leprosy with rifampicin containing regimens. Pattyn, S. R., *et al.* ..... (A) 650
Treatment of paucibacillary leprosy patients with dapsone and rifampin. Samuel, N. M., *et al.* ..... (A) 484
Two groups of *M. avium* complex strains determined according to the susceptibility to rifampicin and ansamycin. Tsukamura, M. ..... (A) 380
[Use of biseptol for preventing rifampin resistance development in tubercle bacilli.] Dolzhansky, V. M. ..... (A) 668

Rifamycin,
In vitro activity of new rifamycins against rifampicin-resistant *M. tuberculosis* and MAIS-complex mycobacteria. Dickinson, J. M. and Mitchison, D. A. ..... (A) 155
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Dickson, J. M. ..... (A) 156

Sarcoidosis,
Monoclonal antibodies distinguish macrophages and epithelioid cells in sarcoidosis and leprosy. Munro, C. S., *et al.* ..... (A) 361

Screening,
Screening of drug resistant strains of *M. leprae* in lepromatous leprosy patients under multidrug treatment. Sreevatsa, *et al.* ..... (A) 484

Senegal,
[*M. leprae* resistance against dapsone and rifampicin; results of a survey carried out in the Cap-Verde region (Senegal).] Grosset, J., *et al.* ..... (A) 482

Sensations,
Bone loss in limbs with decreased or absent sensation: ten year follow-up of the hands in leprosy. MacMoran, J. W. and Brand, P. W. ..... (A) 374
Vibration sensation in leprosy patches. Klenerman, P. and Hammond, C. ..... (C) 466

Sensitivity, drug,
A rapid method for viability and drug sensitivity of *M. leprae* cultured in macrophages and using fluorescein diacetate. Bhagria, A. and Mahadevan, P. R. ..... (A) 144

Serodiagnosis,
A Trial to Compare Serodiagnostic Tests for Leprosy by the International Cooperative Team for Evaluating Serological Tests in Leprosy. ..... (B) 644
Evaluation of a dual-antigen ELISA test for the serodiagnosis of tuberculosis. Raheman, S. F., *et al.* ..... (A) 671
Serodiagnosis of leprosy with PGL-I using ELISA technique. Dandekar, S. R., *et al.* ..... (A) 356
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157
Synthesis of the neoglycoconjugates of phenolic glycolipid-related trisaccharides for the serodiagnosis of leprosy. Fujiwara, T. and Izumi, S. ..... (A) 367
Use of phenolic glycolipid 1 for serodiagnosis of leprosy in a high prevalence village in Papua New Guinea. Baumgart, K., *et al.* ..... (A) 490

Serum,
Antibodies to HIV-1 in sera from patients with mycobacterial infections. ShivRaj, L., *et al.* ..... (O) 546
Antigens of *M. leprae* identified by immunoprecipitation with sera from leprosy and tuberculosis patients. Britton, W. J., *et al.* ..... (A) 491
Assay of testosterone, FSH and LH in serum and spermogram in leprosy patients. Singh, J., *et al.* ..... (A) 654
Leprosy, hypercalcemia, and elevated serum calcitriol levels. Hoffman, V. N. and Korzeniowski, O. M. ..... (A) 486
Mycobacterial carbohydrate antigens for serological testing of patients with leprosy. Levis, W. R., *et al.* ..... (A) 360
Patterns of immunoglobulins in the serum of leprosy patients. Choudhary, M. S., *et al.* ..... (A) 134
Serological activity of natural disaccharide octyl bovine serum albumin (ND-O-BSA)

in sera from patients with leprosy, tuberculosis, and normal controls. Wu, Q.-X., *et al.* ..... (O) 50
Serum and urinary rifampicin and hepatic toxicity. Gupta, P. R., *et al.* ..... (A) 131
Serum antiphospholipid antibodies in leprosy. Quismorio, F. P., Jr. and Rea, T. H. ..... (A) 682
Solubilization of preformed immune complexes in sera of patients with type 1 and type 2 lepra reactions. Chakrabarty, A. K., *et al.* ..... (O) 559
Undernutrition and lepromatous leprosy; serum vitamin A and E levels in leprosy spectrum. Rao, K. N. and Saha, K. ..... (A) 653

Singapore,
Erythema nodosum leprosum in Singapore. Giam, Y. C., *et al.* ..... (A) 652
Histoid leprosy in Singapore. Giam, Y. C. and Seow, C. S. ..... (A) 652
Leprosy in Singapore. Tan, T. ..... (A) 654
2nd Asian Dermatological Congress. ..... (N) 638

Skin,
[A comparison of skin scraping and skin biopsy in mouse foot pad experiments with *M. leprae.*] Wang, H. ..... (A) 371
A study of leprosy and other skin diseases in school children in the state of Amazonas, Brazil. Talhari, S., *et al.* ..... (A) 373
[Characterization of mononuclear phagocytes in leprosy skin lesions: a monoclonal study.] Sarno, E. N., *et al.* ..... (A) 660
Comparative histology of skin and nerve granulomas in leprosy patients. Mukherjee, A. and Misra, R. S. ..... (A) 659
Demonstration of acid-fast bacilli in skin biopsies from indeterminate leprosy cases. Alvarez-Mendoza, A., *et al.* ..... (A) 655
Detection of mycobacterial lipids in skin biopsies from leprosy patients. Venkatesan, K., *et al.* ..... (A) 368
[Differential diagnosis of leprosy in developing countries—skin and oral cavity.] Stingl, P. ..... (A) 353
Effect of shipment of skin-biopsy specimens to a distant laboratory on viability of *M. leprae.* Baras, M. and Levy, L. ..... (C) 115
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kaplan, G., *et al.* ..... (A) 658
Increased pigmentation of skin along course of superficial veins of limbs in chronic plantar ulceration of leprosy patients. Siddalinga Swamy, M. K. and Ratnakar, C. ..... (C) 464
Isolation, purification and quantification of phenolic glycolipid-I from human leprosy skin tissues. Venkatesan, K., *et al.* ..... (A) 664
Nontuberculous mycobacterial skin infection resembling lepromatous leprosy. Love, G. L. ..... (A) 378
Soluble antigen of *M. leprae* coupled with liposome elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45

Skin smear(s),
Are bacterial counts on slit-skin smears in leprosy affected by preparing slides under field conditions? Sayer, J., *et al.* ..... (A) 353
Auramine staining in detecting small number of bacilli in skin smears. Bhatia, V. N., *et al.* ..... (A) 662
Laboratory Aspects of Leprosy; A Technical Manual for Smear Personnel by B. Devasundaram and C. J. G. Chacko. ..... (B) 479
Skin smears and bacterial index in multiple drug therapy. Agrawal, M. N. and Porichha, D. ..... (C) 628
Skin smears and the bacterial index (BI) in multiple drug therapy leprosy control programs: an unsatisfactory and potentially hazardous state of affairs. Georgiev, G. D. and McDougall, A. C. ..... (C) 101

Skin tests,
Comparative study of lepromin reaction in indeterminate leprosy and controls. Ravindranathan, O. and Sarojini, P. A. ..... (A) 654
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kaplan, G., *et al.* ..... (A) 658
Evidence that the Mitsuda reaction to *M. leprae* can be mediated by lymphocytes responsive to *M. tuberculosis.* Roberts, P. O., *et al.* ..... (A) 660

Immunological effects of lepromin testing in Sri Lankan population groups. II. Effect of reactivity to a soluble protein antigen of *M. leprae*. Pinto, M. R. M., *et al.* ..... (A) 362
Soluble antigen of *M. leprae* coupled with liposomes elicits both "early" and "late" delayed hypersensitivity skin reactions. Sengupta, U., *et al.* ..... (O) 45
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae*. I. Reactivity to lepromin A. Pinto, M. R. M., *et al.* ..... (A) 141
... II. Reactivity to a soluble protein antigen. Pinto, M. R. M., *et al.* ..... (A) 362
... III. The post-lepromin test scar in healthy populations in Sri Lanka. Pinto, M. R. M., *et al.* ..... (A) 362
Taxonomic differences between *M. avium* and *M. intracellulare* elucidated in man by skin tests with three new tuberculins. McIntyre, G., *et al.* ..... (A) 379
The influence of antimycobacterial chemotherapy on delayed hypersensitivity skin-test reactions in leprosy patients. Cree, I. A., *et al.* ..... (A) 651
The relationship between reactivities to lepromin A (Fernandez and Mitsuda) and a soluble protein antigen of *M. leprae*. Pemajayantha, V., *et al.* ..... (A) 495
Twenty years observation of lepromin reaction (Mitsuda antigen) in leprosy patients. Takizawa, H. and Kobayashi, S. ..... (A) 488
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ..... (A) 153
Vaccination of human volunteers with heat-killed *M. leprae*: local responses in relation to the interpretation of the lepromin reaction. Gill, H. K., *et al.* ..... (O) 36

Spain,
Fontilles International Courses 1988. ..... (N) 475
[The history and epidemiology of leprosy in the province of Almeria.] Miranda, R. F. and Fernandez, R. M. G. ..... (A) 149

Sperm,
Assay of testosterone, FSH and LH in serum and spermogram in leprosy patients. Singh, J., *et al.* ..... (A) 654

Sri Lanka,
Immunological effects of lepromin testing in Sri Lankan population groups. I. Effects of repeated lepromin testing. Pinto, M. R. M., *et al.* ..... (A) 142
... II. Effect of reactivity to a soluble protein antigen of *M. leprae*. Pinto, M. R. M., *et al.* ..... (A) 362
Studies of reactivity of some Sri Lankan population groups to antigens of *M. leprae*. I. Reactivity to lepromin A. Pinto, M. R. M., *et al.* ..... (A) 141
... II. Reactivity to a soluble protein antigen. Pinto, M. R. M., *et al.* ..... (A) 362
... III. The post-lepromin test scar in healthy populations in Sri Lanka. Pinto, M. R. M., *et al.* ..... (A) 362

Strains,
Auramine staining in detecting small number of bacilli in skin smears. Bhatia, V. N., *et al.* ..... (A) 662
Auramine staining in histopathology sections. Bhatia, V. N., *et al.* ..... (A) 490
In vitro methods for determination of viability of mycobacteria: comparison of ATP content, morphological index, and FDA-EB fluorescent staining in *M. leprae*. Katoch, V. M., *et al.* ..... (A) 664

Subclinical,
[A study of subclinical infection with *M. leprae*. (I). The infection rate among household contacts of leprosy patients and the detection of population at high risk of infection.] Shu, H., *et al.* ..... (A) 508

Superoxide,
M. lepraemurium activates macrophages but fails to trigger release of superoxide anion. Mor, N., *et al.* ..... (A) 669
Superoxide production from macrophages of leprosy patients after stimulation with *M. leprae*. Marolia, J. and Mahadevan, P. R. ..... (A) 360

Surgery,
[A modified method of Brand's extensor to flexor four tailed graft operation.] Zhang, G., *et al.* ..... (A) 510

Cataract surgery on leprosy patients. Suryawanshi, N. and Richard, J. ....(O) 238
Correction of claw fingers in leprosy by the Brand four-tailed tendon graft operation. Kadir, A. H. A. ....(A) 668
Early Surgery for Hansen's Neuritis; an Illustrated Manual by S. Renzo and C. Panciera. Enna, C. D. ....(B) 129
[Long-term results of surgical decompression of the posterior tibial nerve in neuropathy of Hansen's disease.] Chaise, F. and Boucher, P. ....(A) 374
[Surgical correction of deformed thumbs following paralysis of nervus ulnaris.] Zhang, G., *et al.* ....(A) 152

Switzerland,
Basic vaccinology. ....(N) 638
CIBA-GEIGY Leprosy Fund. ....(N) 475
Field research in leprosy. Engers, H. D. and Ji, B. ....(N) 640
Fortieth World Health Assembly. Noordeen, S. K. ....(N) 122
Interrelations of tropical diseases and HIV infection; TDR and GPA call for research proposals. ....(N) 640
New postgraduate fellowships in epidemiology. ....(N) 641
Promotion of research on leprosy reactions and nerve damage. Engers, H. and Ji, B. ..(N) 641
Special Programme for Research and Training in Tropical Diseases; Eighth Report 1987. ....(N) 339
TDR topics for leprosy research in endemic countries. ....(N) 340
THELEP SWG Fifth Meeting. ....(N) 476

Teeth,
Periodontal findings in patients with leprosy. Bombach, B. and Reichart, P. ....(A) 349

Testes,
A comparative study of testicular involvement in lepromatous and borderline lepromatous leprosy. Rea, T. H. ....(O) 383
Gonadal involvement in leprosy—study of gynaecomastia, testicular and epididymal involvement and therapeutic efficacy of indigenous drugs. Nigam, P., *et al.* ....(A) 352

Tetanus,
Tetanus in leprosy patients: report of five cases. Hodes, R. M. and Teferedegne, B. ...(O) 228

Thailand,
Segregation analysis of leprosy in families of northern Thailand. Wagener, D. K., *et al.* ....(A) 667

Thalidomide,
[Observation on the therapeutic effect of 60 cases of cutaneous diseases treated with thalidomide.] Shen, D., *et al.* ....(A) 515
Thalidomide and exfoliative dermatitis. Salafia, A. and Kharkar, R. D. ....(C) 625
[Thalidomide in the treatment of 50 cases (60 treatments) of lupus erythematosus.] Shi, S., *et al.* ....(A) 158
Thalidomide neuropathy: an electrophysiologic study. Lagueny, A., *et al.* ....(A) 351

THELEP,
Persisting *M. leprae* among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical. .. ....(A) 347
THELEP SWG Fifth Meeting. ....(N) 476

Therapy, (see also **Chemotherapy**),
A computer simulation of the effect of multidrug therapy on the incidence of leprosy. Lechat, M. F., *et al.* ....(A) 149
Blister calendar packs for the implementation of multiple drug therapy in DANIDA-assisted leprosy control projects in India. Georgiev, G. D. and Kielstrup, R. W. ....(A) 346
Blister calendar packs—potential for improvement in the supply and utilization of multiple drug therapy in leprosy control programs. Georgiev, G. D. and McDougall, A. C. ....(E) 603
Centilla asciatica Linn (Thankuni) in the treatment of leprosy. Ali, S. M. K., *et al.* ....(A) 131
[Clinical effect of multidrug therapy regimen.] Wang, Z., *et al.* ....(A) 348
Clinical, bacteriological and histopathological assessment of multibacillary leprosy cases

after 1 and 2 years' multidrug therapy; preliminary communication. McNair, A. N., *et al.* ..... (A) 133
Dr. Katoch's response (paucibacillary leprosy treatment). Katoch, K. ..... (C) 105
[Effect of three drug therapy of leprosy.] Gao, Q., *et al.* ..... (A) 482
Evaluation of two regimens of multidrug therapy in multibacillary leprosy (a preliminary report). Grugni, A., *et al.* ..... (A) 649
Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy. Katoch, K., *et al.* ..... (A) 132
[Leprosy therapy today.] Bahmer, F. A. and Menzel, S. ..... (A) 131
Leprous neuritis, classification of leprosy, and multidrug therapy. Negesse, Y. ..... (C) 329
[Management of leprosy.] Hugon, J. and Dumas, M. ..... (A) 132
Manual of multidrug therapy published. Ye, G.-Y. ..... (N) 637
Multidrug therapy in hospitalised leprosy cases. Tiwari, V. D., *et al.* ..... (A) 654
[Multidrug therapy of multibacillary leprosy for one year.] Shen, W., *et al.* ..... (A) 484
Multidrug therapy. ..... (N) 120
Papillary necrosis associated with rifampicin therapy. Mac-Moune Lai, F., *et al.* ..... (A) 346
Pharmacokinetics of aspirin and chloramphenicol in normal and leprotic patients before and after dapsone therapy. Garg, S. K., *et al.* ..... (A) 648
Problems encountered in treating one leprosy patient in a developing country: a case report. Joseph, M. S. and Charoen, W. S. ..... (A) 135
Pyrazinamide as a part of combination therapy for BL and LL patients—a preliminary report. Katoch, K., *et al.* ..... (O) 1
Pyrazinamide as a part of combination therapy for BL and LL patients—a preliminary report. Levy, L. ..... (C) 621
Reply to Dr. Levy (on pyrazinamide as part of combination therapy). Katoch, K. ..... (C) 622
Short term combination therapy for paucibacillary leprosy—histological evaluation & follow-up study. Kumar, B., *et al.* ..... (A) 132
Short-course multidrug therapy for leprosy patients in western Kenya. Preliminary communication. Orege, P. A., *et al.* ..... (A) 346
[Short-course therapy of patients with pulmonary tuberculosis by antituberculous drugs and levamisole.] Feureisl, R. and Papezova, E. ..... (A) 511
Skin smears and the bacterial index in multiple drug therapy. Agrawal, M. N. and Porichha, D. ..... (C) 628
Skin smears and the bacterial index (BI) in multiple drug therapy leprosy control programs: an unsatisfactory and potentially hazardous state of affairs. Georgiev, G. D. and McDougall, A. C. ..... (C) 101
Three years' assessment of multidrug therapy in multibacillary cases. Ganapati, R., *et al.* ..... (A) 131
Treatment regimens in paucibacillary leprosy. Jopling, W. H. ..... (C) 104

Tissue(s),
In vitro cultivation of a chemoautotrophic nocardioform bacterium from armadillo tissue infected with leprosy bacillus. Dastidar, S. G., *et al.* ..... (A) 366
In vitro synthesis of antimycobacterial antibodies with different specificities in various tissues of leprosy patients. Lai A Fat, R. F. M., *et al.* ..... (O) 552
Isolation, purification and quantification of phenolic glycolid-I from human leprosy skin tissues. Venkatesan, K., *et al.* ..... (A) 664
Learning from lesions: patterns of tissue inflammation in leprosy. Modlin, R. L., *et al.* (A) 493
M. chelonei and abscess formation in soft tissues. Hanson, P. J. V., *et al.* ..... (A) 376
Proteolytic and anti-proteolytic regulation in granulomatous tissue reaction. Izaki, S., *et al.* ..... (A) 689
Psychrophilic mycobacteria in *M. leprae*-infected tissues. Kato, L. ..... (C) 631

Training,
A review of health education in leprosy. Lennon, J. L. ..... (E) 611
All-Africa Leprosy and Rehabilitation Centre (ALERT) training courses for 1988. ..... (N) 336
Common Vocational Training Project for the Handicapped (CVTPH). Amrithmahal, A. and Mehta, J. M. ..... (A) 667
Laboratory Aspects of Leprosy; A Technical Manual for Smear Personnel by B. Devasundaram and C. J. G. Chacko. ..... (B) 479
Leprosy; Basic Information and Management by A. C. McDougall and S. J. Yawalkar (B) 128

Slides and tapes on leprosy subjects available from American Leprosy Missions (ALM). ..... (N) 642
Special Programme for Research and Training in Tropical Diseases; Eighth Report 1987. ..... (N) 339

Trials,
A controlled therapeutic trial in paucibacillary leprosy comparing a single dose of rifampicin followed by 1 year of daily dapsone with 10 weekly doses of rifampicin. Pattyn, S. R., *et al.* ..... (A) 347
A field trial among leprosy patients in Nigeria with depot injections of dapsone and monoacetyldapsone. Pieters, F. A. J. M., *et al.* ..... (O) 10
A Trial to Compare Serodiagnostic Tests for Leprosy by the International Cooperative Team for Evaluating Serological Tests in Leprosy. ..... (B) 644
Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan: results 18 months after completion of treatment (Lahore Tuberculosis Study). Aziz, A., *et al.* ..... (A) 510
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore TB Service/BMRC ..... (A) 159
Persisting *M. leprae* among THELEP trial patients in Bamako and Chingleput. Subcommittee on Clinical ... . (A) 347
Study on prevention of leprosy. 2. Chemoprophylaxis trial for leprosy household contact children. Saikawa, K. ..... (A) 508

Tuberculin,
A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Kardjito, T., *et al.* ..... (A) 359
Efficacy of a cell-mediated reaction to purified protein derivative of tuberculin in the disposal of *M. leprae* from human skin. Kuplan, G., *et al.* ..... (A) 658
Taxonomic differences between *M. avium* and *M. intracellulare* elucidated in man by skin tests with three new tuberculins. McIntyre, G., *et al.* ..... (A) 379

Tuberculoid leprosy,
A follow up study of borderline tuberculoid leprosy under sulphone monotherapy. Ramu, G. and Desikan, K. V. ..... (A) 653
A large hypoanesthetic patch in borderline tuberculoid leprosy. Mohamed, K. N. ..... (C) 625
Cell-mediated immunity in tuberculoid leprosy—a study of T lymphocyte population by "E" rosette technique. Behra, R. N., *et al.* ..... (A) 355
Comedones induced by coconut oil in a borderline tuberculoid lesion. Srinivas, C. R., *et al.* ..... (C) 471
Demonstration of *M. leprae* antigen in nerves of tuberculoid leprosy. Barros, U., *et al.* ..... (A) 138
M. leprae-reactive T-cell clones isolated from polar lepromatous and tuberculoid leprosy patients. Launois, P., *et al.* ..... (A) 360
Melkersson-Rosenthal syndrome masquerading as tuberculoid leprosy. Pavithran, K. .. (A) 137
Photoactivated topical 8-methoxypsoralen in repigmentation of a tuberculoid leprosy lesion. Srinivas, C. R. ..... (C) 109
Primary hyperpigmented cutaneous lesions in tuberculoid leprosy. Chattopadhyay, S. P. and Gupta, C. M. ..... (A) 651
Sonographic diagnosis of tuberculoid leprosy. Fornage, B. D. and Nerot, C. ..... (A) 135
Subpolar tuberculoid leprosy. Sadhu, S. K. and Panja, R. K. ..... (A) 488
Tuberculoid leprosy in Mexicans is associated with HLA-DR3. Gorodezky, C., *et al.* .. (A) 372
Vaccination of borderline tuberculoid leprosy patients with BCG plus killed *M. leprae*. Samuel, N. M., *et al.* ..... (A) 496

Tuberculosis,
A comparative study of the immunohistology of leprosy and tuberculosis. Barnes, P. F., *et al.* ..... (A) 688
A comparison of the responsiveness to four new tuberculins among Indonesian patients with pulmonary tuberculosis and healthy subjects. Kardjito, T., *et al.* ..... (A) 359
Active case-finding—for the whole community or for tuberculosis contacts only? Gilpin, T. P. and Hammond, M. ..... (A) 376

Adrenal function in tuberculosis. Ellis, M. E. and Tayoub, F. ..... (A) 156
[Antigens HLA and diverse forms and variants of pulmonary tuberculosis.] Sadykov, A. S., *et al.* ..... (A) 514
Antigens of *M. leprae* identified by immunoprecipitation with sera from leprosy and tuberculosis patients. Britton, W. J., *et al.* ..... (A) 491
Association HLA and other genetic markers in South Indian patients with pulmonary tuberculosis. Papida, S. S., *et al.* ..... (A) 513
Clinical trial of two short-course (6-month) regimens and a standard regimen (12-month) chemotherapy in retreatment of pulmonary tuberculosis in Pakistan: results 18 months after completion of treatment (Lahore Tuberculosis Study). Aziz, A., *et al.* ..... (A) 510
[Dependence of levels of antituberculous antibodies on HLA-DR genotype of patients suffering from tuberculosis.] Litvinov, V. I., *et al.* ..... (A) 378
[Determination of IgG antibodies to tubercle bacilli antigens in patients with pulmonary tuberculosis by enzyme immunoassay.] Gilburd, B. S. ..... (A) 157
[Dynamics of the excretion of bacterial and ultramicro forms of *M. tuberculosis* by patients with pulmonary tuberculosis in the process of chemotherapy.] Golyshevskaya, V. I., *et al.* ..... (A) 512
Enzyme-linked immunosorbent assay using *M. tuberculosis* antigen 5 for the diagnosis of pulmonary tuberculosis in China. Ma, Y., *et al.* ..... (A) 379
Evaluation of a dual-antigen ELISA test for the serodiagnosis of tuberculosis. Raheman, S. F., *et al.* ..... (A) 671
[Fluorescent microscopy for the study of acid-fast bacilli in cutaneous tuberculosis.] Lazarova, A., *et al.* ..... (A) 512
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isonizid, rifampicin and pyrazinamide. Parthasarathy, R., *et al.* ..... (A) 158
[Immunological reactivity of patients with various levels of tuberculosis activity.] Gudz, E. A. and Prilutsky, A. S. ..... (A) 157
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Dickinson, J. M. ..... (A) 156
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Dickinson, J. M. ..... (A) 156
[Informative value of liquid-crystalline thermography of reaction of Mantoux test in estimation of tuberculosis activity in children and adolescents.] Donets, O. T., *et al.* ..... (A) 156
Leprosy and tuberculosis in the Blue Nile Valley of western Ethiopia. Gundersen, S. G. ..... (A) 148
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore TB Service/BMRC ..(A) 159
Manual of the National Leprosy Tuberculosis Programme for the Clinical Officer Tuberculosis and Leprosy. ..... (B) 128
Mycobacterial antigen detection of immunohistochemistry in pulmonary tuberculosis. Humphrey, D. M. and Weiner, M. H. ..... (A) 376
Primary drug-resistant tuberculosis in children. Emergence of primary drug-resistant strains of *M. tuberculosis* to rifampin. Steiner, P., *et al.* ..... (A) 159
[Role of various mycobacterial species in epidemiology of tuberculosis.] Tarasov, A. S., *et al.* ..... (A) 160
Serodiagnosis of pulmonary & extrapulmonary tuberculosis by enzyme linked immunosorbent assay of IgG antibodies using BCG "pressate" antigen. Mohan, C., *et al.* ..... (A) 157
Serological activity of natural disaccharide octyl bovine serum albumin (ND-O-BSA) in sera from patients with leprosy, tuberculosis, and normal controls. Wu, Q.-X., *et al.* ..... (O) 50
[Short-course therapy of patients with pulmonary tuberculosis by antituberculous drugs and levamisole.] Feureisl, R. and Papezova, E. ..... (A) 511
Stress proteins are immune targets in leprosy and tuberculosis. Young, D., *et al.* ..... (A) 661
[Study on relation between distribution of locus DR antigens of HLA system and tuberculosis in various populations.] Pospelov, L. E., *et al.* ..... (A) 513
T4 lymphopenia in human tuberculosis. Onwubalili, J. K., *et al.* ..... (A) 158
Towards new leprosy and tuberculosis vaccines. Kaufmann, S. H. E. ..... (A) 359

Uganda,
Buluba Leprosy Hospital, Uganda: a review of admissions, 1981–84. Kawuma, H. J. ..(A) 343

U.K.,
International Society of Dermatology 1988 meeting notice. ....(N) 340
LEPRA Medical Advisory Board new chairman. ....(N) 123
New editor for Leprosy Review. ....(N) 476
Proceedings of the Indo–U.K. Symposium on Leprosy, Agra, April 7–10, 1986. Hastings, R. C. ....(B) 129
Retirement of LEPRA's Director G. Francis Harris. ....(N) 477
Robert Cochrane Fund for Leprosy. ....(N) 477
Robert White Fellowships in Immunology. ....(N) 341
WHO 1987 Symposium on Ocular Leprosy. ....(N) 477

Ulcer(s),
Care of plantar ulcerations: comparing applications, materials and non-casting. Kaplan, A. and Gelber, R. H. ....(A) 509
Collagen sheet and its usefulness in healing ulcers in leprosy patients. Rao, K. S., *et al.* ....(A) 487
[Effect of treating 255 cases of leprous plantar ulcers.] Jiang, Z., *et al.* ....(A) 152
Increased pigmentation of skin along course of superficial veins of lower limbs in chronic plantar ulceration of leprosy patients. Siddalinga Swamy, M. K. and Ratnakar, C. ..(C) 464
Lipomeningocoele masquerading as leprous trophic ulcers. Koranne, V. and Srivastava, G. ....(A) 486
Malignant melanoma over the trophic ulcer. Arora, S. K. and Mukhija, R. D. ....(A) 485
Malignant transformation in trophic ulcers in leprosy: a study of 12 cases. Sane, S. B. and Mehta, J. M. ....(A) 654
[Remote results of decompression of posterior tibial nerve to prevent plantar ulcers and their recurrences.] Boucher, P. and Hirzel, C. ....(A) 151
Squamous cell carcinoma in trophic ulcer cases. Arora, S. K. and Mukhija, R. D. ....(A) 134

Ultrastructure, (see also **Electron microscopy**),
Effects of freezing and thawing on the viability and the ultrastructure of *in vivo* grown mycobacteria. Portaels, F., *et al.* ....(O) 580
Intracellular growth of pathogenic mycobacteria in the continuous murine macrophage cell line J-774: ultrastructure and drug-susceptibility studies. Rastogi, N., *et al.* ....(A) 379
Ultrastructure of human foetal Schwann cells in tissue culture infected with *M. leprae.* Samuel, N. M., *et al.* ....(A) 502

Urine,
Evaluation of urinary neopterin—a marker of cell-mediated immune response—in patients with leprosy. Schmutzhard, E., *et al.* ....(A) 142
Microbiological assay versus spectrophotometry for determination of rifampicin in urine. George, J., *et al.* ....(A) 649
Serum and urinary rifampicin and hepatic toxicity. Gupta, P. R., *et al.* ....(A) 131

U.S.A.,
Carville's Director retires. ....(N) 341
Dates for 1989 seminars at Carville. ....(N) 643
Dr. W. Felton Ross Damien-Dutton Award winner for 1987. ....(N) 119
Kalaupapa as part of the National Park System. Law, H. G. ....(A) 344
Leprosy in armadillos (*Dasypus novemcinctus*) from Texas. Clark, K. A., *et al.* ....(A) 371
New cases of leprosy reported in 1987. ....(N) 341
New Director at Carville. ....(N) 341
Pathology seminar at Carville. ....(N) 123
Progress in the serology of leprosy at the University of Hawaii. Douglas, J. T. ....(A) 356
Search for leprous infection in some small wild animals of Louisiana. Job, C. K., *et al.* ....(C) 630
Slides and tapes on leprosy subjects available from American Leprosy Missions (ALM). ....(N) 642
The Heiser Program for Research in Leprosy 1989. ....(N) 478

U.S.-Japan Cooperative Medical Science Program,
Twenty-Third Joint Leprosy Research Conference, Nara, Japan, 27 and 29 July 1988, abstracts. ....(A) 673

Vaccination,
Basic vaccinology. ....(N) 638
BCG vaccination in leprosy. Noordeen, S. K. ....(A) 361
Evidence for a biphasic memory T-cell response to high dose BCG vaccination in mice. Orme, I. M. ....(A) 670
Human phagocytic cell responses to *M. leprae* and *M. bovis* bacillus Calmette-Guérin; an *in vitro* comparison of leprosy vaccine components. Holzer, T. J., *et al.* ....(A) 657
Identification of T-cell-activating recombinant antigens shared among three candidate antileprosy vaccines, killed *M. leprae, M. bovis* BCG, and *Mycobacterium w.* Mustafa, A. S. ....(O) 265
Immunogenic "subunit" of the ICRC antileprosy vaccine. Chirmule, N. B., *et al.* ....(O) 27
Leprosy vaccine—a reappraisal. Antia, N. H. and Birdi, T. J. ....(E) 310
Oral *Salmonella typhimurium* vaccine expressing circumsporozoite protein protects against malaria. Sadoff, J. C., *et al.* ....(A) 514
Towards new leprosy and tuberculosis vaccines. Kaufmann, S. H. E. ....(A) 359
Unexpected findings amongst the skin test responses to mycobacteria of BCG vaccinated Kuwaiti school children. Bahr, G. M., *et al.* ....(A) 153
Vaccination of borderline tuberculoid leprosy patients with BCG plus killed *M. leprae.* Samuel, N. M., *et al.* ....(A) 496
Vaccination of human volunteers with heat-killed *M. leprae*: local responses in relation to the interpretation of the lepromin reaction. Gill, H. K., *et al.* ....(O) 36
Vaccines against leprosy. ....(A) 143

Venezuela,
Dr. Jacinto Convit honored. Walsh, G. P. ....(N) 124

Vitamin(s),
Hypercalcaemia and elevated 1,25-dihydroxy-vitamin D3 levels in a patient with multibacillary leprosy and a type 1 leprosy reaction. Fraser, A. G., *et al.* ....(A) 135
Hypercalcemia and abnormal 1,25-dihydroxy vitamin D concentrations in leprosy. Ryzen, E., *et al.* ....(A) 487
Undernutrition and lepromatous leprosy; serum vitamin A and E levels in leprosy spectrum. Rao, K. N. and Saha, K. ....(A) 653

World Health Organization (WHO),
Active case-finding—for the whole community or for tuberculosis contacts only? Gilpin, T. P. and Hammond, M. ....(A) 376
Basic vaccinology. ....(N) 638
Field research in leprosy. Engers, H. D. and Ji, B. ....(N) 640
Follow up of BL/LL patients on a slightly modified WHO regimen of multidrug therapy. Katoch, K., *et al.* ....(A) 132
Interrelations of tropical disease and HIV infection; TDR and GPA call for research proposals. ....(N) 640
New postgraduate fellowships in epidemiology. ....(N) 641
Preliminary appraisal of a WHO-recommended multiple drug regimen in paucibacillary leprosy patients in Malawi. Boerrigter, G., *et al.* ....(O) 408
Promotion of research on leprosy reactions and nerve damage. Engers, H. and Ji, B. ....(N) 641
THELEP SWG Fifth Meeting. ....(N) 476
WHO 1987 Symposium on Ocular Leprosy. ....(N) 477
WHO Regional Committee for South-East Asia Report. ....(N) 339

Zaire,
Reasons for non-response during an ongoing leprosy survey in northern Zaire. Mwanasangezi-Bin-Moussa and Groenen, G. ....(A) 507

INTERNATIONAL JOURNAL OF LEPROSY
and Other Mycobacterial Diseases

CONTENTS

Volume 56, Number 1, March 1988

Original Articles — **Page**

Katoch, Kiran, Sreevatsa, Ramanathan, Usha, and Ramu, Gopal. Pyrazinamide as a Part of Combination Therapy for BL and LL Patients—a Preliminary Report. 1

Pieters, Frans A. J. M., Woonink, Frits, and Zuidema, Jan. A Field Trial Among Leprosy Patients in Nigeria with Depot Injections of Dapsone and Monoacetyldapsone. 10

Marks, Sandy C., Jr. and Grossetete, Gerard. *Facies Leprosa*: Resorption of Maxillary Anterior Alveolar Bone and the Anterior Nasal Spine in Patients with Lepromatous Leprosy in Mali. 21

Chirmule, Narendra B., Chaturvedi, Ramesh M., and Deo, Madhav G. Immunogenic "Subunit" of the ICRC Antileprosy Vaccine. 27

Gill, Harvindar Kaur, Mustafa, Abu Salim, and Godal, Tore. Vaccination of Human Volunteers with Heat-killed *M. leprae*: Local Responses in Relation to the Interpretation of the Lepromin Reaction. 36

Sengupta, Utpal, Sinha, Sudhir, Ramu, Gopal, Lavania, Ravinder K., and Gupta, Chhitar M. Soluble Antigen of *M. leprae* Coupled with Liposomes Elicits Both "Early" and "Late" Delayed Hypersensitivity Skin Reactions 45

Wu, Qin-Xue, Ye, Gan-Yun, and Li, Xin-Yu. Serological Activity of Natural Disaccharide Octyl Bovine Serum Albumin (ND-O-BSA) in Sera from Patients with Leprosy, Tuberculosis, and Normal Controls. 50

Jacob, Mary and Mathai, Rachel. Diagnostic Efficacy of Cutaneous Nerve Biopsy in Primary Neuritic Leprosy. 56

Gormus, Bobby J., Wolf, Robert H., Baskin, Gary B., Ohkawa, Susumu, Gerone, Peter J., Walsh, Gerald P., Meyers, Wayne M., Binford, Chapman H., and Greer, William E. A Second Sooty Mangabey Monkey with Naturally Acquired Leprosy: First Reported Possible Monkey-to-Monkey Transmission. 61

Editorials

Nutrition in Leprosy: A Review. (Ray L. Foster, Albert L. Sanchez, Wilfred Stuyvesant, Frances N. Foster, Carrol Small, and Benjamin H. S. Lau) 66

The 1987 JOURNAL—a Continuing Perspective. (Robert C. Hastings) 82

Correspondence

Skin Smears and the Bacterial Index (BI) in Multiple Drug Therapy Leprosy Control Programs: An Unsatisfactory and Potentially Hazardous State of Affairs. (George D. Georgiev and A. Colin McDougall) 101

Treatment Regimens in Paucibacillary Leprosy. (William H. Jopling) 104

Dr. Katoch's Response. (Kiran Katoch) 105

Allergy and Immunity in Leprosy: Are These Concepts Becoming Obsolete? (Michael G. Corcos) 106

Photoactivated Topical 8-Methoxypsoralen in Repigmentation of a Tuberculoid Leprosy Lesion. (C. R. Srinivas) 109

A Family with Histoid Leprosy. (Malkit Singh, Fatma H. Shahat, M. S. Belhaj, and E. A. Manghoush) 110

Lupus and Lepros. (John M. Grange) 111

Determination of the D and L Configuration of Phenolic Glycolipids of *M. leprae* and *M. bovis*. (Tsuyoshi Fujiwara) 112

Effect of Shipment of Skin-biopsy Specimens to a Distant Laboratory on Viability of *Mycobacterium leprae*. (Mario Baras and Louis Levy) 115

News and Notes 119

Book Reviews 127

Current Literature 131

Special Grantors and Sustaining Members 162

Index to Volume 55 163

CONTENTS

Volume 56, Number 2, June 1988

Original Articles — **Page**

Sirumban, P., Kumar, Ashok, and Neelan, P. N. Healing Time in Untreated Paucibacillary Leprosy: A Cross-sectional Study 223

Hodes, Richard M. and Teferedegne, Befekadu. Tetanus in Leprosy Patients: Report of Five Cases 228

Neylan, Thomas C., Nelson, Kenrad E., Schauf, Victoria, and Scollard, David M. Illness Beliefs of Leprosy Patients: Use of Medical Anthropology in Clinical Practice 231

Suryawanshi, Nivrutti and Richard, J. Cataract Surgery on Leprosy Patients 238

Fine, Paul E. M., Ponnighaus, Jorg M., Burgess, Peter, Clarkson, Jacqueline A., and Draper, Christopher C. Seroepidemiological Studies of Leprosy in Northern Malawi Based on an Enzyme-linked Immunosorbent Assay Using Synthetic Glycoconjugate Antigen 243

Petchclai, Bencha, Khupulsup, Kalayanee, Hiranras, Supaporn, Sampatavanich, Surasak, Sampoonachot, Prasert, and Leelarusamee, Amorn. A Passive Hemagglutination Test for Leprosy Using a Synthetic Disaccharide Antigen 255

Grosset, Jacques H., Guelpa-Lauras, Claire-Cecile, Perani, Evelyne G., and Beoletto, Corinne. Activity of Ofloxacin Against *Mycobacterium leprae* in the Mouse 259

Mustafa, Abu Salim. Identification of T-cell-activating Recombinant Antigens Shared Among Three Candidate Antileprosy Vaccines, Killed *M. leprae, M. bovis* BCG, and *Mycobacterium w* 265

Vadiee, Abdul R., Shannon, Edward J., Gillis, Thomas P., and Hastings, Robert C. Partial Characterization of Antigens from *M. leprae* Evoking IgG and IgM Antibodies in Armadillos 274

Cowley, Sally A., Butter, Colin, Verghese, Susan, Curtis, Jill, and Turk, John L. Nerve Damage Induced by Mycobacterial Granulomas in Guinea Pig Sciatic Nerves 283

Job, Charles K., Sanchez, Rita M., and Hastings, Robert C. Lepromatous Meningoencephalitis in the Nine-banded Armadillo (*Dasypus novemcinctus*) 291

Cree, Ian A., Srinivasan, T., Krishnan, S. A. R., Gardiner, Carol A., Mehta, Jal, Fisher, Crispin A. H., and Beck, J. Swanson. Reproducibility of Histology in Leprosy Lesions 296

Meyers, Wayne M., McDougall, A. Colin, Fleury, Raul N., Neves, Rene, Reyes, Oscar, and Binford, Chapman H. Histologic Responses in Sixty Multibacillary Leprosy Patients Inoculated with Autoclaved *Mycobacterium leprae* and Live BCG 302

Editorials

Leprosy Vaccine—a Reappraisal (Noshir H. Antia and Tannaz J. Birdi) 310

Leprosy: The Immunologist and the Patient (Robert N. Mshana and Rune Nilsen) 314

Obituaries

Bopp, Clovis 323

Klingmüller, Georg 324

Madarang, Monina G. 325

Correspondence

Dapsone Susceptibility of *Mycobacterium leprae* Isolated Before 1977. (Ji Baohong, E. C. de la Cruz, L. Levy, S. R. Pattyn, and R. J. W. Rees) 326

An Electronic Device for Repetitive Auditory Cues. (J. Devasundaram) 328

Leprous Neuritis, Classification of Leprosy, and Multidrug Therapy. (Yohannes Negesse) 329

News and Notes 331

Current Literature 342

Special Grantors and Sustaining Members 381

CONTENTS

Volume 56, Number 3, September 1988

Original Articles — **Page**

Rea, Thomas H. A Comparative Study of Testicular Involvement in Lepromatous and Borderline Lepromatous Leprosy 383

Dhand, Upinder K., Kumar, Bhushan, Dhand, Rajiv, Chopra, Jagjit S., and Kaur, Surrinder. Phrenic Nerve Conduction in Leprosy 389

Agusni, Indropo, Beck, J. Swanson, Potts, Robert C., Cree, Ian A., and Ilias, M. Ibeni. Blood Flow Velocity in Cutaneous Lesions of Leprosy 394

Thangaraj, Harry, Laal, Suman, Thangaraj, Irene, and Nath, Indira. Epidermal Changes in Reactional Leprosy: Keratinocyte Ia Expression as an Indicator of Cell-mediated Immune Responses 401

Boerrigter, Gjalt, Ponnighaus, Jorg M., and Fine, Paul E. M. Preliminary Appraisal of a WHO-recommended Multiple Drug Regimen in Paucibacillary Leprosy Patients in Malawi 408

Jesudasan, Kumar, Pannikar, Vijaykumar, and Christian, Melville. Infectivity of Secondary Dapsone-resistant Cases 418

Vadiee, Abdul R., Shannon, Edward J., Gillis, Thomas P., Mshana, Robert N., and Hastings, Robert C. Armadillo IgG and IgM Antibody Responses to Phenolic Glycolipid-I During Experimental Infection with *M. leprae* 422

Rojas-Espinosa, Oscar, Vega, Rosario, Oltra, Antonina, Arce, Patricia, and Nunez, Augustin. Transitory Macrophage Activation in the Granulomatous Lesions of *Mycobacterium lepraemurium*-induced Lepromatoid Leprosy in the Mouse 428

Job, Charles K., Jacobson, Robert R., and Hastings, Robert C. Simultaneous Upgrading Reaction and Erythema Nodosum Leprosum in a Patient with Lepromatous Leprosy 437

Malaty, Raga, Meyers, Wayne M., Walsh, Gerald P., Binford, Chapman H., Zimmerman, Lorenz E., Baskin, Gary B., Gormus, Bobby J., Martin, Louis N., and Wolf, Robert H. Histopathological Changes in the Eyes of Mangabey Monkeys with Lepromatous Leprosy 443

Smida, Jan, Kazda, Jindrich, and Stackebrandt, Erko. Molecular-Genetic Evidence for the Relationship of *Mycobacterium leprae* to Slow-growing Pathogenic Mycobacteria 449

Editorial

Immunological Approach for Control of *Mycobacterium avium-intracellulare* Infections in AIDS—an Hypothesis (M. G. Deo) 455

Correspondence

Increased Pigmentation of Skin Along Course of Superficial Veins of Lower Limbs in Chronic Plantar Ulceration of Leprosy Patients (M. K. Siddalinga Swamy and C. Ratnakar) 464

Vibration Sensation in Leprosy Patches (Paul Klenerman and Christopher Hammond) 466

Isolation of Mycobacteria from Healthy Persons' Stools (Françoise Portaels, Lennart Larsson, and Pascale Smeets 468

Comedones Induced by Coconut Oil in a Borderline Tuberculoid Lesion (C. R. Srinivas, Ambrish Padhee, C. Balanchandran, S. D. Shenoy, Sandhya Acharya, and K. Ramnarayan) 471

News and Notes 473

Book Reviews 479

Current Literature 481

Statement of Financial Condition 517

Special Grantors and Sustaining Members 521

CONTENTS

Volume 56, Number 4, December 1988

Original Articles — **Page**

Job, Anand and Chacko, Chinoy J. G. Reactional States in the Nasal Mucosa: A Clinical and Histopathological Study — 523

Agis, Frantz, Schlich, Pascal, Cartel, Jean-Louis, Guidi, Claude, and Bach, Marie-Anne. Use of Anti-*M. leprae* Phenolic Glycolipid-I Antibody Detection for Early Diagnosis and Prognosis of Leprosy — 527

Gormus, Bobby J., Ohashi, David K., Ohkawa, Susumo, Walsh, Gerald P., Meyers, Wayne M., Brennan, Patrick J., and Trygg, Cynthia. Serologic Responses to *Mycobacterium leprae*-specific Phenolic Glycolipid-I Antigen in Sooty Mangabey Monkeys with Experimental Leprosy — 537

ShivRaj, Lalita, Patil, Shripad A., Girdhar, Anita, Sengupta, Utpal, Desikan, K. V. and Srinivasan, H. Antibodies to HIV-1 in Sera from Patients with Mycobacterial Infections — 546

Lai A Fat, Rudy F. M., Harboe, Morten, Chan Pin Jin, Jimmy C., Diesselhoff-den Dulk, Martina M. C., and van Furth, Ralph. *In Vitro* Synthesis of Antimycobacterial Antibodies with Different Specificities in Various Tissues of Leprosy Patients — 552

Chakrabarty, Asit K., Kashyap, A., Sehgal, V. N., and Saha, Kunal. Solubilization of Preformed Immune Complexes in Sera of Patients with Type 1 and Type 2 Lepra Reactions — 559

Courtright, Paul D. Defining the Magnitude of Ocular Complications from Leprosy: Problems of Methodology — 566

Roy, B. and Das, R. K. Cytogenetic Effect of Dapsone, an Antileprotic Drug, in the Mouse *in Vivo* System — 574

Portaels, Françoise, Fissette, Krista, De Ridder, Karin, Macedo, Paula M., De Muynck, Aimé, and Silva, Manuel T. Effects of Freezing and Thawing on the Viability and the Ultrastructure of *in Vivo* Grown Mycobacteria — 580

Harris, Eugene B., Franzblau, Scott G., and Hastings, Robert C. Inhibition of Phenolic Glycolipid-I Synthesis in Extracellular *Mycobacterium leprae* as an Indicator of Antimicrobial Activity — 588

Reddi, Prabhakara P., Talwar, G. P., and Khandekar, Pramond S. Repetitive DNA Sequence of *Mycobacterium tuberculosis*: Analysis of Differential Hybridization Pattern with Other Mycobacteria — 592

Al-Mohaya, Suleiman A., Coode, Peter E., Alkhder, Abdullah A., and Al-Suhaibani, Mohammed O. Renal Granuloma and Mesangial Proliferative Glomerulonephritis in Leprosy — 599

Editorials

Blister Calendar Packs—Potential for Improvement in the Supply and Utilization of Multiple Drug Therapy in Leprosy Control Programs (George D. Georgiev and A. Colin McDougall) — 603

A Review of Health Education in Leprosy (Jeffrey L. Lennon) — 611

Correspondence

Nerve Damage in Leprosy (Vanaja P. Shetty and Noshir H. Antia) — 619

Pyrazinamide as a Part of Combination Therapy for BL and LL Patients—a Preliminary Report (Louis Levy) — 621

Reply to Dr. Levy (Kiran Katoch) — 622

Thalidomide and Exfoliative Dermatitis (A. Salafia and R. D. Kharkar) — 625

A Large Hypoanesthetic Patch in Borderline Tuberculoid Leprosy (Kader N. Mohamed) — 625

Arthus-like Phenomenon and Lepromin A—a Case Report (A. Salafia and R. D. Kharkar) — 627

Skin Smears and Bacterial Index in Multiple Drug Therapy (M. N. Agrawal and D. Porichha) — 628

Search for Leprous Infection in Some Small Wild Animals of Louisiana (Charles K. Job, Joe L. Allen, and Robert C. Hastings) — 630

Psychrophilic Mycobacteria in *M. leprae*-infected Tissues (Laszlo Kato) — 631

Multiplication of Armadillo-derived *M. leprae* in Murine Dissociated Schwann Cell Cultures (Noshir H. Antia, Nerges F. Mistry, and Varsha C. Kulkarni) — 632

News and Notes — 636

Book Reviews — 644

Current Literature — 647

U.S.–Japan Cooperative Medical Science Program, Twenty-Third Joint Leprosy Research Conference, Nara, Japan, 1988 — 673

Reviewers — 692

Special Grantors and Sustaining Members — 693

Statement of Ownership — 694